U.S. patent application number 10/181562 was filed with the patent office on 2004-01-29 for integrin expression inhibitors.
Invention is credited to Funahashi, Yasuhiro, Hamaoka, Shinichi, Haneda, Toru, Hata, Naoko, Kamata, Junichi, Nara, Kazumasa, Okabe, Tadashi, Owa, Takashi, Semba, Taro, Takahashi, Keiko, Tsuruoka, Akihiko, Ueda, Norihiro, Wakabayashi, Toshiaki, Yamamoto, Yuji.
Application Number | 20040018192 10/181562 |
Document ID | / |
Family ID | 26584780 |
Filed Date | 2004-01-29 |
United States Patent
Application |
20040018192 |
Kind Code |
A1 |
Wakabayashi, Toshiaki ; et
al. |
January 29, 2004 |
Integrin expression inhibitors
Abstract
The present invention provides an integrin expression inhibitor,
and an agent for treating arterial sclerosis, psoriasis, cancer,
retinal angiogenesis, diabetic retinopathy or inflammatory
diseases, an anticoagulant, or a cancer metastasis suppressor on
the basis of an integrin inhibitory action. Namely, it provides an
integrin expression inhibitor comprising, as an active ingredient,
a sulfonamide compound represented by the following formula (I), a
pharmacologically acceptable salt thereof or a hydrate of them. 1
In the formula, B means a C6-C10 aryl ring or 6- to 10-membered
heteroaryl ring which may have a substituent and in which a part of
the ring may be saturated; K means a single bond, --CH.dbd.CH-- or
--(CR.sup.4bR.sup.5b).sub.m.sup.b-- (wherein R.sup.4b and R.sup.5b
are the same as or different from each other and each means
hydrogen atom or a C1-C4 alkyl group; and m.sup.b means an integer
of 1 or 2); R.sup.1 means hydrogen atom or a C1-C6 alkyl group; Z
means a single bond or --CO--NH--; and R means a C6-C10 aryl ring
or 6- to 10-membered heteroaryl ring which may have a substituent
and in which a part of the ring may be saturated, respectively.
Inventors: |
Wakabayashi, Toshiaki;
(Ibaraki, JP) ; Funahashi, Yasuhiro; (Ibaraki,
JP) ; Hata, Naoko; (Ibaraki, JP) ; Semba,
Taro; (Ibaraki, JP) ; Yamamoto, Yuji;
(Ibaraki, JP) ; Haneda, Toru; (Ibaraki, JP)
; Owa, Takashi; (Ibaraki, JP) ; Tsuruoka,
Akihiko; (Ibaraki, JP) ; Kamata, Junichi;
(Ibaraki, JP) ; Okabe, Tadashi; (Ibaraki, JP)
; Takahashi, Keiko; (Ibaraki, JP) ; Nara,
Kazumasa; (Ibaraki, JP) ; Hamaoka, Shinichi;
(Ibaraki, JP) ; Ueda, Norihiro; (Ibaraki,
JP) |
Correspondence
Address: |
BIRCH STEWART KOLASCH & BIRCH
PO BOX 747
FALLS CHURCH
VA
22040-0747
US
|
Family ID: |
26584780 |
Appl. No.: |
10/181562 |
Filed: |
July 18, 2002 |
PCT Filed: |
February 1, 2001 |
PCT NO: |
PCT/JP01/00713 |
Current U.S.
Class: |
424/144.1 |
Current CPC
Class: |
C07D 217/24 20130101;
C07D 209/30 20130101; A61K 31/404 20130101; A61K 31/4439 20130101;
C07D 209/08 20130101; A61K 31/506 20130101; A61P 35/00 20180101;
A61K 31/18 20130101; C07D 217/02 20130101; C07D 411/12 20130101;
A61P 19/02 20180101; C07D 209/42 20130101; C07D 401/12 20130101;
C07D 209/12 20130101; A61P 17/06 20180101; A61P 35/04 20180101;
A61P 43/00 20180101; A61P 19/10 20180101; C07D 311/04 20130101;
C07D 217/22 20130101; C07D 409/12 20130101; A61K 31/00 20130101;
A61P 9/10 20180101; C07D 417/12 20130101; A61P 7/02 20180101; C07D
405/12 20130101; A61K 31/4045 20130101; C07D 403/12 20130101; C07D
215/38 20130101; A61P 29/00 20180101; C07D 209/34 20130101; C07D
471/04 20130101; C07D 409/14 20130101 |
Class at
Publication: |
424/144.1 |
International
Class: |
A61K 039/395 |
Foreign Application Data
Date |
Code |
Application Number |
Feb 3, 2000 |
JP |
2000-26080 |
Feb 3, 2000 |
JP |
2000-402084 |
Claims
1. 1) An agent for treating arterial sclerosis, psoriasis, cancer,
osteoporosis, retinal angiogenesis, diabetic retinopathy or
inflammatory diseases, 2) an anticoagulant, 3) a cancer metastasis
suppressor or 4) an antiangiogenic agent on the basis of an
integrin expression inhibitory action.
2. 1) The agent for treating arterial sclerosis, psoriasis, cancer,
osteoporosis, retinal angiogenesis, diabetic retinopathy or
inflammatory diseases, 2) an anticoagulant, 3) a cancer metastasis
suppressor or 4) an antiangiogenic agent on the basis of integrin
expression inhibitory action as claimed in claim 1, wherein the
integrin is integrin .alpha.2, .alpha.3, .alpha.5, .alpha.6,
.alpha.v, .beta.1, .beta.3, .beta.4, .beta.5, .alpha.2.beta.1,
.alpha.3.beta.1, .alpha.5.beta.1, .alpha.6.beta.1, .alpha.v.beta.1,
.alpha.v.beta.3 or .alpha.v.beta.5.
3. An integrin expression inhibitor comprising, as an active
ingredient, a sulfonamide compound represented by the formula (I),
a pharmacologically acceptable salt thereof or a hydrate of them.
33In the formula, B represents a C6-C10 aryl ring or a 6- to
10-membered heteroaryl ring which may have a substituent and in
which a part of the ring may be saturated; K represents a single
bond, --CH.dbd.CH-- or --(CR.sup.4bR.sup.5b).sub.m.sup.b-- (where
R.sup.4b and R.sup.5b are the same as or different from each other
and each represents hydrogen atom or a C1-C4 alkyl group; and
m.sup.b means an integer of 1 or 2); R.sup.1 represents hydrogen
atom or a C1-C6 alkyl group; Z represents a single bond or
--CO--NH--; and R represents a C6-C10 aryl ring or a 6- to
10-membered heteroaryl ring which may have a substituent and in
which a part of the ring may be saturated, respectively.
4. An integrin expression inhibitor comprising, as an active
ingredient, the sulfonamide compound as claimed in claim 3, a
pharmacologically acceptable salt thereof or a hydrate of them,
wherein R is indole, quinoline or isoquinoline.
5. An integrin expression inhibitor comprising, as an active
ingredient, a sulfonamide compound represented by the formula
(I.sup.a), a pharmacologically acceptable salt thereof or a hydrate
of them. 34In the formula, the A.sup.a ring a monocyclic or
bicyclic aromatic ring which may have a substituent; the B.sup.a
ring represents an optionally substituted 6-membered cyclic
unsaturated hydrocarbon or unsaturated 6-membered heterocycle
containing one nitrogen atom as a heteroatom; the C.sup.a ring
represents an optionally substituted 5-membered heterocycle
containing 1 or 2 nitrogen atoms; R.sup.1a represents hydrogen atom
or a C1-C6 alkyl group; W.sup.a represents a single bond or
--CH.dbd.CH--; Y.sup.a represents carbon atom or nitrogen atom; and
Z.sup.a represents --N(R.sup.2a)--(wherein R.sup.2a means hydrogen
atom or a lower alkyl group) or nitrogen atom, respectively.
6. An integrin expression inhibitor comprising, as an active
ingredient, the sulfonamide compound as claimed in claim 5, a
pharmacologically acceptable salt thereof or a hydrate of them,
wherein W.sup.a is a single bond.
7. An integrin expression inhibitor comprising, as an active
ingredient, the sulfonamide compound as claimed in claim 5, a
pharmacologically acceptable salt thereof or a hydrate of them,
wherein W.sup.a is a single bond; Z.sup.a is --NH--; and Y.sup.a is
carbon atom.
8. The integrin expression inhibitor comprising, as an active
ingredient, a the sulfonamide compound as claimed in any of claims
5, 6 and 7, a pharmacologically acceptable salt thereof or a
hydrate of them, wherein the B.sup.a ring is an optionally
substituted benzene or pyridine.
9. An integrin expression inhibitor comprising, as an active
ingredient, the sulfonamide compound as claimed in any of claims 5
to 8, a pharmacologically acceptable salt thereof or a hydrate of
them, wherein the C.sup.a ring is an optionally substituted
pyrrole.
10. An integrin expression inhibitor comprising, as an active
ingredient, the sulfonamide compound as claimed in claim 5, a
pharmacologically acceptable salt thereof or a hydrate of them,
wherein the A.sup.a ring is a benzene or pyridine which may have a
substituent; the B.sup.a ring is benzene which may have a
substituent; the C.sup.a ring is pyrrole which may have a
substituent; W.sup.a is a single bond; and Z.sup.a is --NH--.
11. An integrin expression inhibitor comprising, as an active
ingredient, a sulfonamide-containing heterocyclic compound
represented by the formula (I.sup.b), a pharmacologically
acceptable salt thereof or a hydrate of them. 35In the formula,
A.sup.b represents hydrogen atom, a halogen atom, hydroxyl group, a
C1-C4 alkyl or alkoxy group which may be substituted with a halogen
atom, cyano group, --(CO).sub.k.sup.bNR.sup.2b- R.sup.3b (wherein
R.sup.2b and R.sup.3b are the same as or different from each other
and each means hydrogen atom or a C1-C4 alkyl group which may be
substituted with a halogen atom; and k.sup.b means 0 or 1), a C2-C4
alkenyl or alkynyl group which may have a substituent, or a phenyl
or phenoxy group which may have a substituent selected from the
following group A; B.sup.b means an aryl group or monocyclic
heteroaryl group which may have a substituent selected from the
following group A, or the following formula: 36(wherein the ring
Q.sup.b means an aromatic ring which may have one or two nitrogen
atoms; and the ring M.sup.b means a C5-C12 unsaturated monocycle or
heterocycle having a double bond in common with the ring Q.sup.b.
The ring may have 1 to 4 hetero atoms selected from nitrogen atom,
oxygen atom and sulfur atom, the ring Q.sup.b and the ring M.sup.b
may jointly have nitrogen atom, and the ring Q.sup.b and the ring
M.sup.b may have a substituent selected from the following group
A); K.sup.b means a single bond or
--(CR.sup.4bR.sup.5b)m.sup.b--(wherein R.sup.4b and R.sup.5b are
the same as or different from each other and each means hydrogen
atom or a C1-C4 alkyl group; and m.sup.b means an integer of 1 or
2); T.sup.b, W.sup.b, X.sup.b and Y.sup.b are the same as or
different from each other and each means .dbd.C(D.sup.b)--(wherein
D.sup.b represents hydrogen atom, a halogen atom, hydroxyl group, a
C1-C4 alkyl or alkoxy group which may be substituted with a halogen
atom, cyano group, --(CO).sub.n.sup.bNR.sup.6b- R.sup.7b (wherein
R.sup.6b and R.sup.7b are the same as or different from each other
and each means hydrogen atom or a C1-C4 alkyl group which may be
substituted with a halogen atom; and n.sup.b means 0 or 1) or a
C2-C4 alkenyl or alkynyl group which may have a substituent,
respectively) or nitrogen atom; U.sup.b and V.sup.b are the same as
or different from each other and each means
.dbd.C(D.sup.b)--(wherein D.sup.b has the same meaning as above),
nitrogen atom, --CH.sub.2--, oxygen atom or --CO--; Z.sup.b means a
single bond or --CO--NH--; R.sup.1b means hydrogen atom or a C1-C4
alkyl group; and means a single bond or a double bond. Group A: a
halogen atom, hydroxyl group, a C1-C4 alkyl or alkoxy group which
may be substituted with a halogen atom, cyano group,
--R.sup.8bR.sup.9bN(NH).sub.p.sup.b--(wherein R.sup.8b and R.sup.9b
are the same as or different from each other and each means
hydrogen atom or a C1-C4 alkyl group which may be substituted with
a halogen atom; and p.sup.b means 0 or 1. Further, R.sup.8b and
R.sup.9b may form a 5- or 6-membered ring together with the
nitrogen atom to which they are bound, and the ring may further
contain nitrogen atom, oxygen atom or sulfur atom, and also may
have a substituent.), an aminosulfonyl group which may be
substituted with a mono- or di-C1-C4 alkyl group, a C1-C8 acyl
group which may have a substituent, a C1-C4
alkyl-S(O).sub.s.sup.b--C1-C4 alkylene group (wherein s.sup.b means
an integer of 0, 1 or 2), a phenylsulfonylamino group which may
have a C1-C4 alkyl or a substituent,
--(CO).sub.q.sup.bNR.sup.10bR.sup.11b (wherein R.sup.10b and
R.sup.11b are the same as or different from each other and each
means hydrogen atom, or a C1-C4 alkyl group which may substituted
with an amino group which may be substituted with a halogen atom or
a C1-C4 alkyl group; and q.sup.b means 0 or 1), or an aryl group or
heteroaryl group which may have a substituent.
12. An integrin expression inhibitor comprising, as an active
ingredient, the sulfonamide-containing heterocyclic compound as
claimed in claim 11, a pharmacologically acceptable salt thereof or
a hydrogen of them, wherein U.sup.b and V.sup.b are
.dbd.C(D.sup.b)--(wherein D.sup.b has the same meaning as above) or
nitrogen atom.
13. An integrin expression inhibitor comprising, as an active
ingredient, the sulfonamide-containing heterocyclic compound as
claimed in claim 11 or 12, a pharmacologically acceptable salt
thereof or a hydrate of them, wherein Z.sup.b is a single bond.
14. An integrin expression inhibitor comprising, as an active
ingredient, a sulfonamide-containing heterocyclic compound as
claimed in any of claims 11 to 13, a pharmacologically acceptable
salt thereof or a hydrate of them, wherein at least one of T.sup.b,
U.sup.b, V.sup.b, W.sup.b, X.sup.b and Y.sup.b is nitrogen
atom.
15. An integrin expression inhibitor comprising, as an active
ingredient, the sulfonamide-contain ng heterocyclic compound as
claimed in any of claims 11 to 14, a pharmacologically acceptable
salt thereof or a hydrate of them, wherein A.sup.b represents a
halogen atom, a C1-C4 alkyl group or alkoxy group which may be
substituted with a halogen atom, cyano group,
--(CO).sub.r.sup.bNR.sup.12bR.sup.13b (wherein R.sup.12b and
R.sup.13b are the same as or different from each other and each
represents hydrogen atom or a C1-C4 alkyl group which may be
substituted with a halogen atom; and r.sup.b means 0 or 1) or a
C2-C4 alkenyl or alkynyl group which may have a substituent.
16. An integrin expression inhibitor comprising, as an active
ingredient the sulfonamide-containing heterocyclic compound as
claimed in any of claims 11 to 15, a pharmacologically acceptable
salt thereof or a hydrate of them, wherein only one of T.sup.b,
U.sup.b, V.sup.b, W.sup.b, X.sup.b and Y.sup.b is nitrogen
atom.
17. An integrin expression inhibitor comprising, as an active
ingredient, the sulfonamide-containing heterocyclic compound as
claimed in any of claims 11 to 16, a pharmacologically acceptable
salt thereof or a hydrate of them, wherein only one of T.sup.b,
W.sup.b and Y.sup.b is nitrogen atom.
18. An integrin expression inhibitor comprising, as an active
ingredient, the sulfonamide compound as claimed in any of claims 5
to 17, a pharmacologically acceptable salt thereof or a hydrate of
them, wherein the integrin is integrin .alpha.2, .alpha.3, 5,
.alpha.6, .alpha.v, .beta.1, .beta.3, .beta.4 or .beta.5.
19. An integrin expression inhibitor comprising, as an active
ingredient, the sulfonamide compound as claimed in any of claims 5
to 17, a pharmacologically acceptable salt thereof or a hydrate of
them, wherein the integrin is integrin .alpha.2.beta.1,
.alpha.3.beta.1, .alpha.5.beta.1, .alpha.6.beta.1, .alpha.v.beta.1,
.alpha.v.beta.3 or .alpha.v.beta.5.
20. 1) An agent for treating arterial sclerosis, psoriasis, cancer,
retinal angiogensis, diabetic retinopathy or inflammatory diseases,
2) an anticoagulant, 3) a cancer metastasis suppressor or 4) an
antiangiogenic agent on the basis of an integrin expression
inhibitory action, which comprises, as an active ingredient, the
sulfonamide compound as claimed in any of claims 5 to 17, a
pharmacologically acceptable salt thereof or a hydrate of them.
21. 1) An agent for treating arterial sclerosis, psoriasis or
osteoporosis or 2) an anticoagulant on the basis of an integrin
expression inhibitory action, which comprises, as an active
ingredient, the sulfonamide compound as claimed in any of claims 5
to 17, a pharmacologically acceptable salt thereof or a hydrate of
them.
22. A method for preventing, treating or improving a disease
against which an integrin expression inhibition is effective, by
administering a pharmacologically effective dose of the compound as
claimed in any of claims 3, 5 and 11, a pharmacologically
acceptable salt thereof or a hydrate of them to a patient.
23. Use of the compound as claimed in any of claims 3, 5 and 11, a
pharmacologically acceptable salt of the compound or hydrate of
them, for producing an agent for preventing, treating or improving
a disease against which integrin expression inhibition is
effective.
Description
TECHNICAL FIELD
[0001] The present invention relates to an integrin expression
inhibitor, specifically, an integrin .alpha.2.beta.1,
.alpha.3.beta.1, .alpha.5.beta.1, .alpha.6.beta.1, .alpha.v.sym.1,
.alpha.v.beta.3 or .alpha.v.beta.5 expression inhibitor. Further it
relates to an angiogenesis agent, an anticoagulant, an anticancer
agent, a cancer metastasis suppressor, and an agent for treating
retinal angiogenesis, diabetic retinopathy, inflammatory diseases,
arterial sclerosis, psoriasis and osteoporosis, on the basis of
integrin expression inhibitory action.
PRIOR ART
[0002] Integrin structurally consists of a heterodimer in which two
types of sub-unit, namely, integrin .alpha. and integrin .beta. are
associated with each other by non-covalent binding. At least 16
types of .alpha. chains and 8 types of .beta. chains have been
found. A variety of molecular groups differing in ligand
specificity are formed by the combination of these .alpha. and
.beta. chains and 22 types of integrins have been known. Integrin
has a function as cell membrane receptor protein for an adhesive
molecule of an animal cell, expresses on a cell membrane and
participates in the adhesion between a cell and an extracellular
matrix (ECM) or between cells. When the cell adhesive molecule is
combined with integrin, a signaling system in a cell starts moving
and as a result, not only cell adhesion, but also cell evolution,
cell proliferation, apoptosis, differentiation, cytoskeleton
orientation, cell migration, histogenesis, cancer infiltration and
metastasis, wound healing, blood coagulation and the like operate.
It has been known that among these integrins, integrin
.alpha.2.beta.1 of which the adhesive molecules are collagen and
laminin participates in platelet aggregation, cancer infiltration
and metastasis (HAYASHI Masao & MIYAMOTO Yasunori, PROTEIN,
NUCLEIC ACID, ENZYME, Vol 44, pp130-135, (1999)) and angiogenesis
(Donald R. Senger et al, Proc. Natl. Acad. Sci. USA, 94,
13612-13617, (1997)). It has come to be clarified that among these
symptoms, the proliferation of cancer is closely related to
angiogenesis. In recent years, it has been demonstrated
experimentally that an antiangiogenesis agent can inhibit and
further reduce proliferative cancer and no resistant cancer is
generated in a transplant cancer model and there is shown a
correlation between angiogenesis and exacerbations of many solid
cancers such as mammary cancer, prostatic cancer, lung cancer and
colonic cancer in clinical examinations (T. Boem et al, Nature, 390
(27) 404-407, (1997)). Also, .alpha.v.beta.1 of which the adhesive
molecules are fibronectin and vitronectin participates in the
adhesion of a cancer cell to a substrate and .alpha.v.beta.3 of
which the adhesive molecules are vitronectin and thrombospongin and
.alpha.v.beta.5 of which the adhesive molecule is vitronectin
participate in angiogenesis, cancer metastasis and the regeneration
of bone (Shattil, S. J., Thromb. Haemost., 74, 149-155, (1995),
Friedlander M, et al, Sceience, 270, 1500-1502, (1995)). Further,
it has been known that .alpha.3.beta.1 of which the adhesive
molecules are fibronectin, collagen, laminin, laminin 5 and the
like, .alpha.5.beta.1 of which the adhesive molecule is fibronectin
and .alpha.6.beta.1 of which the adhesive molecules are laminin and
laminin 5 participate in cancer infiltration and metastasis
(MATSUURA Nariaki et al., JAPAN CLINIC, Vol 53, pp1643-1647,
(1995), OTA Ichiro et al, CLINICAL PATHOLOGY, Vol 45, 528-533,
(1997)).
[0003] WO9950249 discloses the antagonist of integrin
.alpha.v.beta.3, however there is no suggestion concerning the
expression inhibitory action of integrin .alpha.v.beta.3. In JP-A
7-165708 and JP-A 8-231505, the same sulfonamide compound as that
used in the present invention is disclosed; however, there is
neither description nor hint concerning integrin expression
inhibitory action. WO9301182 discloses-anti-tumor agents utilizing
a specific tyrosine kinase inhibitive action of a compound having
an indole skeleton. These agents are indolylmethylene-2-indolinone
compounds, which differ from that of the present invention.
WO964016 likewise discloses anti-tumor agents utilizing a specific
tyrosine kinase inhibitory action of a compound having an indole
skeleton. However, these agents are 2-indolinone-3-methylene
derivatives, which differ from that of the present invention.
[0004] An antiangiogenesis agent, an anticancer agent, a cancer
metastasis suppressor, an anticoagulant agent, and an agent for
treating arterial sclerosis, psoriasis, retinal angiogenesis,
diabetic retinopathy or inflammatory diseases on the basis of an
integrin expression inhibitory action have not been known so
far.
[0005] The present invention provides an agent for treating a
disease against which an integrin expression inhibitiory action is
effective. Specifically, it is an object of the present invention
to provide an antiangiogenic agent, an anticancer agent, a cancer
metastasis suppressor, an anticoagulant, and an agent for treating
arterial sclerosis, psoriasis, osteoporosis, retinal angiogenesis,
diabetic retinopathy or inflammatory diseases, which comprises, as
an active ingredient, a compound having an integrin expression
inhibitory action. Another object of the present invention is to
provide an integrin expression inhibitor comprising a sulfonamide
compound.
DISCLOSURE OF THE INVENTION
[0006] The present inventors have made earnest studies and as a
result, found that a sulfonamide compound having a bicyclic
heterocycle has an integrin expression inhibitory action. Thus,
they have completed the present invention.
[0007] Accordingly, the present invention relates to: 1. 1) an
agent for treating arterial sclerosis, psoriasis, cancer,
osteoporosis, retinal angiogenesis, diabetic retinopathy or
inflammatory diseases, 2) an anticoagulant, 3) a cancer metastasis
suppressor or 4) an antiangiogenic agent on the basis of an
integrin expression inhibitory action, 2. 1) the agent for treating
arterial sclerosis, psoriasis, cancer, osteoporosis, retinal
angiogenesis, diabetic retinopathy or inflammatory diseases, 2) an
anticoagulant, 3) a cancer metastasis suppressor or 4) an
antiangiogenic agent on the basis of integrin expression inhibitory
action as described in 1., wherein the integrin is integrin
.alpha.2, .alpha.3, .alpha.5, .alpha.6, .alpha.v, .beta.1, .beta.3,
.beta.4, .beta.5, .alpha.2.beta.1, .alpha.3.beta.1,
.alpha.5.beta.1, .alpha.6.beta.1, .alpha.v.beta.1, .alpha.v.beta.3
or .alpha.v.beta.5, 3. an integrin expression inhibitor comprising,
as an active ingredient, a sulfonamide compound represented by the
formula (I), a pharmacologically acceptable salt thereof or a
hydrate of them: 2
[0008] (in the formula, B represents a C6-C10 aryl ring or a 6- to
10-membered heteroaryl ring which may have a substituent and in
which a part of the ring may be saturated; K represents a single
bond, --CH.dbd.CH-- or --(CR.sup.4bR.sup.5b).sub.m.sup.b-- (where
R.sup.4b and R.sup.5b are the same as or different from each other
and each represents hydrogen atom or a C1-C4 alkyl group; and
m.sup.b means an integer of 1 or 2); R.sup.1 represents hydrogen
atom or a C1-C6 alkyl group; Z represents a single bond or
--CO--NH--; and R represents a C6-C10 aryl ring or a 6- to
10-membered heteroaryl ring which may have a substituent and in
which a part of the ring may be saturated, respectively), 4. an
integrin expression inhibitor comprising, as an active ingredient,
the sulfonamide compound as described in 3., a pharmacologically
acceptable salt thereof or a hydrate of them, wherein R is indole,
quinoline or isoquinoline, 5. an integrin expression inhibitor
comprising, as an active ingredient, a sulfonamide compound
represented by the formula (I.sup.a), a pharmacologically
acceptable salt thereof or a hydrate of them: 3
[0009] (in the formula, the A.sup.a ring a monocyclic or bicyclic
aromatic ring which may have a substituent; the B.sup.a ring
represents an optionally substituted 6-membered cyclic unsaturated
hydrocarbon or unsaturated 6-membered heterocycle containing one
nitrogen atom as a heteroatom; the C.sup.a ring represents an
optionally substituted 5-membered heterocycle containing 1 or 2
nitrogen atoms; R.sup.1a represents hydrogen atom or a C1-C6 alkyl
group; W.sup.a represents a single bond or --CH.dbd.CH--; Y.sup.a
represents carbon atom or nitrogen atom; and Z.sup.a represents
--N(R.sup.2a)-- (wherein R.sup.2a means hydrogen atom or a lower
alkyl group) or nitrogen atom, respectively), 6. an integrin
expression inhibitor comprising, as an active ingredient, the
sulfonamide compound as described in 5., a pharmacologically
acceptable salt thereof or a hydrate of them, wherein W.sup.a is a
single bond, 7. an integrin expression inhibitor comprising, as an
active ingredient, the sulfonamide compound as described in 5., a
pharmacologically acceptable salt thereof or a hydrate of them,
wherein W.sup.a is a single bond; Z.sup.a is --NH--; and Y.sup.a is
carbon atom, 8. the integrin expression inhibitor comprising, as an
active ingredient, a the sulfonamide compound as described in any
of 5., 6. and 7., a pharmacologically acceptable salt thereof or a
hydrate of them, wherein the B.sup.a ring is an optionally
substituted benzene or pyridine, 9. an integrin expression
inhibitor comprising, as an active ingredient, the sulfonamide
compound as described in any of 5. to 8., a pharmacologically
acceptable salt thereof or a hydrate of them, wherein the C.sup.a
ring is an optionally substituted pyrrole, 10. an integrin
expression inhibitor comprising, as an active ingredient, the
sulfonamide compound as described in 5., a pharmacologically
acceptable salt thereof or a hydrate of them, wherein the A.sup.a
ring is a benzene or pyridine which may have a substituent; the
B.sup.a ring is benzene which may have a substituent; the C.sup.a
ring is pyrrole which may have a substituent; W.sup.a is a single
bond; and Z.sup.a is --NH--, 11. an integrin expression inhibitor
comprising, as an active ingredient, a sulfonamide-containing
heterocyclic compound represented by the formula (I.sup.b), a
pharmacologically acceptable salt thereof or a hydrate of them:
4
[0010] (in the formula, A.sup.b represents hydrogen atom, a halogen
atom, hydroxyl group, a C1-C4 alkyl or alkoxy group which may be
substituted with a halogen atom, cyano group,
--(CO).sub.k.sup.bNR.sup.2bR.sup.3b (wherein R.sup.2b and R.sup.3b
are the same as or different from each other and each means
hydrogen atom or a C1-C4 alkyl group which may be substituted with
a halogen atom; and k.sup.b means 0 or 1), a C2-C4 alkenyl or
alkynyl group which may have a substituent, or a phenyl or phenoxy
group which may have a substituent selected from the following
group A; B.sup.b means an aryl group or monocyclic heteroaryl group
which may have a substituent selected from the following group A,
or the following formula: 5
[0011] (wherein the ring Q.sup.b means an aromatic ring which may
have one or two nitrogen atoms; and the ring M.sup.b means a C5-C12
unsaturated monocycle or heterocycle having a double bond in common
with the ring Q.sup.b. The ring may have 1 to 4 hetero atoms
selected from nitrogen atom, oxygen atom and sulfur atom, the ring
Q.sup.b and the ring M.sup.b may jointly have nitrogen atom, and
the ring Q.sup.b and the ring M.sup.b may have a substituent
selected from the following group A); K.sup.b means a single bond
or --(CR.sup.4bR.sup.5b)m.sup.b-- (wherein R.sup.4b and R.sup.5b
are the same as or different from each other and each means
hydrogen atom or a C1-C4 alkyl group; and m.sup.b means an integer
of 1 or 2); T.sup.b, W.sup.b, X.sup.b and Y.sup.b are the same as
or different from each other and each means=C(D.sup.b)--(wherein
D.sup.b represents hydrogen atom, a halogen atom, hydroxyl group, a
C1-C4 alkyl or alkoxy group which may be substituted with a halogen
atom, cyano group, --(CO).sub.n.sup.bNR.sup.6bR.sup.7b (wherein
R.sup.6b and R.sup.7b are the same as or different from each other
and each means hydrogen atom or a C1-C4 alkyl group which may be
substituted with a halogen atom; and n.sup.b means 0 or 1) or a
C2-C4 alkenyl or alkynyl group which may have a substituent,
respectively) or nitrogen atom; U.sup.b and V.sup.b are the same as
or different from each other and each means=C(D.sup.b)--(wher- ein
D.sup.b has the same meaning as above), nitrogen atom,
--CH.sub.2--, oxygen atom or --CO--; Z.sup.b means a single bond or
--CO--NH--; R.sup.1b means hydrogen atom or a C1-C4 alkyl group;
and means a single bond or a double bond.
[0012] Group A: a halogen atom, hydroxyl group, a C1-C4 alkyl or
alkoxy group which may be substituted with a halogen atom, cyano
group, --R.sup.8bR.sup.9bN(NH).sub.p.sup.b-- (wherein R.sup.8b and
R.sup.9b are the same as or different from each other and each
means hydrogen atom or a C1-C4 alkyl group which may be substituted
with a halogen atom; and p.sup.b means 0 or 1. Further, R.sup.8b
and R.sup.9b may form a 5- or 6-membered ring together with the
nitrogen atom to which they are bound, and the ring may further
contain nitrogen atom, oxygen atom or sulfur atom, and also may
have a substituent.), an aminosulfonyl group which may be
substituted with a mono- or di-C1-C4 alkyl group, a C1-C8 acyl
group which may have a substituent, a C1-C4
alkyl-S(O).sub.s.sup.b--C1-C4 alkylene group (wherein s.sup.b means
an integer of 0, 1 or 2), a phenylsulfonylamino group which may
have a C1-C4 alkyl or a substituent, --(CO).sub.q.sup.bNR10b
R.sup.11b (wherein R.sup.10b and R.sup.11b are the same as or
different from each other and each means hydrogen atom, or a C1-C4
alkyl group which may substituted with an amino group which may be
substituted with a halogen atom or a C1-C4 alkyl group; and q.sup.b
means 0 or 1), or an aryl group or heteroaryl group which may have
a substituent), 12. an integrin expression inhibitor comprising, as
an active ingredient, the sulfonamide-containing heterocyclic
compound as described in 11., a pharmacologically acceptable salt
thereof or a hydrogen of them, wherein U.sup.b and V.sup.b are
.dbd.C(D.sup.b)--(where- in D.sup.b has the same meaning as above)
or nitrogen atom, 13. an integrin expression inhibitor comprising,
as an active ingredient, the sulfonamide-containing heterocyclic
compound as described in 11. or 12., a pharmacologically acceptable
salt thereof or a hydrate of them, wherein Z.sup.b is a single
bond, 14. an integrin expression inhibitor comprising, as an active
ingredient, a sulfonamide-containing heterocyclic compound as
described in any of 11. to 13., a pharmacologically acceptable salt
thereof or a hydrate of them, wherein at least one of T.sup.b,
U.sup.b, V.sup.b, W.sup.b, X.sup.b and Y.sup.b is nitrogen atom,
15. an integrin expression inhibitor comprising, as an active
ingredient, the sulfonamide-containing heterocyclic compound as
described in any of 11. to 14., a pharmacologically acceptable salt
thereof or a hydrate of them, wherein A.sup.b represents a halogen
atom, a C1-C4 alkyl group or alkoxy group which may be substituted
with a halogen atom, cyano group,
--(CO).sub.r.sup.bNR.sup.12bR.sup.13b (wherein R.sup.12b and
R.sup.13b are the same as or different from each other and each
represents hydrogen atom or a C1-C4 alkyl group which may be
substituted with a halogen atom; and r.sup.b means 0 or 1) or a
C2-C4 alkenyl or alkynyl group which may have a substituent, 16. an
integrin expression inhibitor comprising, as an active ingredient,
the sulfonamide-containing heterocyclic compound as described in
any of 11. to 15., a pharmacologically acceptable salt thereof or a
hydrate of them, wherein only one of T.sup.b, U.sup.b, V.sup.b,
W.sup.b, X.sup.b and Y.sup.b is nitrogen atom, 17. an integrin
expression inhibitor comprising, as an active ingredient, the
sulfonamide-containing heterocyclic compound as described in any of
11. to 16., a pharmacologically acceptable salt thereof or a
hydrate of them, wherein only one of T.sup.b, W.sup.b and y.sup.b
is nitrogen atom, 18. an integrin expression inhibitor comprising,
as an active ingredient, the sulfonamide compound as described in
any of 5. to 17., a pharmacologically acceptable salt thereof or a
hydrate of them, wherein the integrin is integrin .alpha.2,
.alpha.3, .alpha.5, .alpha.6, .alpha.v, .beta.1, .beta.3, .beta.4
or .beta.5, 19. an integrin expression inhibitor comprising, as an
active ingredient, the sulfonamide compound as described in any of
5. to 17., a pharmacologically acceptable salt thereof or a hydrate
of them, wherein the integrin is integrin .alpha.2.beta.1,
.alpha.3.beta.1, .alpha.5.beta.1, .alpha.6.beta.1, .alpha.v.sym.1,
.alpha.v.beta.3 or .alpha.v.beta.5, 20. 1) an agent for treating
arterial sclerosis, psoriasis, cancer, retinal angiogensis,
diabetic retinopathy or inflammatory diseases, 2) an anticoagulant,
3) a cancer metastasis suppressor or 4) an antiangiogenic agent on
the basis of an integrin expression inhibitory action, which
comprises, as an active ingredient, the sulfonamide compound as
described in any of 5. to 17., a pharmacologically acceptable salt
thereof or a hydrate of them, and 21. 1) an agent for treating
arterial sclerosis, psoriasis or osteoporosis or 2) an
anticoagulant on the basis of an integrin expression inhibitory
action, which comprises, as an active ingredient, the sulfonamide
compound as described in any of 5. to 17., a pharmacologically
acceptable salt thereof or a hydrate of them.
[0013] The present invention provides a method for preventing,
treating or improving a disease against which an integrin
expression inhibition is effective, by administering a
pharmacologically effective dose of the compound represented by any
of formulae (I), (Ia) and (Ib), a pharmacologically acceptable salt
thereof or a hydrate of them to a patient.
[0014] Further, the present invention provides use of the compound
represented by any of formulae (I), (Ia) and (Ib), a
pharmacologically acceptable salt of the compound or hydrate of
them, for producing an agent for preventing, treating or improving
a disease against which integrin expression inhibition is
effective.
[0015] In the present invention, the diseases against which
integrin expression inhibition is effective include arterial
sclerosis, psoriasis, cancer, osteoporosis, retinal angiogenesis,
diabetic retinopathy and inflammatory diseases.
[0016] Also, in the present invention, the agent for preventing,
treating or improving a disease against which an integrin
expression inhibition is effective includes an agent for treating
arterial sclerosis, psoriasis, cancer, osteoporosis, retinal
angiogenesis, diabetic retinopathy or inflammatory diseases, an
anticoagulant agent, a cancer metastasis suppressor and an
antiangiogenesis agent.
[0017] The present invention will be hereinafter explained in
detail.
[0018] In B and R, the C6-C10 aryl ring or 6-membered to
10-membered heteroaryl ring which may have a substituent and in
which a part of the ring may be saturated means an aromatic
hydrocarbon group having 6 to 10 carbon atoms or a 6-membered to
10-membered aromatic heterocycle containing at least one atom among
nitrogen atom, oxygen atom and sulfur atom as a heteroatom, and may
have one or more substituents on the ring and a part of the ring
may be saturated. Specific examples thereof include benzene,
pyridine, pyrimidine, pyrazine, pyridazine, naphthalene, quinoline,
isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline,
cinnoline, indole, isoindole, indolizine, indazole, benzofuran,
benzothiophene, benzoxazole, benzimidazole, benzopyrazole,
benzothiazole, 4,5,6,7-tetrahydroindole,
1,2,3,4-tetrahydroisoquinoline, 2,3-dihydrobenzofuran, indane,
tetralone, indoline, isoindoline, chroman and tetralin. The
above-mentioned aromatic ring may have 1 to 3 substituents. In the
case where plural substituents are present, these substituents may
be the same or different. Examples of the substituent may include
an amino group which may be substituted with a lower alkyl group or
lower cycloalkyl group, a lower alkyl group, a lower alkoxy group,
hydroxyl group, nitro group, mercapto group, cyano group, a lower
alkylthio group, a halogen group, a group represented by the
formula -a.sup.a-b.sup.a (wherein a.sup.a means a single bond,
--(CH.sub.2).sub.k.sup.a--, --O--(CH.sub.2).sub.k.sup.a--,
--S--(CH.sub.2).sub.k.sup.a-- or
--N(R.sup.3a)--(CH.sub.2).sub.k.sup.a-- (wherein k.sup.a means an
integer of 1 to 5; and R.sup.3a means hydrogen atom or a lower
alkyl group); and b.sup.a means --CH.sub.2-d.sup.a (wherein d.sup.a
means an amino group which may be substituted with a lower alkyl
group, a halogen atom, hydroxyl group, a lower alkylthio group,
cyano group or lower alkoxy group)), a group represented by the
formula -a.sup.a-e.sup.a-f.sup.a (wherein a.sup.a has the same
meaning as above; e.sup.a means --S(O)-- or --S(O).sub.2--; and
f.sup.a means an amino group which may be substituted with a lower
alkyl group or lower alkoxy group, a lower alkyl group,
trifluoromethyl group, --(CH.sub.2).sub.m.sup.a-b.sup.a or
--N(R.sup.4a)--(CH.sub.2).sub.m.sup.a- -b.sup.a (wherein b.sup.a
has the same meaning as above; R.sup.4a means hydrogen atom or a
lower alkyl group; and m.sup.a means an integer from 1 to 5)), a
group represented by the formula -a.sup.a-g.sup.a-h.sup.a (wherein
a.sup.a has the same meaning as above; g.sup.a means --C(O)-- or
--C(S)--; and h.sup.a means an amino group which may be substituted
with a lower alkyl group, hydroxyl group, a lower alkyl group, a
lower alkoxy group, --(CH.sub.2).sub.n.sup.a-b.sup.a or
--N(R.sup.5a)--(CH.sub.2).sub.- n.sup.a-b.sup.a (wherein b.sup.a
has the same meaning as above; R.sup.5a means hydrogen atom or a
lower alkyl group; and n.sup.a means an integer from 1 to 5)), a
group represented by the formula -a.sup.a-N(R.sup.6a)-g.-
sup.a-i.sup.a (wherein a.sup.a and g.sup.a have the same meanings
as above; R.sup.6a means hydrogen atom or a lower alkyl group;
i.sup.a means hydrogen atom, a lower alkoxy group or f.sup.a
(f.sup.a has the same meaning as above)), a group represented by
the formula -a.sup.a-N(R.sup.7a)-e.sup.a-f.sup.a (wherein a.sup.a,
e.sup.a and f.sup.a have the same meanings as above; R.sup.7a means
hydrogen atom or a lower alkyl group), the formula
--(CH.sub.2).sub.p.sup.a-j.sup.a-(CH.su- b.2).sub.q.sup.a-b.sup.a
(wherein j.sup.a means oxygen atom or a sulfur atom; b.sup.a has
the same meaning as above; and p.sup.a and q.sup.a are the same as
or different from each other and each means an integer from 1 to
5), the formula --(CH.sub.2).sub.u.sup.a-Ar.sup.a (wherein Ar.sup.a
means a phenyl group or heteroaryl group which may be substituted
with a lower alkyl group, lower alkoxy group or halogen atom; and
u.sup.a means 0 or an integer from 1 to 5), the formula
--CONH--(CH.sub.2).sub.u.sup.a-- Ar.sup.a (wherein Ar.sup.a and
u.sup.a have the same meanings as above) or a group represented by
the formula --SO.sub.2--(CH.sub.2).sub.u.sup.a-Ar.- sup.a (wherein
Ar.sup.a and u.sup.a have the same meanings as above).
[0019] Compounds represented by the formula (I), in which R is
indole, quinoline or isoquinoline, are preferable.
[0020] In the formula (I.sup.a), the "monocyclic or bicyclic
aromatic ring which may have a substituent" represented by the
A.sup.a ring is an aromatic hydrocarbon or an aromatic heterocycle
containing at least one of nitrogen atom, oxygen atom and sulfur
atom, wherein 1 to 3 substituents may exist on the ring. Examples
of main aromatic rings contained in the A.sup.a ring include
pyrrole, pyrazole, imidazole, thiophene, furan, thiazole, oxazole,
benzene, pyridine, pyrimidine, pyrazine, pyridazine, naphthalene,
quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline,
quinazoline, cinnoline, indole, isoindole, indolizine, indazole,
benzofuran, benzothiophene, benzoxazole, benzimidazole,
benzopyrazole and benzothiazole. The above-mentioned aromatic ring
may have 1 to 3 substituents. When plural substituents are present,
these substituents may be the same or different. Examples of the
substituent may include an amino group which may be substituted
with a lower alkyl group or a lower cycloalkyl group, lower alkyl
group, lower alkoxy group, hydroxyl group, nitro group, mercapto
group, cyano group, lower alkylthio group, halogen group, a group
represented by the formula -a.sup.a-b.sup.a (wherein a.sup.a means
a single bond, --(CH.sub.2).sub.k.sup.a--,
--O--(CH.sub.2).sub.k.sup.a--, --S--(CH.sub.2).sub.k.sup.a-- or
--N(R.sup.3a)--(CH.sub.2).sub.k.sup.a--; k.sup.a means an integer
of 1 to 5; R.sup.3a means hydrogen atom or a lower alkyl group; and
ba represents --CH.sub.2-d.sup.a (where d.sup.a means an amino
group which may be substituted with a lower alkyl group, a halogen
atom, hydroxyl group, a lower alkylthio group, cyano group or a
lower alkoxy group)), a group represented by the formula
-a.sup.a-e.sup.a-f.sup.a (wherein a.sup.a has the same meaning as
above; e.sup.a means --S(O)-- or --S(O).sub.2--; f.sup.a means an
amino group which may be substituted with a lower alkyl group or
lower alkoxy group, a lower alkyl group, trifluoromethyl group,
--(CH.sub.2).sub.m.sup.a-b.su- p.a or
--N(R.sup.4a)--(CH.sub.2).sub.m.sup.a-b.sup.a (wherein b.sup.a has
the same meaning as above; R.sup.4a means hydrogen atom or a lower
alkyl group; and m.sup.a means an integer from 1 to 5)), a group
represented by the formula -a.sup.a-g.sup.a-h.sup.a (wherein
a.sup.a has the same meaning as above; g.sup.a means --C(O)-- or
--C(S)--; h.sup.a means an amino group which may be substituted
with a lower alkyl group, hydroxyl group, a lower alkyl group, a
lower alkoxy group, --(CH.sub.2).sub.n.sup.- a-b.sup.a or
--N(R.sup.5a)--(CH.sub.2).sub.n.sup.a-b.sup.a (wherein b.sup.a has
the same meaning as above; R.sup.5a means hydrogen atom or a lower
alkyl group; and n.sup.a means an integer from 1 to 5)), a group
represented by the formula -a.sup.a-N(R.sup.6a)-g.sup.a-i.sup.a
(wherein a.sup.a and g.sup.a have the same meanings as above;
R.sup.6a means hydrogen atom or a lower alkyl group; and i.sup.a
means hydrogen atom, a lower alkoxy group or f.sup.a (f.sup.a has
the same meaning as above)), a group represented by the formula
-a.sup.a-N(R.sup.7a)-e.sup.a-f.sup.a (wherein a.sup.a, e.sup.a and
f.sup.a have the same meanings as above; and R.sup.7a means
hydrogen atom or a lower alkyl group), the formula
--(CH.sub.2).sub.p.sup.a-j.sup.a-(CH.sub.2).sub.q.sup.a-b.sup.a
(wherein j.sup.a means oxygen atom or sulfur atom; b.sup.a has the
same meaning as above; and p.sup.a and q.sup.a are the same as or
different from each other and each means an integer from 1 to 5),
the formula --(CH.sub.2).sub.u.sup.a-Ar.sup.a (wherein Ar.sup.a
means a phenyl group or heteroaryl group which may be substituted
with a lower alkyl group, lower alkoxy group or halogen atom; and
u.sup.a means 0 or an integer from 1 to 5), the formula
--CONH--(CH.sub.2).sub.u.sup.a-Ar.sup.a (wherein Ar.sup.a and
u.sup.a have the same meanings as above) or a group represented by
the formula --SO.sub.2--(CH.sub.2).sub.u.sup.a-Ar.sup.a (wherein
Ar.sup.a and u.sup.a have the same meanings as above).
[0021] In the aforementioned examples of the substituent, when the
amino group is substituted with two alkyl groups, these alkyl
groups may be bound together to form a 5- to 6-membered ring.
Further, in the case where the A.sup.a ring is a
nitrogen-containing heterocycle having hydroxyl group or mercapto
group, the A.sup.a ring may have the form of an oxo group or thioxo
group by allowing these groups to form a resonance structure.
[0022] The "6-membered cyclic unsaturated hydrocarbon or the
unsaturated six-membered heterocycle which contains one nitrogen
atom as a heteroatom, which may have a substituent" represented by
the B.sup.a ring is a benzene or pyridine a part of which may be
hydrogenated and may have one or two substituents on the ring. When
two substituents are present, these substituents may be the same or
different.
[0023] The "five-membered heterocycle which may have a substituent
and contains one or two nitrogen atoms" represented by the C.sup.a
ring is pyrrole, pyrazole or imidazole a part of which may be
hydrogenated and may have one or two substituents on the ring. When
two substituents are present, these substituents may be the same or
different.
[0024] Examples of the substituent which the B.sup.a ring and the
C.sup.a ring may have may include a halogen group, cyano group, a
lower alkyl group, a lower alkoxy group, hydroxyl group, oxo group,
the formula --C(O)-r.sup.a (wherein r.sup.a means hydrogen atom, an
amino group which may be substituted with a lower alkyl group, a
lower alkyl group, a lower alkoxy group or hydroxyl group), an
amino group which may be substituted with a lower alkyl group and
trifluoromethyl group.
[0025] Examples of the lower alkyl group in the definiteion of the
substituent which R.sup.1a, R.sup.2a, and the A.sup.a, B.sup.a and
C.sup.a rings may have in the above formula (I.sup.a) mean a linear
or branched alkyl group having 1 to 6 carbon atoms, for example,
methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl
group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl
group (amyl group), isopentyl group, neopentyl group, tert-pentyl
group, 1-methylbutyl group, 2-methylbutyl group, 1,2-dimethylpropyl
group, n-hexyl group, isohexyl group, 1-methylpentyl group,
2-methylpentyl group, 3-methylpentyl group, 1,1-dimethylbutyl
group, 1,2-dimethylbutyl group, 2,2-dimethylbutyl group,
1,3-dimethylbutyl group, 2,3-dimethylbutyl group, 3,3-dimethylbutyl
group, 1-ethylbutyl group, 2-ethylbutyl group,
1,1,2-trimethylpropyl group, 1,2,2-trimethylpropyl group,
1-ethyl-1-methylpropyl group and 1-ethyl-2-methylpropyl group. As
preferable groups among these groups, methyl group, ethyl group,
n-propyl group, isopropyl group, n-butyl group and isobutyl group
may be proposed. Among these preferable groups, methyl group, ethyl
group, n-propyl group and isopropyl group are most preferable
groups.
[0026] Examples of the lower cycloalkyl group in the definiteion of
the substituent which the Aa ring may have include a cyclopropyl
group, cyclopentyl group and cyclohexyl group.
[0027] The lower alkoxy group in the definiteion of the substituent
which the A.sup.a ring, the B.sup.a ring and the C.sup.a ring may
have means a lower alkoxy groups derived from the above-mentioned
lower alkyl groups such as methoxy group, ethoxy group, n-propoxy
group, isopropoxy group, n-butoxy group, isobutoxy group and
tert-butoxy group. Among these groups, methoxy group and ethoxy
group may be given as most preferable examples. Also, examples of
the halogen atom include fluorine atom, chlorine atom and bromine
atom.
[0028] Among these substituents, particularly preferable examples
include 1)
N-(3-cyano-4-methyl-1H-indole-7-yl)-3-cyanobenzenesulfonamide; 2)
N-(3-cyano-4-methyl-1H-indole-7-yl)-6-chloro-3-pyridinesulfonamide;
3)
N-(3-bromo-5-methyl-1H-indole-7-yl)-4-sulfamoylbenzenesulfonamide;
4)
N-(5-bromo-3-chloro-1H-indole-7-yl)-6-amino-3-pyridinesulfonamide;
5) N-(3-bromo-5-methyl-1H-indole-7-yl)-3-cyanobenzenesulfonamide;
6) N-(4-bromo-1H-indole-7-yl)-4-cyanobenzenesulfonamide; 7)
N-(4-chloro-1H-indole-7-yl)-6-amino-3-pyridinesulfonamide; 8)
N-(3-bromo-4-chloro-1H-indole-7-yl)-6-amino-3-pyridinesulfonamide;
9)
N-(3-bromo-5-methyl-1H-indole-7-yl)-5-cyano-2-thiophenesulfonamide;
10)
N-(4-bromo-3-chloro-1H-indole-7-yl)-2-amino-5-pyrimidinesulfonamide;
and 11)
N-(3-chloro-1H-indole-7-yl)-4-sulfamoylbenzenesulfonamide.
[0029] There is the case where the sulfonamide derivative
represented by the above formula (I.sup.a) forms a salt in
combination with an acid or a base. The present invention also
involves salts of the compound (I.sup.a). Examples of the salt of
an acid include inorganic acid salts such as hydrochloride,
hydrobromide and sulfate, and salts of organic acids such as acetic
acid, lactic acid, succinic acid, fumaric acid, maleic acid, citric
acid, benzoic acid, methanesulfonic acid and p-toluenesulfonic
acid. Examples of the salt of a base may include inorganic salts
such as sodium salts, potassium salts and calcium salts and salts
of organic bases such as triethylamine, arginine and lysine.
[0030] In the present invention, the "aromatic ring which may have
one or two nitrogen atoms" represented by the ring Q.sup.b means an
aromatic hydrocarbon or a 6-membered aromatic heterocycle having
one or two nitrogen atoms. Examples of primary aromatic rings
included in the ring Q.sup.b include benzene, pyridine, pyrimidine,
pyrazine and pyridazine. Also, the ring M represented by the term
"means a C5-C12 unsaturated monocycle or multi-cycle, which may
have 1 to s4 heteroatoms selected from nitrogen atom, oxygen atom
and sulfur atom" means a monocycle or a multi-cycle having a double
bond together with the ring Q.sup.b and specifically means aromatic
hydrocarbons such as benzene and naphthalene, unsaturated
hydrocarbons such as cyclopentene, cyclohexene, cycloheptene,
cyclooctene, cyclopentadiene, cycloheptadiene and cyclooctadiene,
and unsaturated heterocycles such as tetrahydropyridine, pyrrole,
furan, thiophene, oxazole, isoxazole, thiazole, isothiazole,
pyrazole, imidazole, triazole, pyridine, pyrimidine, pyrazine,
pyridazine, triazine, indole, isoindole, quinoline, isoquinoline,
indazolizine, naphthyridine, benzofuran, benzopyran,
benzothiophene, benzimidazole benzoxazole, benzothiazole,
pyrrolopyridine, pyridopyrimidine and imidazopyridine. Also, the
term "the ring Q.sup.b possesses one nitrogen atom together with
the ring M.sup.b" means the case where the nitrogen atom is present
at the position where both rings are condensed. Examples of the
ring formed in this manner include indazolizine,
imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine and
pyrazolo[1,5-a]pyrimidine.
[0031] In the present invention, the C1-C4 alkyl group in R.sup.1b,
R.sup.4b and R.sup.5b or in the "C1-C4 alkyl group which may be
substituted with a halogen atom" in A.sup.b, D.sup.b, R.sup.1b,
R.sup.2b, R.sup.3b, R.sup.6b, R.sup.7b, R.sup.8b, R.sup.9b,
R.sup.10b, R.sup.11b, R.sup.12b, R.sup.13b, R.sup.14b, R.sup.15b,
G.sup.1b, G.sup.2b and the A group means a linear or branched alkyl
group having 1 to 4 carbons atoms. For example, methyl group, ethyl
group, n-propyl group, isopropyl group, n-butyl group, isobutyl
group, sec-butyl group and tert-butyl group may be proposed. The
term "may be substituted with a halogen atom" means that the alkyl
group may be substituted with a halogen atom selected from fluorine
atom, chlorine atom, bromine atom and iodine atom. For example,
monofluoromethyl group, monochloromethyl group, difluoromethyl
group, trifluoromethyl group, 1- or 2-monofluoromethyl group, 1- or
2-monochloroethyl group, 1- or 2-monobromoethyl group,
1,2-difluoroethyl group, 1,2-dichloroethyl group,
1,1,2,2,2-pentafluoroethyl group and 3,3,3-trifluoropropyl group
may be proposed. Preferable examples among these groups include
monofluoromethyl group, difluoromethyl group, trifluoromethyl
group, 1- or 2-monofluoroethyl group, 1,2-difluoroethyl group and
1,1,2,2,2-pentafluoroethyl group.
[0032] In the present invention, the C1-C4 alkoxy group in the
"C1-C4 alkoxy group which may be substituted with a halogen atom"
in A.sup.a, D.sup.b and the group A means a linear or branched
alkoxy group having 1 to 4 carbon atoms. For example, methoxy
group, ethoxy group, n-propyloxy group, isopropyloxy group,
n-butyloxy group, isobutyloxy group, sec-butyloxy group and
tert-butyloxy group may be proposed. The term "may be substituted
with a halogen atom" means that the alkoxy group may be substituted
with a halogen atom selected from fluorine atom, chlorine atom,
bromine atom and iodine atom. For example, monofluoromethoxy group,
difluoromethoxy group, trifluoromethoxy group, 1- or
2-monofluoroethoxy group, 1- or 2-monochloroethoxy group, 1- or
2-monobromoethoxy group, 1,2-difluoroethoxy group,
1,1,2,2,2-pentafluoroethoxy group and 3,3,3-trifluoropropyloxy
group may be proposed. Among these groups, preferable examples
include monofluoromethoxy group, difluoromethoxy group,
trifluoromethoxy group, 1- or 2-monofluoroethoxy group,
1,2-difluoroethoxy group and 1,1,2,2,2-pentafluoroethoxy group.
[0033] In the present invention, the C2-C4 alkenyl or alkynyl group
appeared in A.sup.b and D.sup.b means an alkenyl or alkynyl group
having 2 to 4 carbon atoms. For example, vinyl group, allyl group,
2- or 3-butenyl group, 1,3-butadienyl group, ethynyl group,
2-propynyl group, 2-methylethynyl group and 2- or 3-butynyl group
may be proposed.
[0034] In the present invention, the aryl group appeared in B.sup.b
and the group A means an aromatic hydrocarbon, and phenyl group and
naphthyl group may be exemplified. Also, the heteroaryl group means
a monocycle or multi-cycle having one or two or more of nitrogen
atom, oxygen atom and sulfur atom. For example, pyrrolyl,
imidazolyl group, pyrazolyl group, triazolyl group, furyl group,
thienyl group, oxazolyl group, isoxazolyl group, thiazolyl group,
isothiazolyl group, thiadiazolyl group, pyridyl group, pyrimidyl
group, pyrazyl group, indolyl group, indolizinyl group,
benzoimidazolyl group, benzothiazolyl group, benzoxazolyl group,
quinolinyl group, isoquinolinyl group, quinazolinyl group and
phthalazinyl group may be proposed.
[0035] In the present invention, the term "R.sup.8b and R.sup.9b
may form a 5- or 6-membered ring together with the nitrogen atom to
which they are bound, and the ring may further contain nitrogen
atom, oxygen atom or sulfur atom" in the definition of R.sup.8b and
R.sup.9b means that R.sup.8b and R.sup.9b form pyrrolidinyl group,
piperidinyl group, morpholino group, thiomorpholino group,
piperazinyl group etc. together with the nitrogen atom to which
they are bound.
[0036] In the present invention, the aminosulfonyl group which may
be substituted with a mono- or di-C1-C4 alkyl group, C1-C4
alkyl-S(O).sub.a.sup.b-C1-C4-alkylene group, or phenylsulfonylamino
group which may have a C1-C4 alkyl group or a substituent and a
C1-C4 alkyl group which may be substituted with a C1-C4 alkyl group
in the defineition of A group means the same alkyl group as above,
and examples of the alkylene group may include methylene group,
ethylene group, propylene group, butylene group, methylmethylene
group, 1- or 2-methylethylene group, 1-, 2- or 3-methylpropylene
group and dimethylmethylene group.
[0037] Also, the C1-C8 alkanoyl group means, for example, formyl
group, acetyl group, propionyl group, butyryl group, isobutyryl
group, valeryl group and benzoyl group.
[0038] The protective group in the term "an amino group which may
have a protective group" appeared in J.sup.b of the present
invention may be any group as far as it is known as a protective
group in the usual organic synthesis and no particular limitation
is imposed on the protective group. For example, benzyloxycarbonyl
group, t-butoxycarbonyl group, formyl group, acetyl group,
chloroacetyl group, 2,2,2-trichloroethyl group, benzylidene group,
benzhydryl group and trityl group may be proposed. Also, the
protective group in the carboxy group which may have a protective
group and the protective group of the carboxy group in R.sup.16b
may be any group as far as it is known as a protective group in the
usual organic synthesis and no particular limitation is imposed on
the protective group. For example, methyl group, ethyl group,
propyl group, isopropyl group, t-butyl group, methoxymethyl group,
2,2,2-trichloroethyl group, pivaloyloxymethyl group and benzyl
group may be proposed.
[0039] In the present invention, the substituent in the term "may
have a substituent" means the above-mentioned halogen atom, C1-C4
alkyl group or alkoxy group which may be substituted with a halogen
atom, hydroxyl group, hydroxy C1-C4 alkyl group, amino group which
may be substituted with a mono- or di-C1-C4 alkyl group, C2-C4
alkenyl or alkynyl group, cyano group, C1-C8 acyl group,
aminosulfonyl group which may be substituted with a mono or di
C1-C4 alkyl group, carboxy group, C1-C4 alkoxycarbonyl group and
carbamoyl group which may be substituted with a mono- or di-C1-C4
alkyl group.
[0040] The sulfonamide-containing heterocyclic compound represented
by the above formula (I.sup.b) occasionally forms a salt in
combination with an acid or a base. The present invention also
includes salts of the compound (I.sup.b). Examples of the salt of
an acid include inorganic acid salts such as hydrochloride,
hydrobromide and sulfate and salts of organic acids such as acetic
acid, lactic acid, succinic acid, fumaric acid, maleic acid, citric
acid, benzoic acid, methanesulfonic acid and p-toluenesulfonic
acid. Also, as the salt of a base, inorganic salts such as sodium
salts, potassium salts and calcium salts and salts of organic bases
such as triethylamine, arginine and lysine may be given.
[0041] Also, it is needless to say that as well as hydrates of
these compounds, optical isomers, if these isomers are present, are
included in the present invention. The present invention also
includes compounds showing an antiangiogenesis action and produced
from the present compound following in vivo metabolism such as
oxidation, reduction, hydrolysis and conjugation. Also, the present
invention further includes compounds producing the compound of the
present invention following in vivo metabolism such as oxidation,
reduction and hydrolysis.
[0042] The compound (I.sup.a) according to the present invention
can be produced by various methods. For example, several methods
among these methods are specifically disclosed in the publications
of JP-A 7-165708 and JP-A 8-231505.
[0043] As aforementioned, the compound (I.sup.a) of the present
invention may be produced using various methods. Among these
methods, typical methods are shown as follows.
[0044] 1) It May be Produced by Reacting a Sulfonic Acid
Represented by the Formula (II.sup.a): 6
[0045] (wherein the Aa.sup.a ring represents a monocyclic or
bicyclic aromatic ring which may have a protected or unprotected
substituent; and W.sup.a has the same meaning as above) or its
reactive derivative with a compound represented by the formula
(III.sup.a): 7
[0046] wherein the Ba.sup.a ring represents a 6-membered
unsaturated hydrocarbon or unsaturated 6-membered heterocycle which
contains on nitrogen atom as a heteroatom, which may have a
protected or unprotected substituent; the Ca.sup.a ring a
5-membered ring which may have a protected or unprotected
substituent and contains one or two nitrogen atoms; and X.sup.a,
Y.sup.a and Z.sup.a have the same meanings as above.
[0047] Examples of the reactive derivative of the sulfonic acid
(II.sup.a) may include reactive derivatives usually used frequently
such as sulfonyl halides, sulfonic acid anhydrides and
N-sulfonylimidazolides. Particularly preferable examples are
sulfonyl halides. Although no particular limitation is imposed on
the solvent used in the reaction, it is desirable to use a solvent
which dissolves raw materials and does not react with these raw
materials with ease. For example, pyridine, tetrahydrofuran,
dioxane, benzene, ethyl ether, dichloromethane and
dimethylformamide, or a mixed solvent using two or more solvents
selected from these solvents may be utilized. Also, in the
reaction, in the case where a free acid appears with the progress
of the reaction as shown in the case of using a sulfonyl halide,
the reaction is preferably run in the presence of a proper
deoxidizer. Therefore, the use of a basic solvent such as pyridine
is particularly preferable. When a neutral solvent is used, a basic
substance such as an alkali carbonate and an organic tertiary amine
may be added. It is needless to say that usable solvents are not
limited to these exemplified solvents. Although the reaction
generally proceeds at room temperature, the raw materials may be
cooled or heated according to the need. The reaction time is
generally 10 minutes to 20 hours but is selected according to the
type of raw material and the reaction temperature.
[0048] In the case where the amino group or the hydroxyl group is
protected in the resulting product, a sulfonamide derivative or
sulfonate derivative (I.sup.a) having a free hydroxyl group or
amino group can be obtained by a usual deprotecting method such as
acid treatment, alkali treatment and catalytic reduction, as
required.
[0049] 2) It May be Produced by Reacting a Compound Represented by
the Formula (IV.sup.a): 8
[0050] (wherein the Aa.sup.a ring, the Ba.sup.a ring, W.sup.a,
X.sup.a and Z.sup.a have the same meanings as above) with a
halogenating agent. As the halogenating agent, N-chlorosuccinimide,
N-bromosuccinimide, 1,3-dibromo-5,5-dimethylhydantoin,
N-bromoacetamide, chlorine and bromine may be proposed. Although no
particular limitation is imposed on the solvent to be used in the
reaction, an alkyl chloride compound such as dichloromethane,
chloroform and carbon tetrachloride, or an aromatic chloride such
as chlorobenzene and dichlorobenzene is generally used, and a
water-soluble solvent such as dimethylformamide, dioxane, pyridine
and acetonitrile may be also used. Although the reaction
temperature differs depending on the types of halogenating agent
and substrate, it is usually run at -50.degree. C. to 100.degree.
C.
[0051] In the case where the amino group or the hydroxyl group is
protected in the resulting product, a sulfonamide derivative or
sulfonate derivative (I.sup.a) having a free hydroxyl group or
amino group can be obtained by a usual deprotecting method such as
acid treatment, alkali treatment and catalytic reduction, as
required.
[0052] 3) It May be Produced by Reacting a Compound Represented by
the Formula (V.sup.a): 9
[0053] (wherein the Aa.sup.a ring, the Ba.sup.a ring, W.sup.a,
X.sup.a and Z.sup.a have the same meanings as above; and E.sup.a
represents a substituent convertible into cyano group by
dehydration) with a dehydrating agent. As the substituent
convertible into cyano group by dehydration, (hydroxyimino) methyl
group and carbamoyl group may be proposed.
[0054] Also, it is possible that an oxime or an acid amide is first
synthesized from an aldehyde or a carboxylic acid used as a
starting material and then reacted with a dehydrating agent without
isolating it. As examples of the dehydrating agent, those used in a
usual method of synthesizing nitrile, for example, acetic acid
anhydride, thionyl chloride, phosphorous oxychloride, selenium
dioxide and 1,3-dicyclohexylcarbodiimide may be given. Although no
particular limitation is imposed on the solvent to be used in the
reaction, those which do not react with these materials with ease
is desirable, for example pyridine, ethyl ether, benzene,
dimethylformamide, carbon tetrachloride, acetonitrile and
tetrahydrofuran, or a mixed solvent of two or more solvents
selected from these solvents may be utilized. Although the reaction
temperature differs depending on the types of dehydrating agent and
substrate, the reaction is usually run at -50.degree. C. to
150.degree. C.
[0055] In the case where the amino group or the hydroxyl group is
protected in the resulting product, a sulfonamide derivative or
sulfonate derivative (I.sup.a) having a free hydroxyl group or
amino group can be obtained using a usual deprotecting method such
as acid treatment, alkali treatment and catalytic reduction, as
required.
[0056] 4) It May be Produced by Reacting a Compound Represented by
the Formula (VI.sup.a): 10
[0057] (wherein the Ab.sup.a ring represents a monocyclic or
bicyclic aromatic ring which has a substituent convertible into
amino group by reduction and may also have a protected or
unprotected substituent; and the Ba.sup.a ring, the Ca.sup.a ring,
W.sup.a, X.sup.a, Y.sup.a and Z.sup.a have the same meanings as
above) with a reducing agent. As the substituent convertible into
amino group by reduction, nitro group, nitroso group, hydroxyamino
group and azo group may be exemplified.
[0058] A nitro group-reducing method which is commonly examples of
the reducing method, catalytic reduction using, as a catalyst,
palladium-carbon and platinum oxide and reduction using zinc, iron
or tin with an acid may be given. The catalytic reduction may be
usually carried out under normal pressure or under pressure in an
organic solvent such as methanol, tetrahydrofuran or
dimethylformamide.
[0059] In the case where the hydroxyl group is protected in the
resulting product, a sulfonamide derivative or sulfonate derivative
(I.sup.a) having a free hydroxyl group can be obtained using a
usual deprotecting method such as acid treatment, alkali treatment
and catalytic reduction, as required.
[0060] 5) It May be Produced by Reacting a Compound Represented by
the Formula (VII.sup.a): 11
[0061] (wherein the Ac.sup.a ring means a monocyclic or bicyclic
aromatic ring which has a dissociable group on the ring or in a
substituent, and may also have a protected or unprotected
substituent; and the Ba.sup.a ring, the Ca.sup.a ring, W.sup.a,
X.sup.a, Y.sup.a and Z.sup.a have the same meanings as above) with
a nucleophilic agent. Examples of the leaving group may include a
halogen group, methanesulfonyloxy group and p-toluenesulfonyloxy
group. Examples of the nucleophilic agent may include amines,
alcohols and thiols. In the case of alcohols or thiols, these
compounds may have the form of a salt of an alkali metal or the
like upon reaction. Although no particular limitation is imposed on
the solvent to be used in the reaction, a solvent which dissolves
raw materials and does not react with these materials with ease is
desirable. For example, tetrahydrofuran, dioxane, dimethylformamide
or water may be utilized. Although the reaction temperature differs
depending on the type of substrate, the reaction is usually run at
-50.degree. C. to 150.degree. C.
[0062] In the case where the amino group or the hydroxyl group is
protected in the resulting product, a sulfonamide derivative or
sulfonate derivative (I.sup.a) having a free hydroxyl group or
amino group can be obtained by a usual deprotecting method such as
acid treatment, alkali treatment and catalytic reduction, as
required.
[0063] Next, methods for producing the raw material compound
(II.sup.a) and its reactive derivative and the compound (III.sup.a)
used in the present invention will be explained.
[0064] The raw material compound (II.sup.a) and its reactive
derivative include known compounds and novel compounds. In the case
of these novel compounds, these compounds may be produced by
applying a method of synthesizing a known compound which has been
already reported or by using a combination of these known methods.
For example, a novel sulfonyl chloride may be produced by a method
obtained by applying synthetic methods described in Chem. Ber., 90,
841 (1957), J. Med. Chem., 6, 307 (1963), J. Chem. Soc.(c), 1968,
1265, Chem. Lett., 1992, 1483, J. Am. Chem. Soc., 59, 1837 (1937),
J. Med. Chem., 23, 1376 (1980), J. Am. Chem. Soc., 70, 375 (1948),
J. Am. Chem. Soc., 78, 2171 (1956) etc.
[0065] The raw material compound (III.sup.a) includes known
compounds and novel compounds. In the case where H--X.sup.a--
represents an amino group H.sub.2N-- in the raw material compound
(III.sup.a), an H.sub.2N body (III.sup.a) can be obtained by
reducing the nitro compound by using a nitro group-reducing method
which is usually used. Preferable examples of the reducing methods
include catalytic reduction using a palladium-carbon catalyst and
reduction using a zinc powder-hydrochloric acid. The catalytic
reduction may be usually carried out under normal pressure or under
pressure in an organic solvent such as methanol, tetrahydrofuran
and dimethylformamide.
[0066] In the case where H--X.sup.a-- means hydroxyl group (HO--)
in the raw material compound (III.sup.a), a HO compound (III.sup.a)
can be obtained by diazotizing the above amino compound and then
hydrolyzing the resulting product.
[0067] In the case where the raw material compounds are these novel
compounds, these compounds may be produced by applying a method of
synthesizing a known compound which has been already reported or by
using a combination of these known methods. A novel compound may be
produced by applying the methods described in Can. J. Chem., 42,
1235 (1964), Chem. Abst., 59, 8855f (1963), Tetrahedron Lett., 30,
2129 (1989) etc. through, for example, the following route. 12
[0068] In the formula, Q.sup.as mean the same or different
substituents; G.sup.a means a halogen group; and t.sup.a means an
integer from 0 to 2. 13
[0069] In the formula, Q.sup.a and t.sup.a have the same meanings
as above. 14
[0070] In the formula, Q.sup.a, G.sup.a and t.sup.a have the same
meanings as above; and DPPA means diphenylphosphorylazide. 15
[0071] In the formula, Q.sup.a, G.sup.a and t.sup.a have the same
meanings as above; and DDQ means
2,3-dichloro-5,6-dicyano-1,4-benzoquinone.
[0072] Next, the compound (I.sup.b) of the present invention may be
produced by various methods. Among them, typical methods are as
follows.
[0073] 1) When Z.sup.b is a Single Bond 16
[0074] In the formula, A.sup.b, B.sup.b, T.sup.b, U.sup.b, V.sup.b,
W.sup.b, X.sup.b and T.sup.b have the same meanings as above. It
may be produced by reacting the sulfonic acid represented by the
formula (V.sup.b) or its reactive derivative with the compound
represented by the formula (VI.sup.b).
[0075] As examples of the reactive derivative of the sulfonic acid
(V.sup.b), reactive derivatives generally utilized frequently such
as sulfonyl halides, sulfonic acid anhydrides and
N-sulfonylimidazolides may be proposed. A particularly preferable
example is a sulfonyl halide. Although no particular limitation is
imposed on the solvent to be used in the reaction, those which
dissolve the raw material and do not react with the raw material
with ease are desirable. For example, pyridine, tetrahydrofuran,
dioxane, benzene, ethyl ether, dichloromethane and
dimethylformamide, or a mixed solvent of two or more solvents
selected from these may be utilized. Also, in this reaction, in the
case where a free acid appears with the progress of the reaction as
shown in the case of using a sulfonyl halide, the reaction is
preferably run in the presence of a proper deoxidizer. Therefore,
the use of a basic solvent such as pyridine is particularly
preferable. When a neutral solvent is used, a basic substance such
as an alkali carbonate and an organic tertiary amine may be added.
It is needless to say that usable solvents are not limited to these
exemplified solvents. Although this reaction generally proceeds at
room temperature, the raw materials may be cooled or heated
according to the need. The reaction time is generally 10 minutes to
20 hours but is optionally selected according to the type of raw
material and the reaction temperature.
[0076] In the case where the amino group or the hydroxyl group is
protected in the resulting product, a sulfonamide derivative
(VII.sup.b) having a free hydroxyl group or amino group can be
obtained using a usual deprotecting method such as acid treatment,
alkali treatment and catalytic reduction, as required.
[0077] 2) When Z.sup.b is --CO--NH-- 17
[0078] In the formula, L.sup.b means chlorine atom or bromine atom;
R.sup.17b represents a C1-C4 alkyl group or benzyl group; and
A.sup.b, B.sup.b, T.sup.b, U.sup.b, V.sup.b, W.sup.b, X.sup.b and
T.sup.b have the same meanings as above.
[0079] It may be produced by reacting a compound represented by the
formula (VIII.sup.b) isocyanate with a sulfonamide compound
represented by the formula (IX.sup.b).
[0080] The reaction is run in water or a water-miscible
non-reactive solvent such as tetrahydrofuran and acetone in the
presence of abase such as sodium hydroxide, potassium hydroxide,
lithium hydroxide, sodium methoxide and sodium hydride. The
reaction is run at a temperature from 0.degree. C. up to
100.degree. C. and preferably about 20 to 30.degree. C.
[0081] Another preferable reaction is attained by a method in which
an amine represented by the formula (XI.sup.b) is reacted with a
carbamate represented by the formula (XII.sup.b) obtained by
reacting a sulfonamide represented by the formula (IX.sup.b) with a
haloformate represented by the formula (XIII.sup.b).
[0082] The reaction between the sulfonamide represented by the
formula (IX.sup.b) with the haloformate represented by the formula
(XIII.sup.b) is run in a non-reactive solvent such as acetone,
tetrahydrofuran and methyl ethyl ketone in the presence of an acid
scavenger such as potassium carbonate, sodium carbonate, potassium
hydroxide and sodium hydroxide. The reaction is run at a
temperature from about 30.degree. C. to a refluxing temperature.
Next, the reaction between the carbamate represented by the formula
(XII.sup.b) and the amine represented by the formula (XI.sup.b) is
run in an inert and high-boiling point solvent such as dioxane,
toluene and diglym under heating at a temperature from about
50.degree. C. to a refluxing temperature.
[0083] The amine compound represented by the formula (VI.sup.b) or
(XI.sup.b) as the raw material of the sulfonamide or
sulfonylurea-containing heterocyclic compound of the present
invention may be produced using a combination of known methods.
[0084] For example, quinoline and isoquinoline derivatives may be
produced in the following production steps. 18
[0085] In the formula wherein A.sup.b, E.sup.2b, G.sup.2b and
R.sup.16b have the same meanings as above; and R.sup.18b means a
C1-C4 alkyl group or benzyl group. 19
[0086] In the formula, A.sup.b and G.sup.2b have the same meanings
as above. 20
[0087] In the formula, R.sup.18b has the same meaning as above; and
R.sup.19b means a C1-C4 alkyl group. 21
[0088] In the formula, R.sup.18b and E.sup.2b have the same
meanings as above; R.sup.20b and R.sup.21b respectively means
hydrogen atom or a C1-C4 alkyl group; R.sup.22b represents a C1-C4
alkoxy group, a phenoxy group or phenyl group which may have a
substituent, cyano group or an amino group which may be substituted
with a mono- or di-C1-C4 alkyl group; and E.sup.3b represents
hydrogen atom, a halogen atom, a C1-C4 alkoxy group, a phenoxy
group or phenyl group which may have a substituent, cyano group or
an amino group which may be substituted with a mono- or di-C1-C4
alkyl group.
[0089] When the compound of the present invention is used as drugs,
it is administered orally or parenterally. The dose of the compound
differs depending on the degree of symptoms, the ages, sexes,
weights and a difference in sensitivity of patients, the
administration method, the time of administration, administration
interval, the features of drug preparations, prescription and types
of drug preparations, the types of active ingredients etc. and no
particular limitation is imposed on the dose. However, the dose is
generally 10 to 6000 mg, preferably about 50 to 4000 mg and more
preferably 100 to 3000 mg per day for an adult and the drug is
generally administered at the defined dose in one to three protons
a day.
[0090] When preparing oral solid preparations, a filler and
further, as required, a binder, a disintegrator, a lubricant, a
colorant and a flavoring agent were added to a base drug and then
the mixed drugs are made into tablets, coated tablets, granules,
fine granules, powders or capsule agents.
[0091] As the filler, for example, lactose, cornstarch, saccharose,
glucose, sorbitol, crystalline cellulose or silicon dioxide; as the
binder, for example, polyvinyl alcohol, ethyl cellulose, methyl
cellulose, gum arabic, hydroxypropyl cellulose or
hydroxypropylmethyl cellulose; as the lubricant, for example,
magnesium stearate, talc or silica; as the colorant, those
permitted to be added to drugs; and as the flavor, cocoa powder,
menthol, aromatic acid, peppermint oil, borneol, cinnamon powder
etc. is used. These tablets and granules may be provided with sugar
coating or gelatin coating and in addition, may be properly coated
as required.
[0092] In the case of preparing injections, a pH regulator, a
buffer, a suspending agent, a solubilizer, a stabilizer, an
isotonic agent, a preservative etc. are added to a base drug
according to the need and the mixture is then made into intravenous
injections, subcutaneous injections or intramuscular injections by
a usual method. At this time, these injections are occasionally
made into freeze-dried products.
[0093] Examples of the suspending agent may include methyl
cellulose, polysorbate 80, hydroxyethyl cellulose, gum arabic,
traganth powder, carboxymethyl cellulose sodium and polyoxyethylene
sorbitan monolaurate.
[0094] Examples of the solubilizer may include polyoxyethylene
hydrogenated castor oil, polysorbate 80, nicotinic acid amide,
polyoxyethylene sorbitan monolaurate, macrogol and castor oil fatty
acid ethyl ester.
[0095] Also, examples of stabilizers may include sodium sulfite and
sodium methasulfite; and examples of the preservative may include
methyl paraoxybenzoate, ethyl paraoxybenzoate, sorbic acid, phenol,
cresol and chlorocresol.
BRIEF DESCRIPTION OF THE DRAWINGS
[0096] FIG. 1 shows, on the upper side, the results obtained by
measuring the quantity of integrin expression after 48 hours when
using a compound A (untreated and 0.05 .mu.g/ml) for human
umbilical venous endothelial cells and, on the lower side, T/C
expressed as % as to the effect of the compound A as compared with
the untreated case.
[0097] FIG. 2 shows the integrin expression inhibitory action of
the compound A (0.05 .mu.g/ml) on a human colonic cancer cell line
(HCT116-C9) after 48 hours: the effect of the compounds A as
compared with the untreated case is expressed as T/C (%).
[0098] FIG. 3 shows the integrin expression inhibitory action of
the compound A with a high concentration (0.5 .mu.g/ml and 5
.mu.g/ml) on a human normal fibroblast cell line (WI38) after 48
hours: the effect of the compounds A as compared with the untreated
case is expressed as T/C (%).
[0099] FIG. 4 shows the integrin .alpha.2 expression inhibitory
action of each compound (0.5 .mu.g/ml) on human umbilical cord
endothelial cells (HUVEC) after 48 hours: the rate of the quantity
of integrin .alpha.2 expressed as compared with the untreated case
is expressed as (%). (The name of each compound is shown by
Synthetic Example number.)
[0100] The effect of the compound of the present invention will be
shown below by way of examples of pharmacological experiments.
[0101] It is to be noted that the compound A in the examples of
pharmacological experiments indicates the compound obtained in
Synthetic Example 1.
EXAMPLE 1
[0102] Integrin Expression Inhibitory Action on a Human Umbilical
Venous Endothelial Cells (HUVEC)
[0103] Human umbilical venous endothelial cells (HUVEC) of
5.times.10.sup.5 in number were seeded in a 75 cm.sup.2 cell
culture bottle and then cultured using an EGM medium (Sanko
Junyaku) at 37.degree. C. in a CO.sub.2 incubator. Then, after 3
hours, the EGM medium was exchanged for the same medium including
compound A, which was then cultured for further 48 hours. Next, the
cells were collected and washed with a bovine serum
albumin-containing phophate buffer solution and the above buffer
solution containing various anti-human integrin mouse antibodies
was added to the cells and the solution containing cells was
allowed to stand at 4.degree. C. for 30 minutes. After washed, FITC
connective anti-mouse IgG antibody was added to the cells, which
was then allowed to stand for 30 minutes and washed again. Next,
the cells were fixed and the amount of antibody connected per cell
was measured as the amount of FITC by using a flow cytometer.
[0104] As shown in FIG. 1 described later, the compound A inhibited
the expression of integrins .alpha.2, .alpha.3, .alpha.5, .alpha.6,
.alpha.v, .beta.1, .beta.3 and .beta.5 on the surface of the cell
in a concentration of 0.05 .mu.g/ml.
EXAMPLE 2
[0105] Integrin Expression Inhibitory Action on a Human Colonic
Cancer Cell Line (HCT116-C9)
[0106] The integrin expression inhibitory action of the compound A
on the above cells was examined in the same manner as in Example
1.
[0107] As shown in FIG. 2 described later, the compound A inhibited
the expression of integrins .alpha.2, .alpha.3, .alpha.5, .alpha.6,
.beta.1 and .beta.4 in a concentration of 0.05 .mu.g/ml and in a
concentration of 0.5 .mu.g/ml.
EXAMPLE 3
[0108] Integrin Expression Inhibitory Action on a Human Normal
Fibroblast Cell Line (WI38)
[0109] The integrin expression inhibitory action of the compound A
on the above cells was examined in the same manner as in Example
1.
[0110] As shown in FIG. 3 described later, the compound A having a
higher concentration than in Examples 1 and 2 slightly inhibited
the expression of integrins .alpha.2, .alpha.3 and .alpha.4, but
had no influence on the expression of integrins .alpha.1, .alpha.5,
.alpha.6 and .beta.1.
[0111] As mentioned above, it is clear that the compound A inhibits
the expression of integrin in endothelial cells and cancer cells
but exerts almost no inhibitory action on normal fibroblast
cells.
EXAMPLE 4
[0112] Antiangiogenic Effect-1
[0113] The inhibition degree of angiogenesis which was observed
when aorta pieces of rat were incubated in collagen was defined as
an antiangiogenic effect. That is, the aorta excised from male rat
of Sprague-Dawley strain (10-12 weeks age) was washed with a Hanks'
solution so that fat tissues around there were removed minutely.
The aorta was incised to prepare pieces of 2 mm square and they
were allowed to stand in a 24-well plate holding the endothelial
cells upside. Then, 500 .mu.l of neutralized Type I collagen (Cell
Matrix Type I-A; manufactured by Nitta Gelatin) were poured over
each well and allowed to stand at room temperature for about 20
minutes in a clean bench to solidify the gel. After confirming that
the gel was solidified, 500 .mu.l of MCDB 131 medium (manufactured
by Chlorella Kogyo) were added thereto followed by incubating in a
CO.sub.2 incubator (5% CO.sub.2) at37.degree. C. On the next day,
the culture medium was exchanged with 500 .mu.l of MCDB 131 medium
containing the test compound and the incubation was continued.
After three days, the medium was again exchanged with 500 .mu.l of
MCDB 131 medium containing the test compound and, at the stage of
the 7th day from the initiation of addition of the test compound,
numbers of capillaries formed around the aorta were counted under a
microscope. The solution containing the test compound was prepared
in a three-fold dilution system where 10 .mu.g/ml was the highest
concentration.
[0114] Inhibiting rate was calculated from the following formula
and 50% inhibiting concentration (IC.sub.50) for each test compound
was determined.
Inhibiting Rate (%)=(C-T)/C.times.100
[0115] C: Numbers of capillaries when no compound was added
[0116] T: Numbers of capillaries when a compound was added
[0117] The compound according to the present invention showed an
IC.sub.50 value of 0.05 to 3 .mu.g/ml.
EXAMPLE 5
[0118] Antiangiogenic Effect-2
[0119] 0.4 ml of type I collagen was added to a 24-well plate and
solidified. Human umbilical venous endothelial cells (HUVEC) of
8.times.10.sup.4 in number were seeded on the collagen and cultured
overnight by using endotherial cells culture solution (Gibco BRL)
containing 10 ng/ml EGF and 20 ng/ml bFGF. Next, the supernatant
was removed and then 0.4 ml of the same collagen was overlaid. A
culture solution containing 1.5 ml of the compound A was further
added and the cells were cultured for 4 days. Thereafter, the area
of the formed tube was measured quantitatively by image
analysis.
[0120] The IC.sub.50 of the compound A was 0.12 .mu.g/ml. It was
confirmed that an .alpha.2 antibody had the same effect, but this
effect was not observed in the case of an .alpha.5 antibody.
EXAMPLE 6
[0121] Antianigiogenic Effect-3 (in Vivo)
[0122] The above activity was evaluated using a method obtained by
improving a mouse air capsule method (Sakamoto et al., Cancer Res.,
1, 55-57, 1986) in part. Specifically, a millipore ring (Nippon
Millipore) was sealed using a 0.22 .mu.m membrane filter (HAWPO,
Nippon Millipore) to form a chamber. 1.times.10.sup.7 human colic
cancer cell strains (WiDr) which were suspended in a phosphoric
acid buffer solution were sealed into the chamber. Next, an air
capsule was formed on a subcutaneous site of the backside of a C57
Black female mouse of 6 to 8 weeks age and the foregoing chamber
was transplanted to the air capsule. The compound A was orally
administered after about 6 hours passed after the transplantation
was finished and afterwards administered in sequence once a day for
3 days. The erythrocytes of the mouse that was labeled with
.sup.51Cr was injected from the tail vein 4 days after the chamber
was transplanted. After one hour, the skin at the portion which was
in contact with the chamber was resected under anesthesia. After
the skin was frozen, only the portion which was in contact with the
chamber was separated precisely to measure the amount of blood by
using .gamma. counter. Then, a value obtained by subtracting the
amount of blood measured in the case of the chamber including no
cancer cell from the above amount of blood was determined as the
amount of angiogenesis. In the experiment, the control groups
consisted of 10 mice per group and the compound-administrated
groups consisted of 5 mice per group.
[0123] If the results are evaluated by T/C (%): the amount of
angiogenesis of the compound-administered groups/the amount of
angiogenesis of the vehicle-administered groups.times.100, the
compound A had such an effect as T/C=53% at a dose of 50 mg/kg.
EXAMPLE 7
[0124] Integrin .alpha.2 Expression Inhibitory Action on a Human
Umbilical Venous Endothelial Cells (HUVEC)
[0125] Human umbilical venous endothelial cells (HUVEC) of
5.times.10.sup.5 in number were seeded in a 75 cm.sup.2 cell
culture bottle and then cultured using an EGM medium (Sanko
Junyaku) at 37.degree. C. in a CO.sub.2 incubator. Then, after 3
hours, the EGM medium was exchanged for the same medium including a
compound of 0.5 .mu.g/ml, which was then cultured for further 48
hours. Next, the cells were collected and washed with a bovine
serum albumin-containing phosphate buffer solution and the above
buffer solution containing an anti-human integrin .alpha.2 mouse
antibody was added thereto and the solution was allowed to stand at
4.degree. C. for 30 minutes. After washed, FITC connective
anti-mouse IgG antibody was added to the cells, which was then
allowed to stand for 30 minutes and washed again. Next, the cells
were fixed and the amount of antibody connected per cell was
measured as the amount of FITC by using a flow cytometer. The
inhibitory action of each compound is shown by the ratio (%) of the
amount of expression to that obtained in the untreated compound.
The name of each compound is shown by Synthetic Example number.
[0126] As shown in FIG. 4 described later, each compound inhibited
the expression of integrin .alpha.2 on the surface of the cell in a
concentration of 0.5 .mu.g/ml.
[0127] Compounds according to the present invention are disclosed
concretely in JP-A 7-165708 and JP-A 8-231505. Further, Production
Examples and Synthetic Examples of typical compounds of the
compound of the present invention will be given hereinbelow. It is
needless to say that the present invention is not limited only to
these Examples.
PRODUCTION EXAMPLE 1
[0128] Ethyl Pyruvate N-(5-methyl-2-nitrophenyl)hydrazone
[0129] 75.0 g (493 mmol) of 5-methyl-2-nitroaniline was added to a
mixed solution of 160 ml of water and 170 ml of concentrated
hydrochloric acid and the mixture was stirred. To the mixture was
added dropwise 80 ml of an aqueous solution containing 36.0 g (517
mmol) of sodium nitrite at -20.degree. C. The reaction solution was
added to a solution obtained by dissolving ethyl
2-methylacetoacetate in 100 ml of ethanol and then adding 200 ml of
a 12N aqueous potassium hydroxide thereto, at -20.degree. C. over
30 minutes under stirring. After stirring at the same temperature
for 30 minutes, 100 ml of concentrated hydrochloric acid was added
thereto. The resulting precipitates were collected by filtration,
washed with water and dried under reduced pressure overnight. A
mixed solution of diethyl ether and hexane was added thereto and
the crystals were collected by filtration, to give 130 g of the
title compound.
[0130] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.29 (3H, t, J=7.2
Hz), 2.16 (3H, s), 2.40 (3H, s), 4.25 (2H, q, J=7.2 Hz), 6.91 (1H,
dd, J=8.8, 2.0 Hz), 7.63 (1H, s), 8.07 (1H, d, J=8.8 Hz), 10.69
(1H, s)
PRODUCTION EXAMPLE 2
[0131] Ethyl 4-methyl-7-nitro-1H-indole-2-carboxylate
[0132] To a xylene suspension (250 ml) of 25.0 g (94.2 mmol) of the
compound of Production Example 1 was added 100 g of polyphosphoric
acid, followed by heating under reflux for 3 hours. Under
ice-cooling, to the reaction mixture were added 80 ml of water and
300 ml of ethyl acetate. The insoluble matters were filtered off
and washed with 1.5 l of ethyl acetate, and the filtrate was
extracted with ethyl acetate. The organic layer was successively
washed with an aqueous saturated sodium bicarbonate, water and
brine, dried over magnesium sulfate and concentrated to dryness. To
the residue was added a mixed solution of tert-butyl methyl ether
and hexane, and the crystals were collected by filtration, to give
11.1 g of the title compound.
[0133] 1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.35(3H, t, J=7.2 Hz),
2.65(3H, s), 4.38(2H, q, J=7.2 Hz), 7.16(1H, d, J=8.4 Hz), 7.51(1H,
s), 8.19(1H, d, J=8.4 Hz), 11.29(1H, br s)
PRODUCTION EXAMPLE 3
[0134] 4-Methyl-7-nitro-1H-indole-2-carboxylic Acid
[0135] 150 ml of a 1 N aqueous sodium hydroxide was added to a
tetrahydrofuran solution (150 ml) containing 11.0 g (44.3 mmol) of
the compound of Production Example 2, followed by heating under
stirring at 80.degree. C. for 30 minutes. The reaction solution was
concentrated and 40 ml of 5N hydrochloric acid was added to the
residue under ice-cooling to adjust the solution to pH 1. The
resulting precipitates were collected by filtration and washed with
water. The precipitates were dissolved in 300 ml of
tetrahydrofuran, and the mixture was extracted with ethyl acetate.
The organic layer was washed with brine, dried over magnesium
sulfate and concentrated to dryness, to give 9.60 g of the title
compound.
[0136] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.62 (3H, s), 7.13
(1H, d, J=8.0 Hz), 7.42 (1H, s), 8.15 (1H, d, J=8.0 Hz), 11.00 (1H,
br s)
PRODUCTION EXAMPLE 4
[0137] 4-Methyl-7-nitro-1H-indole
[0138] 9.58 g (43.5 mmol) of the compound of Production Example 3
was dissolved in 60 ml of 1,3-dimethyl-2-imidazolidinone. To the
mixture was added 1.04 g (4.35 mmol) of basic copper carbonate,
followed by heating under stirring at 180.degree. C. for 4 hours.
120 ml of ethyl acetate was added to the reaction solution under
ice-cooling, the insoluble matters were filtered off, and the
filtrate was extracted with ethyl acetate. The organic layer was
successively washed with water and brine, dried over magnesium
sulfate and concentrated. Then, the residue was purified by silica
gel column chromatography, to give 4.87 g of the title
compound.
[0139] .sup.1H-NMR (DMSO-d.sub.6) .delta. (ppm): 2.59 (3H, s), 6.74
(1H, s), 7.03 (1H, d, J=8.4 Hz), 7.48(1H, s), 8.00(1H, d, J=8.4
Hz), 11.86(1H, br s)
PRODUCTION EXAMPLE 5
[0140] 3-Formyl-4-methyl-7-nitro-1H-indole
[0141] 1.5 ml (16.1 mmol) of phosphorous oxychloride was added to
12 ml (154 mmol) of dimethylformamide at 0.degree. C. in nitrogen
atmosphere, followed by stirring at the same temperature for 20.5
hours. A dimethylformamide solution (20 ml) containing 2.0 g (11.4
mmol) of the compound of Production Example 4 was added thereto at
0.degree. C., followed by heating under stirring at 90.degree. C.
for 21 hours. 100 ml of a 1N aqueous sodium hydroxide was added to
the reaction solution under ice-cooling, and the mixture was
extracted with ethyl acetate. The organic layer was successively
washed with water and brine, dried over magnesium sulfate and
concentrated to dryness. A mixed solution of tert-butyl methyl
ether and hexane was added to the residue, and the crystals were
collected by filtration, to give 2.23 g of the title compound.
[0142] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.90(3H, s),
7.21(1H, d, J=8.4 Hz), 8.11(1H, d, J=8.4 Hz), 8.39(1H, s),
10.01(1H, s), 12.71(1H, br s)
PRODUCTION EXAMPLE 6
[0143] 3-Cyano-4-methyl-7-nitro-1H-indole
[0144] 2.21 g (10.8 mmol) of the compound of Production Example 5
was dissolved in 100 ml of dimethylformamide, followed by adding
900 mg (13.0 mmol) of hydroxylamine hydrochloride and 1.05 ml (13.0
mmol) of pyridine. After heating under stirring at60.degree. C. for
40 minutes, 1,1-carbonyldiimidazole (53.9 mmol) was added to the
reaction solution under ice-cooling. After heating under stirring
at 60.degree. C. for further 30 minutes, 3.0 ml (21.5 mmol) of
triethylamine was added to the reaction solution and the mixture
was heated under stirring at the same temperature for further one
hour. 50 ml of ice-water was added to the reaction mixture solution
under ice-cooling, and the mixture was extracted with ethyl
acetate. The organic layer was successively washed with water and
brine, dried over magnesium sulfate and concentrated to dryness. A
mixed solution of tert-butyl methyl ether and hexane was added to
the residue and the crystals were collected by filtration, to give
1.95 g of the title compound.
[0145] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.78 (3H, s), 7.22
(1H, d, J=8.0 Hz) 8.14 (1H, d, J=8.0 Hz), 8.41 (1H, s), 12.76 (1H,
br s)
PRODUCTION EXAMPLE 7
[0146] 7-Bromo-4-methyl-1H-indole
[0147] 1 l (1 mol) of a tetrahydrofuran solution containing 1.0 M
vinylmagnesium bromide was added to a tetrahydrofuran solution (300
ml) containing 65.0 g (301 mmol) of 2-bromo-5-methylnitrobenzene at
-60.degree. C. under stirring for one hour in nitrogen atmosphere.
An aqueous saturated ammonium chloride and ethyl acetate were added
to the reaction mixture solution, and the insoluble matters were
filtered off. The filtrate was dried over magnesium sulfate and
concentrated. Then, the residue was purified by silica gel column
chromatography, to give 35.5 g of the title compound.
[0148] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.42(3H, s),
6.55(1H, s), 6.73(1H, d, J=7.6 Hz), 7.16(1H, d, J=7.6 Hz), 7.35(1H,
s), 11.24(1H, br s)
PRODUCTION EXAMPLE 8
[0149] 4-Methyl-1H-indole-7-carboxylic Acid
[0150] 240 ml (384 mmol) of a hexane solution containing 1.6 M
butyl lithium was added to a tetrahydrofuran solution (200 ml)
containing 35.5 g (169 mmol) of the compound of Production Example
7 at -78.degree. C. under stirring in nitrogen atmosphere. After
stirring under ice-cooling for 40 minutes, carbon dioxide was
passed through the reaction solution at -50.degree. C. and the
mixture was stirred as it was for 15 minutes. Water was added to
the reaction mixture solution at the same temperature and the
solvent was evaporated. The resulting precipitates were collected
by filtration and washed with water. The precipitates was dissolved
in 300 ml of tetrahydrofuran, dried over magnesium sulfate and
concentrated to dryness, to give 25.9 g of the title compound.
[0151] 1H-NMR (DMSO-d.sub.6) .delta. (ppm): 2.51 (3H, s), 6.53 (1H,
s), 6.88 (1H, d, J=7.6 Hz), 7.31 (1H, s), 7.62 (1H, d, J=7.6 Hz),
10.99 (1H, br s), 12.79(1H, br s)
PRODUCTION EXAMPLE 9
[0152] 7-(N-tert-Butoxycarbonyl)amino-4-methyl-1H-indole
[0153] 7.0 g (40.0 mmol) of the compound of Production Example 8
was suspended in 80 ml of toluene, 22 ml (160 mmol) of
triethylamine and 11.2 ml (52 mmol) of diphenylphosphorylazide were
added to the mixture in nitrogen atmosphere, and the mixture was
stirred at room temperature for 30 minutes. 8 ml (84 mmol) of
tert-butanol was added to the reaction solution, followed by
heating under stirring at 100.degree. C. for 2.5 hours. Then, the
reaction solution was concentrated, and the residue was dissolved
in ethyl acetate. The mixture was successively washed with 0.1 N
hydrochloric acid, water and brine, dried over magnesium sulfate
and concentrated to dryness. A mixed solution of diethyl ether and
hexane was added to the residue and the crystals were collected by
filtration, to give 7.87 g of the title compound.
[0154] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.48(9H, s),
2.38(3H, s), 6.37-6.44(1H, m), 6.68(1H, d, J=8.4 Hz), 7.22-7.31(2H,
m), 8.86(1H, br s), 10.73(1H, br s)
PRODUCTION EXAMPLE 10
[0155]
7-(N-tert-Butoxycarbonyl)amino-3-formyl-4-methyl-1H-indole
[0156] 40 ml (429 mmol) of phosphorous oxychloride was added to 400
ml (5.2 mol) of dimethylformamide at 0.degree. C. in nitrogen
atmosphere, followed by stirring at the same temperature for 25
minutes. 74.0 g (300 mmol) of the compound of Production Example 9
was added thereto at 0.degree. C., followed by stirring at room
temperature for 1.5 hours. The reaction mixture was adjusted to pH
8 by adding 250 ml of a 5N aqueous sodium hydroxide thereto under
ice-cooling. The organic layer was separated by adding
tetrahydrofuran, ethyl acetate and water thereto. It was
successively washed with water and brine, and dried over magnesium
sulfate. Then, the solvent was evaporated, a mixed solution of
diethyl ether and hexane was added to the residue, and the crystals
were collected by filtration, to give 53.7 g of the title
compound.
[0157] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.50 (9H, s), 2.71
(3H, s), 6.90 (1H, d, J=7.6 Hz), 7.32-7.41 (1H, m), 8.21 (1H, d,
J=1.6 Hz), 8.99 (1H, br s), 9.93 (1H, s), 11.88 (1H, br s)
PRODUCTION EXAMPLE 11
[0158]
7-(N-tert-Butoxycarbonyl)amino-3-cyano-4-methyl-1H-indole
[0159] 4.43 g (16.2 mmol) of the compound of Production Example 10
was dissolved in 50 ml of dimethylformamide, followed by adding
1.35 g (19.4 mmol) of hydroxylamine hydrochloride and 1.6 ml (19.8
mmol) of pyridine thereto. After heating under stirring at
60.degree. C. for 45 minutes, 1,1-carbonyldiimidazole (80.8 mmol)
was added to the reaction solution under ice-cooling. After heating
under stirring at 60.degree. C. for further 30 minutes, 4.5 ml
(32.3 mmol) of triethylamine was added to the reaction solution,
and the mixture was heated under stirring at the same temperature
for further 30 minutes. Water was added to the reaction mixture
solution under ice-cooling, and the mixture was extracted with
ethyl acetate. The organic layer was successively washed with water
and brine, dried over magnesium sulfate and then concentrated to
dryness, to give 4.27 of the target compound.
[0160] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.49 (9H, s), 2.60
(3H, s), 6.89 (1H, d, J=8.0 Hz), 7.34-7.42 (1H, m), 8.20 (1H, d,
J=2.8 Hz), 9.04 (1H, br s), 11.80 (1H, br s)
PRODUCTION EXAMPLE 12
[0161] 7-Amino-3-cyano-4-methyl-1H-indole
[0162] 12.6 g (62.6 mmol) of the compound of Production Example 6
was dissolved in a mixed solution of 100 ml of tetrahydrofuran and
100 ml of methanol, and the mixture was hydrogenated at an ordinary
temperature under 3 atoms in the presence of 430 mg (1.87 mmol) of
platinum oxide. The catalyst was filtered off and the filtrate was
concentrated to dryness. Then, a mixed solution of tert-butyl
methyl ether and hexane was added to the residue and the crystals
were collected by filtration, to give 10.7 g of the title compound.
50.5 g (186 mmol) of the compound of Production Example 11 was
dissolved in 400 ml of dichloromethane. In nitrogen atmosphere, 210
ml (2.76 mol) of trifluoroacetic acid was added thereto at
0.degree. C., followed by stirring at room temperature for 40
minutes. The reaction mixture was adjusted to pH 7 by adding a 5N
aqueous sodium hydroxide thereto. The solvent was removed, and then
the residue was extracted with ethyl acetate. The organic layer was
successively washed with water and brine, dried over magnesium
sulfate and concentrated to dryness. A mixed solution of diethyl
ether and hexane was added to the residue and the crystals were
collected by filtration, to give 24.5 g of the title compound.
[0163] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.47(3H, s),
5.07(2H, s), 6.34(1H, d, J=7.6 Hz), 6.64(1H, d, J=7.6 Hz), 8.10(1H,
s), 11.70(1H, br s)
PRODUCTION EXAMPLE 13
[0164] 3-Cyanobenzenesulfonyl Chloride
[0165] 25.0 g (212 mmol) of 3-cyanoaniline was added to a mixed
solution of 200 ml of water and 250 ml of concentrated hydrochloric
acid and the mixture was stirred. An aqueous solution (80 ml)
containing 15.5 g (223 mmol) of sodium nitrite was added dropwise
into the mixture at -10.degree. C. The reaction solution was added
to a sulfur dioxide saturated acetic acid solution (solution
prepared by saturating 250 ml of acetic acid with sulfur dioxide
and then adding 2.1 g of cuprous chloride thereto) under
ice-cooling with stirring. After one hour, the reaction solution
was poured into 500 ml of ice-water and extracted with diethyl
ether. The extract was successively washed with an aqueous
saturated sodium bicarbonate, water and brine, and dried over
magnesium sulfate. The solvent was evaporated, and to the residue
was added a mixed solution of diethyl ether and hexane. The
crystals were collected by filtration, to give 16.0 g of the title
compound.
[0166] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.55 (1H, t, J=8.0
Hz), 7.78 (1H, dd, J=8.0, 1.2 Hz), 7.86-7.92 (2H, m)
PRODUCTION EXAMPLE 14
[0167] 4-Sulfamoylbenzenesulfonyl Chloride
[0168] 25.0 g (145 mmol) of 4-aminobenzenesulfonamide was added to
a mixed solution of 80 ml of water and 50 ml of concentrated
hydrochloric acid, followed by stirring. To the mixture was added
dropwise an aqueous solution (20 ml) containing 10.5 g (152 mmol)
of sodium nitrite at -13.degree. C. to -10.degree. C. over 15
minutes. After 10 minutes, the reaction solution was added to a
sulfur dioxide saturated mixture solution (solution prepared by
saturating a mixed solution of 150 ml of acetic acid and 12.5 ml of
concentrated hydrochloric acid with sulfur dioxide and then adding
3.7 g of cuprous chloride thereto) at -30.degree. C. under
stirring. After one hour, 500 ml of ice-water was added to the
reaction solution, and the precipitates were collected by
filtration. The precipitates were dissolved in a mixed solution of
450 ml of toluene and 150 ml of ethyl acetate. After filtering off
the insoluble matters, the filtrate was extracted with ethyl
acetate. The organic layer was successively washed with an aqueous
saturated sodium bicarbonate and brine, and dried over magnesium
sulfate. The solvent was evaporated, and 100 ml of toluene was
added to the residue. The crystals were collected by filtration, to
give 20.9 g of the title compound.
[0169] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.65-7.69 (2H, m),
7.71-7.78 (4H, m)
PRODUCTION EXAMPLE 15
[0170] 5-Bromo-3-chloro-7-nitro-1H-indole
[0171] 1.4 ml of dimethylformamide and 6.98 g (52.3 mmol) of
N-chlorosuccinimide were added to a tetrahydrofuran solution (140
ml) containing 12.00 g (49.8 mmol) of 5-bromo-7-nitro-1H-indole,
followed by stirring at room temperature overnight. An aqueous 10%
sodium thiosulfate was added thereto, followed by extracting with
ethyl acetate. The organic layer was successively washed with water
and brine, dried over magnesium sulfate and concentrated to
dryness, to give 14.84 g of the title compound.
[0172] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.79(1H, s),
8.15(1H, s), 8.23(1H, s), 12.32(1H, br s)
PRODUCTION EXAMPLE 16
[0173] 7-Amino-5-bromo-3-chloro-1H-indole Hydrochloride
[0174] 70 ml of concentrated hydrochloric acid and 31.97 g (269
mmol) of a tin powder were added to a methanol solution (250 ml)
containing 14.84 g (53.9 mmol) of the compound of Production
Example 15, and the mixture was stirred at room temperature for 80
minutes. Under ice-cooling, the mixture was adjusted to pH 10 by
adding a 5N aqueous sodium hydroxide solution thereto. Then, the
resulting precipitates were filtered off and the filtrate was
extracted with ethyl acetate. The organic layer was successively
washed with an aqueous saturated sodium bicarbonate and brine,
dried over magnesium sulfate and concentrated. Then, the residue
was purified by silica gel column chromatography, to give 14.35 g
of 7-amino-5-bromo-3-chloro-1H-indole. The product was dissolved in
ethyl acetate, and 17 ml of a 4N aqueous hydrogen chloride-ethyl
acetate solution was added thereto. The resulting precipitates were
collected by filtration and washed with hexane, to give 13.23 g of
the title compound.
[0175] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 5.11(3H, br s),
6.64(1H, s), 6.93(1H, s), 7.50(1H, d, J=2.0 Hz), 11.38(1H, br
s)
PRODUCTION EXAMPLE 17
[0176] Ethyl pyruvate 2-(4-methyl-2-nitrophenyl)hydrazone
[0177] 30.00 g (0.197 mol) of 4-methyl-2-nitroaniline was suspended
in 110 ml of water, to which was then added 66 ml of concentrated
hydrochloric acid. An aqueous solution (35 ml) containing 16.33 g
(0.237 mol) of sodium nitrite was added dropwise to the mixture at
10.degree. C. or less and the resulting mixture was stirred under
ice-cooling for 40 minutes to prepare a diazonium salt
solution.
[0178] 28.43 g (0.197 mol) of ethyl 2-methylacetoacetate was
dissolved in a mixed solution of 150 ml of ethanol and 300 ml of
water. Under ice-cooling, an aqueous solution (120 ml) containing
53.36 g (0.808 mol) of potassium hydroxide was added thereto. In
succession, the diazonium salt solution which was previously
prepared was added dropwise thereinto at the same temperature and
the resulting mixture was stirred under ice-cooling for 20 minutes.
The mixture was adjusted to pH 1 by adding concentrated
hydrochloric acid thereto. The resulting precipitates were
collected by filtration, washed with water and dried over
phosphorous pentaoxide under reduced pressure, to give 46.42 g of
the title compound.
[0179] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.40(3H, t, J=7.2
Hz), 2.23(3H, s), 2.36(3H, s), 4.35(2H, q, J=7.2 Hz), 7.44(1H, dd,
J=8.8, 1.6 Hz), 7.93(1H, d, J=8.8 Hz), 8.00(1H, s), 10.87(1H, br
s)
PRODUCTION EXAMPLE 18
[0180] Ethyl 5-methyl-7-nitro-1H-indole-2-carboxylate
[0181] 65.33 g of polyphosphoric acid was added to a xylene
solution (320 ml) containing 15.92 g (60 mmol) of the compound of
Production Example 18, followed by heating under reflux overnight.
Water and ethyl acetate were added thereto, and the insoluble
matters were filtered off. The organic layer was separated,
successively washed with water and brine, dried over magnesium
sulfate and concentrated. Then, the residue was purified by silica
gel column chromatography, to give 7.32 g of the title
compound.
[0182] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.34(3H, t, J=7.0
Hz), 2.47(3H, s), 4.36(2H, q, J=7.0 Hz), 7.35(1H, s), 7.99(1H, s),
8.11(1H, s), 11.25(1H, br s)
PRODUCTION EXAMPLE 19
[0183] 5-Methyl-7-nitro-1H-indole
[0184] 150 ml of an aqueous 1 N sodium hydroxide solution was added
to a tetrahydrofuran solution (80 ml) containing 7.86 g (31.7 mmol)
of the compound of Example 19 and the mixture was stirred at room
temperature for 3.5 hours. Under ice-cooling, the mixture was
adjusted to pH 1 by adding 2N hydrochloric acid and then extracted
with ethyl acetate. The organic layer was successively washed with
water and brine, dried over magnesium sulfate and concentrated to
dryness, to give 7.13 g of 5-methyl-7-nitro-1H-indole-2-carboxylic
acid. The product was dissolved in 160 ml of
1,3-dimethyl-2-imidazolidinone, 716 mg (3.24 mmol) of basic copper
carbonate was added thereto, and the mixture was stirred at
185.degree. C. for 2 hours. The reaction solution was poured into
water, the insoluble matters were filtered off and the filtrate was
extracted with ethyl acetate. The organic layer was successively
washed with water and brine, dried over magnesium sulfate and
concentrated. Then, the residue was purified by silica gel column
chromatography, to give 4.50 g of the title compound.
[0185] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.46(3H, s),
6.62(1H, d, J=2.8 Hz), 7.47(1H, d, J=2.8 Hz), 7.87(1H, s), 7.92(1H,
s), 11.77(1H, br s)
PRODUCTION EXAMPLE 20
[0186] 3-Bromo-5-methyl-7-nitro-1H-indole
[0187] 0.7 ml of dimethylformamide and 4.78 g of (26.9 mmol) of
N-bromosuccinimide were added to a tetrahydrofuran solution (70 ml)
containing 4.50 g (25.5 mmol) of the compound of Production Example
20, followed by stirring at room temperature for 70 minutes. An
aqueous 10% sodium thiosulfate solution was added thereto, and the
mixture was extracted with ethyl acetate. The organic layer was
successively washed with water and brine, dried over magnesium
sulfate and then concentrated to dryness, to give 6.53 g of the
title compound.
[0188] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.50(3H, s),
7.67(1H, s), 7.73(1H, s), 8.02(1H, s), 12.10(1H, br s)
PRODUCTION EXAMPLE 21
[0189] 7-Amino-3-bromo-5-methyl-1H-indole
[0190] 6.76 g (26.5 mmol) of the compound of Production Example 20
was suspended in a mixed solution of 150 ml of methanol and 75 ml
of water. To the mixture were added 11.34 g (212 mmol) of ammonium
chloride and 5.92 g (106 mmol) of an iron powder. After stirring at
80.degree. C. for one hour, the insoluble matters were filtered off
and the filtrate was adjusted to pH 8 by adding an aqueous
saturated sodium bicarbonate thereto. The mixture was extracted
with ethyl acetate, and the organic layer was successively washed
with an aqueous saturated bicarbonate, water and brine, dried over
magnesium sulfate and concentrated. Then, the residue was purified
by silica gel column chromatography, to give 3.30 g of the title
compound.
[0191] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.24(3H, s),
5.08(2H, brs), 6.20(1H, s), 6.41(1H, s), 7.35(1H, s), 10.86(1H, br
s)
PRODUCTION EXAMPLE 22
[0192] 6-Amino-3-pyridinesulfonyl Chloride
[0193] Under ice-cooling, 10.00 g (0.106 mol) of 2-aminopyridine
was added little by little to 123.8 g (1.06 mol) of chlorosulfonic
acid. To the mixture was added 50.56 g (0.425 mol) of thionyl
chloride. The mixture was heated under reflux for 2.5 hours, and
further stirred at 150.degree. C. for 7 hours. The reaction
solution was poured into ice-water, neutralized by adding sodium
bicarbonate and extracted with ethyl acetate. The organic layer was
successively washed with an aqueous saturated sodium bicarbonate,
water and brine, dried over magnesium sulfate, and then
concentrated to dryness. The residue was suspended in ethyl ether
and the insoluble matters were filtered off. The filtrate was
concentrated to dryness and the residue was recrystallized from
ethyl ether/hexane, to give 6.58 g of the title compound.
PRODUCTION EXAMPLE 23
[0194] 4.7-Dibromo-1H-indole
[0195] The title compound (27.2 g) was obtained from 62.0 (0.224
mol) g of 2,5-dibromonitrobenzene in the same manner as in the
Production Example 1 of JP-A 7-165708.
[0196] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.52 (1H, d, J=3.2
Hz), 7.18 (1H, d, J=8.0 Hz), 7.26 (1H, d, J=8.0 Hz), 7.53 (1H, d,
J=3.2 Hz), 11.75 (1H, br s)
PRODUCTION EXAMPLE 24
[0197] 7-Amino-4-bromo-1H-indole Hydrochloride
[0198] Into a tetrahydrofuran solution (300 ml) containing 27.2 g
(98.9 mmol) of the compound of Production Example 23 was added
dropwise a 186 ml (116.3 mmol) of a hexane solution containing 1.6
Mn-butyllithium at -78.degree. C. in a nitrogen atmosphere,
followed by stirring under ice-cooling for one hour. After cooling
again to -78.degree. C., 28 ml (0.13 mmol) of
diphenylphosphrylazide was added dropwise thereinto. The mixture
was stirred at -78.degree. C. for one hour and in succession, at
-40.degree. C. for one hour. A toluene solution (150 g) containing
3.4 M sodium bis(2-methoxyethoxy)aluminum hydride was added thereto
at -40.degree. C., followed by stirring at room temperature for one
hour. Water (120 ml) was added thereto, the insoluble matters were
collected by filtration and the filtrate was extracted with ethyl
ether. The organic layer was successively washed with an aqueous
saturated sodium bicarbonate and brine, dried over magnesium
sulfate and concentrated. Then, the residue was dissolved in ethyl
ether, and 50 ml of a 4 N-hydrochloric acid/ethyl acetate solution
was added thereto. The resulting precipitates were collected by
filtration, to give 14.5 g of the title compound.
[0199] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.41-6.43 (1H, m),
6.80 (1H, d, J=8.0 Hz), 7.16 (1H, d, J=8.0 Hz), 7.54 (1H, t, J=2.8
Hz), 11.57 (1H, br s)
PRODUCTION EXAMPLE 25
[0200] 7-Bromo-4-chloro-1H-indole
[0201] The title compound was obtained in the same manner as in
Production Example 23.
[0202] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.60-6.61 (1H, m),
7.04 (1H, d, J=8.1 Hz), 7.32 (1H, d, J=8.1 Hz), 7.53 (1H, t, J=2.7
Hz), 11.74 (1H, br s)
PRODUCTION EXAMPLE 26
[0203] 7-Amino-4-chloro-1H-indole Hydrochloride
[0204] The title compound was obtained in the same manner as in
Production Example 24.
[0205] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.54-6.55 (1H, m),
7.05 (1H, d, J=8.1 Hz), 7.11 (1H, d, J=8.1 Hz), 7.60 (1H, t, J=2.7
Hz), 11.82 (1H, br s)
PRODUCTION EXAMPLE 27
[0206] 5-Bromo-2-thiophenecarboxyaldehyde
[0207] 27.0 ml (43.4 mmol) of a hexane solution containing 1.6 M
n-butyllithium was added dropwise into a tetrahydrofuran solution
(80 ml) containing 10.0 g (41.3 mmol) of 5-dibromothiophene at
-78.degree. C. in a nitrogen atmosphere, followed by stirring for
10 minutes at the same temperature. Then, 3.5 ml (45.5 mmol) of
dimethylformamide was added thereto at the same temperature,
followed by stirring for 20 minutes. Water was added thereto, and
the mixture was extracted with ethyl acetate. The organic layer was
successively washed with an aqueous 0.1 N hydrochloric acid
solution, water and brine, dried over magnesium sulfate and
concentrated to dryness, to give 6.4 g of the title compound.
[0208] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.49 (1H, d, J=4.0
Hz), 7.87 (1H, d, J=3.9 Hz), 9.81 (1H, s)
PRODUCTION EXAMPLE 28
[0209] 5-Bromo-2-thiophenecarbonitrile
[0210] 3.3 g (51.7 mmol) of hydroxylamine hydrochloride and 4.1 g
(51.7 mmol) of pyridine were added to a dimethylformamide solution
(40 ml) containing 8.2 g (43.1 mmol) of the compound of Production
Example 28 and the mixture was stirred at room temperature for 30
minutes. Then, 34.9 g (215.5 mmol) of 1,1'-carbonyldiimidazole was
added under ice-cooling and the resulting mixture was stirred at
room temperature for one hour. Ice-water was added to the reaction
solution, and the mixture was extracted with ethyl acetate. The
organic layer was successively washed with an aqueous 0.1 N
hydrochloric acid, water and brine, dried over magnesium sulfate
and concentrated. Then, the residue was purified by silica gel
chromatography, to give 6.7 g of the title compound.
[0211] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.45 (1H, d, J=4.0
Hz), 7.84 (1H, d, J=4.0 Hz)
PRODUCTION EXAMPLE 29
[0212] 5-Benzylthio-2-thiophenecarbonitrile
[0213] 585 mg (13.4 mmol, oily component: 55%) of sodium hydride
was suspended in 10 ml of dimethyl sulfoxide, 1.4 g (11.2 mmol) of
benzylmercaptan was added thereto, and the mixture was stirred for
10 minutes. Then, 2.1 g (11.2 mmol) of the compound of Production
Example 14 was added, followed by stirring at room temperature for
one hour. Water was added to the reaction solution, and the mixture
was extracted with ethyl acetate. The organic layer was
successively washed with water and brine, dried over magnesium
sulfate and concentrated. Then, the residue was purified by silica
gel chromatography, to give 1.51 g of the title compound.
[0214] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 4.26 (2H, s), 7.18
(1H, d, J=4.0 Hz), 7.27-7.30 (5H, m), 7.83 (1H, d, J=4.0 Hz)
PRODUCTION EXAMPLE 30
[0215] 4-Bromo-1H-indolecarboxylic Acid
[0216] 34 g of the title compound was obtained from 51 g of the
compound of Production Example 23 in the same manner as in
Production Example 8.
[0217] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 6.51-6.52(1H, m),
7.35(1H, d, J=8.0 Hz), 7.48(1H, t, J=2.8 Hz), 7.66(1H, d, J=8 Hz),
11.4(1H, brs), 13.2(1H, br s)
PRODUCTION EXAMPLE 31
[0218] 7-(N-tert-Butoxycarbonyl)amino-4-bromo-1H-indole
[0219] 32 g of the title compound was obtained from 34 g of the
compound of Production Example 30 in the same manner as in
Production Example 9.
[0220] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.51(9H, s),
6.38-6.39(1H, m), 7.13(1H, d, J=8.0 Hz),7.44-7.46(2H, m), 9.11(1H,
brs), 11.2(1H, br s)
PRODUCTION EXAMPLE 32
[0221]
7-(N-tert-Butoxycarbonyl)amino-4-bromo-3-chloro-1H-indole
[0222] N-Chlorosuccinimide was treated in a
tetrahydrofuran-dimethylformam- ide solution containing the
compound of Production Example 31, to give the title compound.
[0223] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.50(9H, s), 7.19(1H,
d, J=8.4 Hz), 7.45(1H, d, J=8.4 Hz), 7.62(1H, d, J=2.8 Hz),
9.08(1H, brs), 11.41(1H, br s)
PRODUCTION EXAMPLE 33
[0224] 7-Amino-4-bromo-3-chloro-1H-indole Hydrochloride
[0225] 10.87 (31.5 mmol) of the compound of Production Example 32
was dissolved in methanol (120 ml). To the mixture was added
concentrated hydrochloric acid (20 ml), followed by stirring at
60.degree. C. for 40 minutes. After the reaction was finished, the
solvent was removed, and the mixture was subjected to azeotropic
distillation for 3 times using ethanol. The resulting solid was
washed with ether, to give 8.5 g of the title compound.
[0226] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 6.67(1H, d, J=8.0
Hz), 7.13(1H, d, J=8.0 Hz), 7.65(1H, d, J=2.8 Hz), 11.74(1H, br
s)
PRODUCTION EXAMPLE 34
[0227] 2-Amino-5-pyrimidinesulfonyl Chloride
[0228] 21 ml (0.316 mol) of chlorosulfonic acid was cooled in
ice-water and 3 g (0.032 mol) of 2-aminopyrimidine was added
thereto little by little under stirring. 9.2 ml (0.126 mol) of
thionyl chloride was further added thereto, followed by stirring at
150.degree. C. for 70 hours. The reaction solution was returned to
room temperature, poured into water and extracted with ethyl
acetate. The extract was dried over sodium sulfate and then
concentrated to dryness, to give 1.7 g of the title compound.
[0229] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 5.97(2H, broad),
8.83(2H, s)
SYNTHETIC EXAMPLE 1
[0230]
N-(3-Cyano-4-methyl-1H-indole-7-yl)-3-cyanobenzenesulfonamide
22
[0231] 2.00 g (11.7 mmol) of the compound of Production Example 12
was dissolved in 60 ml of tetrahydrofuran, followed by adding 4.0
ml (49.5 mmol) of pyridine and 2.60 g (12.9 mmol) of the compound
of Production Example 13 thereto. After stirring at room
temperature for 16 hours, the mixture was adjusted to pH 1 to 2 by
adding 2 N hydrochloric acid and extracted with ethyl acetate. The
organic layer was successively washed with water and brine, dried
over magnesium sulfate and concentrated. Then, the residue was
purified by silica gel chromatography, to give 3.90 g of the title
compound. (The compound hereinafter is referred to as Compound
A.)
[0232] Melting point: 220-221.degree. C. (recrystallized from
ethanol/n-hexane)
[0233] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.55 (3H, s), 6.50
(1H, d, J=8.0 Hz) 6.77 (1H, d, J=8.0 Hz), 7.71 (1H, t, J=8.0 Hz),
7.90 (1H, d, J=8.0 Hz), 8.05-8.13 (2H, m), 8.16 (1H, s), 10.11 (1H,
br s), 12.01 (1H, br s)
SYNTHETIC EXAMPLE 2
[0234]
N-(3-Cyano-4-methyl-1H-indole-7-yl)-6-chloro-3-pyridinesulfonamide
23
[0235] 700 mg (4.09 mmol) of the compound of Production Example 12
was dissolved in 20 ml of tetrahydrofuran, followed by adding 1.3
ml (16.1 mmol) of pyridine and 950 mg (4.48 mmol) of
6-chloro-3-pyridinesulfonyl chloride thereto. After stirring at
room temperature for 2 hours, the reaction solution was adjusted to
pH 1 to 2 by adding 1 N hydrochloric acid and extracted with ethyl
acetate. The organic layer was successively washed with water and
brine, dried over magnesium sulfate and concentrated. Then, the
residue was purified by silica gel column chromatography, to give
1.16 g of the title compound.
[0236] Melting point: 262 to 263.degree. C. (recrystallized from
ethanol/n-hexane).
[0237] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.57 (3H, s), 6.55
(1H, d, J=7.6 Hz), 6.82 (1H, d, J=7.6 Hz), 7.69 (1H, d, J=8.4 Hz),
8.01 (1H, dd, J=8.4, 2.4 Hz), 8.17 (1H, d, J=2.8 Hz), 8.60 (1H, d,
J=2.4 Hz), 10.21 (1H, br s), 12.03 (1H, br s)
SYNTHETIC EXAMPLE 3
[0238]
N-(3-Bromo-5-methyl-1H-indole-7-yl)-4-sulfamoylbenzenesulfonamide
24
[0239] 200 mg (0.89 mmol) of the compound of Production Example 22
was dissolved in 6 ml of tetrahydrofuran, followed by adding 0.3 ml
(3.71 mmol) of pyridine and 300 mg (1.17 mmol) of the compound of
Production Example 14 thereto. After stirring at room temperature
for 48 hours, the mixture was adjusted to pH 1 to 2 by adding 1 N
hydrochloric acid and extracted with ethyl acetate. The organic
layer was successively washed with water and brine, dried over
magnesium sulfate and concentrated. Then, a mixed solution of
diethyl ether and hexane was added to the residue and the resulting
crystals were collected by filtration, to give 387 mg of the title
compound.
[0240] Melting point: 196-197.degree. C. (recrystallized from
ethanol/n-hexane)
[0241] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.24 (3H, s), 6.60
(1H, s), 6.98 (1H, s), 7.44 (1H, s), 7.55 (2H, br s), 7.85-7.95
(4H, m), 10.13 (1H, br s), 11.01 (1H, br s)
SYNTHETIC EXAMPLE 4
[0242]
N-(5-Bromo-3-chloro-1H-indole-7-yl)-6-amino-3-pyridinesulfonamide
25
[0243] 1.00 g (3.55 mmol) of the compound of Production Example 16
was suspended in 25 ml of tetrahydrofuran, followed by adding 0.86
ml (10.6 mmol) of pyridine and 718 mg (3.73 mmol) of the compound
of Production Example 8 thereto under ice-cooling. After stirring
at room temperature for 3 hours, water was added thereto and the
mixture was extracted with ethyl acetate. The organic layer was
successively washed with water and brine, dried over magnesium
sulfate and concentrated. Then, the residue was purified by silica
gel column chromatography, to give 1.27 g of the title
compound.
[0244] Melting point: started coloring from a temperature close to
237.degree. C. and decomposed at 240 to 242.degree. C.
(recrystallized from ethanol-water)
[0245] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.37(1H, d, J=8.8
Hz), 6.94(2H, br s), 6.97(1H, s), 7.36(1H, s), 7.54-7.57(2H, m),
8.16(1H, d, J=2.8 Hz), 9.94(1H, br s), 11.17(1H, br s)
[0246] Hydrochloride
[0247] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.59(1H, d, J=9.2
Hz), 7.00(1H, s), 7.40(1H, s), 7.56(1H, d, J=2.4 Hz), 7.70(1H, dd,
J=9.2, 2.0 Hz), 8.20(1H, d, J=2.0 Hz), 10.20(1H, br s), 11.37(1H,
br s)
SYNTHETIC EXAMPLE 5
[0248]
N-(3-Bromo-5-methyl-1H-indole-7-yl)-3-cyanobenzenesulfonamide
26
[0249] Under ice-cooling, 0.19 ml (2.35 mmol) of pyridine and 280
mg (1.39 mmol) of 3-cyanobenzenesulfonyl chloride were added to a
tetrahydrofuran solution (6 ml) containing 260 mg (1.16 mmol) of
the compound of Production Example 22, followed by stirring at room
temperature overnight. Then, 0.2 N hydrochloric acid was added
thereto and the mixture was extracted with ethyl acetate. The
organic layer was successively washed with water and brine, dried
over magnesium sulfate and concentrated. Then, the residue was
purified by silica gel column chromatography, to give 360 mg of the
title compound.
[0250] Melting point: started decomposing gradually from a
temperature close to 148.degree. C. and decomposed rapidly at 163
to 164.degree. C. (recrystallized from ethanol/n-hexane).
[0251] .sup.1H-NMR(DMSO-d6) .delta. (ppm): 2.25(3H, s), 6.54(1H,
s), 7.01(1H, s), 7.42(1H, d, J=2.8 Hz), 7.71(1H, t, J=7.6 Hz),
7.93(1H, d, J=7.6 Hz), 8.07-8.11(2H, m), 10.09(1H, br s), 11.04(1H,
br s)
SYNTHETIC EXAMPLE 6
[0252] N-(4-Bromo-1H-indole-7-yl)-4-cyanobenzenesulfonamide 27
[0253] 700 mg (2.8 mmol) of the compound of Production Example 25
and 685 mg (3.4 mmol) of 4-cyanobenzenesulfonyl chloride were
processed in the same manner as in Synthetic Example 1, to give 686
mg of the title compound.
[0254] Melting point: 214 to 216.degree. C.
[0255] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.35 (1H, d, J=2.6
Hz), 6.53 (1H, d, J=8.0 Hz), 7.04 (1H, d, J=8.0 Hz), 7.41 (1H, t,
J=2.8 Hz), 7.85 (2H, d, J=8.0 Hz), 8.00 (2H, d, J=8.0 Hz), 10.24
(1H, brs), 11.19 (1H, brs)
SYNTHETIC EXAMPLE 7
[0256] N-(4-Chloro-1H-indole-7-yl)-6-amino-3-pyridinesulfonamide
28
[0257] 1330 mg (6.4 mmol) of the compound of Production Example 23
and 1000 mg (4.9 mmol) of the compound of Production Example 12
were processed in the same manner as in Synthetic Example 1, to
give 961 mg of the title compound.
[0258] Melting point: 204 to 206.degree. C.
[0259] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.38 (1H, d, J=9.0
Hz), 6.43 (1H, t, J=2.2 Hz), 6.77 (1H, d, J=7.7 Hz), 6.86 (2H,
brs), 7.42 (1H, t, J=2.6 Hz), 7.56 (1H, dd, J=2.6, 9.0 Hz), 8.14
(1H, d, J=2.6 Hz), 9.70 (1H, brs), 11.07 (1H, brs)
SYNTHETIC EXAMPLE 8
[0260]
N-(3-Bromo-4-chloro-1H-indole-7-yl)-6-amino-3-pyridinesulfonamide
and a Hydrochloride 29
[0261] 1 ml of dimethylformamide and 359 mg (2.0 mmol) of
N-bromosuccinimide were added to a tetrahydrofuran solution (10 ml)
containing 650 mg (2.0 mmol) of the compound of Synthetic Example
7, followed by stirring at room temperature overnight. Then, an
aqueous 0.2 N hydrochloric acid was added thereto, and the mixture
was extracted with ethyl acetate. The organic layer was
successively washed with an aqueous sodium thiosulfate, water and
brine, dried over magnesium sulfate and concentrated. Then, the
residue was purified by silica gel column chromatography, to give
662 mg of the title compound.
[0262] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.38 (1H, d, J=8.8
Hz), 6.76 (1H, d, J=8.4 Hz), 6.88 (2H, brs), 6.97 (1H, d,=8.4 Hz),
7.52-7.56 (2H, m) 8.12 (1H, d, J=2.4 Hz), 9.68 (1H, brs), 11.44
(1H, brs)
[0263] The resulting title compound (660 mg) was dissolved in 3 ml
of acetone, followed by adding 0.62 ml of a 4 N-hydrochloric
acid/ethyl acetate solution thereto. The resulting precipitates
were collected by filtration, to give 590 mg of a
hydrochloride.
[0264] Melting point: started decomposing gradually from a
temperature close to 267.degree. C.
[0265] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.65 (1H, d, J=9.2
Hz), 6.78 (1H, d, J=8.1 Hz), 6.98 (1H, d, J=8.2 Hz), 7.57 (1H,
d,=2.6 Hz), 7.73 (1H, dd, J=2.0, 9.0 Hz ), 8.15 (1H, d, J=2.4 Hz),
10.00 (1H, brs), 11.67 (1H, brs)
SYNTHETIC EXAMPLE 9
[0266]
N-(3-Bromo-5-methyl-1H-indole-7-yl)-5-cyano-2-thiophenesulfonamide
30
[0267] Under ice-cooling, chlorine gas was introduced into a
concentrated hydrochloric solution (15 ml) containing 1.3 g (5.6
mmol) of the compound of Production Example 30. After stirring for
30 minutes, the reaction solution was added to ice-water and
extracted with ethyl acetate. The organic layer was successively
washed with water and brine, dried over magnesium sulfate and
concentrated. The residue was added to a pyridine solution (6 ml)
containing 1.2 g (5.35 mmol) of the compound of Production Example
22, followed by stirring at room temperature overnight. Water was
added thereto, and the mixture was extracted with ethyl acetate.
The organic layer was successively washed with an aqueous 1 N
hydrochloric acid, water and brine, dried over magnesium sulfate
and concentrated. Then, the residue was purified by silica gel
chromatography, to give 1227 mg of the title compound.
[0268] Melting point: 166 to 169.degree. C. (decomposed)
[0269] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.30(3H, s),
6.65(1H, s), 7.07 (1H, s), 7.44 (1H, s), 7.54 (1H, d, J=4.0 Hz),
7.94 (1H, d, J=4.0 Hz), 10.47 (1H, brs), 11.04 (1H, brs)
SYNTHETIC EXAMPLE 10
[0270]
N-(4-Bromo-3-chloro-1H-indole-7-yl)-2-amino-5-pyrimidinesulfonamide
31
[0271] 513 mg (2.65 mmol) of the compound of Production Example 35
was added to 5 ml of a pyridine solution containing 712 mg (2.52
mmol) of the compound of Production Example 34, followed by
stirring for 15 hours. Water was added to the reaction solution,
and extracted with a mixed solution of ethyl acetate and
tetrahydrofuran (10:1). The organic layer was dried over magnesium
sulfate and then concentrated. The residue was purified by silica
gel column chromatography, to give 950 mg of the title
compound.
[0272] Melting point: 285 to 289.degree. C.
[0273] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.75(1H, d, J=8.0
Hz), 7.19(1H, d, J=8.0 Hz), 7.59(1H, d, J=3.0 Hz), 7.65(2H, s),
8.37(2H, s), 9.82(1H, s), 11.43(1H, s)
SYNTHETIC EXAMPLE 11
[0274] N-(3-Chloro-1H-indole-7-yl)-4-sulfamoylbenzenesulfonamide
32
[0275] 767 mg (3.0 mmol) of 4-sulfamoylbenzenesulfonyl chloride was
reacted with 264 mg (2.0 mmol) of 7-amino-1H-indole and treated, to
give 445 mg of N-(1H-indole-7-yl)-4-sulfanoylbenzenesulfonamide.
The resulting compound was chlorinated using N-chlorosuccinimide in
dichloromethane, to give 349 mg of the title compound.
[0276] Melting point: started coloring partially in a black color
from a temperature close to 220.degree. C. and decomposed gradually
from a temperature close to 240.degree. C. (recrystallized from
ethanol-n-hexane).
[0277] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.75(1H, d, J=7.6
Hz), 6.96(1H, dd, J=8.0, 7.6 Hz), 7.29(1H, d, J=7.6 Hz), 7.50(1H,
d, J=2.8 Hz), 7.58(2H, s), 7.90-7.98(4H, m), 10.23(1H, s),
11.07-11.17(1H, m)
PRODUCTION EXAMPLE 1a
[0278] 7-Bromo-1H-indole
[0279] 100 ml (100 mmol) of a tetrahydrofuran solution containing
1.0 M vinylmagnesium bromide was added to a tetrahydrofuran
solution (250 ml) containing 5.05 g (25 mmol) of
2-bromonitrobenzene at -40.degree. C. in nitrogen atmosphere,
followed by stirring as it was for 40 minutes. The reaction mixture
was poured into 500 ml of an aqueous saturated ammonium chloride,
and the mixture was extracted with ethyl ether. The extract was
dried over magnesium sulfate and concentrated. Then, the residue
was purified by silica gel column chromatography, to give 2.89 g of
the title compound.
[0280] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.56(1H, dd, J=2.9,
1.8 Hz), 6.94(1H, t, J=7.8 Hz), 7.30(1H, d, J=7.8 Hz), 7.40(1H, t,
J=2.9 Hz), 7.56(1H, d, J=7.8 Hz), 11.16-11.46(1H, br m)
PRODUCTION EXAMPLE 2a
[0281] 7-Amino-1H-indole
[0282] 16.5 ml (41.3 mmol) of a hexane solution containing 2.5 M
n-butyllithium was added dropwise to a tetrahydrofuran solution (50
ml) containing 2.70 g (13.8 mmol) of Production Example 1 a at
-70.degree. C. in nitrogen atmosphere, and the mixture was stirred
at -70.degree. C. for 15 minutes and then at -20 to -10.degree. C.
for 30 minutes. After cooling to -70.degree. C. again, 3.9 ml (18
mmol) of diphenylphosphorylazide was added dropwise thereinto. The
mixture was stirred at -70.degree. C. for one hour and then at
-40.degree. C. for one hour. After adding 22.3 ml (75.8 mmol) of a
toluene solution containing 3.4 M sodium
bis(2-methoxyethoxy)aluminum hydride thereto at -40.degree. C., the
mixture was stirred at -30 to -20.degree. C. for 30 minutes and
then at room temperature for 30 minutes. A phosphoric acid buffer
solution having a pH of 7.0 was added thereto, the insoluble
matters were collected by filtration and the filtrate was extracted
with ethyl ether. The organic layer was successively washed with an
aqueous saturated sodium bicarbonate and brine, dried over
magnesium sulfate and concentrated. Then, the residue was purified
by silica gel column chromatography, to give 1.29 g of the title
compound.
[0283] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 5.01(2H, br s),
6.25-6.33(2H, m), 6.70(1H, dd, J=7.9, 7.3 Hz), 6.78(1H, dd, J=7.9,
0.7 Hz), 7.23(1H, t, J=2.7 Hz), 10.48-10.72(1H, br m)
[0284] The following raw material compounds were synthesized from
2-bromonitrobenzene derivatives in the same manner as in Production
Examples 1a and 2a.
[0285] 7-amino-4-methoxy-1H-indole
[0286] 7-amino-4-bromo-1H-indole
PRODUCTION EXAMPLE 3a
[0287] 7-Bromo-3-chloro-4-methyl-1H-indole
[0288] 4.0 g (30.0 mmol) of N-chlorosuccinimide was added to an
acetonitrile solution (250 ml) containing 5.8 g (27.6 mmol) of
7-bromo-4-methyl-1H-indole synthesized from
2-bromo-5-methylnitrobenzene in the same manner as in Production
Example 1a, followed by stirring at room temperature overnight. 50
ml of a 1N aqueous sodium hydroxide was added thereto, and the
mixture was extracted with ethyl acetate. The organic layer was
washed with water, dried over magnesium sulfate and concentrated.
Then, the residue was purified by silica gel column chromatography,
to give 6.7 g of the title compound.
[0289] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 2.74 (3H, s),
6.75-7.26 (3H, m), 8.23 (1H, brs)
PRODUCTION EXAMPLE 4a
[0290] 7-Amino-3-chloro-4-methyl-1H-indole
[0291] 2.6 g of the title compound was obtained from 6.37 g (26.1
mmol) of the compound of Production Example 3a in the same manner
as in Production Example 2a.
[0292] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 2.70(3H, s),
6.39-7.14(3H, m), 8.15(1H, br s)
PRODUCTION EXAMPLE 5a
[0293] 4-Sulfamoylbenzenesulfonyl Chloride
[0294] 6.4 g (37.2 mmol) of 4-aminobenzenesulfonamide was added to
a mixed solution of 12.5 ml of water and 6.3 ml of concentrated
hydrochloric acid, followed by stirring. An aqueous saturated
solution containing 2.56 g (37.1 mmol) of sodium nitrite was added
dropwise thereinto at 0.degree. C. or less. The reaction solution
was added to an acetic acid solution saturated with sulfur dioxide
(solution obtained by saturating 35 ml of acetic acid with sulfur
dioxide and then adding 1.5 g of cupric chloride.multidot.dihydrate
thereto) under ice-cooling with stirring. After 10 minutes, the
reaction solution was poured into ice-water, and the precipitates
were collected by filtration and washed with water. The
precipitates were dissolved in tetrahydrofuran, dried over
magnesium sulfate and then concentrated to dryness, to give 3.5 g
of the title compound.
PRODUCTION EXAMPLE 6a
[0295] 4-(Sulfamoylmethyl)benzenesulfonyl Chloride
[0296] 5.0 g (23.1 mmol) of 4-nitrophenylmethanesulfonamide was
suspended in 90% acetic acid, which was then hydrogenated at normal
temperature under normal pressure in the presence of
palladium-carbon. After filtering off the catalyst, the filtrate
was concentrated to dryness, to give 4.3 g of
4-aminophenylmethanesulfonamide. The obtained compound was added to
a mixed solution of 40 ml of water and 4.1 ml of concentrated
hydrochloric acid, followed by stirring. An aqueous saturated
solution containing 1.63 g (23.6 mmol) of sodium nitrite was added
dropwise thereinto at 0.degree. C. or less. The reaction solution
was added to an acetic acid solution saturated with sulfur dioxide
(solution obtained by saturating 30 ml of acetic acid with sulfur
dioxide and then adding 0.97 g of cupric
chloride.multidot.dihydrate thereto) under ice-cooling with
stirring. After stirring at room temperature for 40 minutes, the
reaction solution was poured into ice-water and the mixture was
saturated with sodium chloride. The mixture was extracted with
ethyl acetate, and the extract was dried over magnesium sulfate and
then concentrated to dryness, to give 1.7 g of the title
compound.
[0297] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 4.26 (2H, s), 7.32
(2H, d, J=8.4 Hz), 7.59 (2H, d, J=8.4 Hz)
[0298] The following compounds were synthesized in the same manner
as in Production Example 5a or 6a.
[0299] 4-(N-methylsulfamoyl)benzenesulfonyl chloride
[0300] 4-(N-ethylsulfamoyl)benzenesulfonyl chloride
[0301] 4-(N-methoxysulfamoyl)benzenesulfonyl chloride
[0302] 4-[(methanesulfonamide)methyl]benzenesulfonyl chloride
[0303] 4-(N-methylmethanesulfonamide)benzenesulfonyl chloride
[0304] 4-(1-pyrrolidinylsulfonyl)benzenesulfonyl chloride
[0305] 4-(1-pyrrolidinylcarbonyl)benzenesulfonyl chloride
[0306] 3-cyanobenzenesulfonyl chloride
[0307] 4-(methylsulfonyl)benzenesulfonyl chloride
[0308] 4-[(N-methylmethanesulfonamide)methyl]benzenesulfonyl
chloride
PRODUCTION EXAMPLE 7a
[0309] 3-Cyano-7-nitro-1H-indole
[0310] 10.15 g (53.4 mmol) of 3-formyl-7-nitro-1H-indole was
dissolved in 150 ml of dimethylformamide, and 3.93 g (56.0 mmol)of
hydroxylamine hydrochloride and 4.5 ml (55.6 mmol) of pyridine were
added thereto. After heating under stirring at 70 to 80.degree. C.
for 2 hours, 6.3 g (56.8 mmol) of selenium dioxide and about 5 g of
magnesium sulfate were added thereto. After heating at 70 to
80.degree. C. for further 2.5 hours, the insoluble matters were
filtered off and the filtrate was concentrated. Water was added
thereto, and the resulting crystals were collected by filteration
and successively washed with water and ethyl ether. The crystals
were dissolved in a mixed solution of tetrahydrofuran and acetone,
and the insoluble matters were filtered off. After concentrating
the filtrate, ethyl acetate was added to the residue and the
crystals were collected by filtration, to give 8.61 g of the title
compound.
[0311] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.48(1H, t, J=8.1
Hz), 8.17(1H, d, J=8.1 Hz), 8.27 (1H, d, J=8.1 Hz), 8.47 (1H, s),
12.70-13.00 (1H, br)
PRODUCTION EXAMPLE 8a
[0312] 7-Amino-3-cyano-1H-indole
[0313] 2.80 g (15.0 mmol) of the compound of Production Example 7a
was suspended in 100 ml of methanol and hydrogenated under normal
pressure at normal temperature in the presence of palladium-carbon.
After filtering off the catalyst, the reaction mixture was
concentrated to dryness, to give 2.31 g of the title compound.
[0314] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 5.32, 5.34(2H,
s+s), 6.47(1H, d, J=7.5 Hz), 6.81(1H, d, J=7.9 Hz), 6.94(1H, dd,
J=7.9, 7.5 Hz), 8.13(1H, s), 11.55-11.90(1H, br),
PRODUCTION EXAMPLE 9a
[0315] 7-Amino-3,4-dichloro-1H-indole
[0316] 7-Bromo-4-chloro-1H-indole obtained from
2-bromo-5-chloronitrobenze- ne in the same manner as in Production
Example 1a was first chlorinated in the same manner as in
Production Example 3a, and then the bromo group was converted into
an amino group, to give the title compound.
[0317] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 5.26(2H, s),
6.29(1H, d, J=8.1 Hz), 6.74(1H, d, J=8.1 Hz), 7.45-7.51(1H, m),
11.08-11.27(1H, m)
[0318] 7-Amino-4-tert-butyldimethylsilyloxy-3-chloro-1H-indole was
synthesized in the same manner.
PRODUCTION EXAMPLE 10a
[0319] 7-Amino-3-chloro-1H-indole
[0320] 1.076 g (6.64 mmol) of 7-nitro-1H-indole was dissolved in 30
ml of acetonitrile, and 920 mg (6.89 mmol) of N-chlorosuccinimide
was added thereto. After stirring at room temperature for 36 hours,
an aqueous saturated sodium bicarbonate was added thereto. The
precipitates were collected by filtration and washed with water, to
give 1.2 g of 3-chloro-7-nitro-1H-indole. 863 mg (4.39 mmol) of the
powder was suspended in 10 ml of ethanol, and 4.95 g (21.9 mmol) of
stannous chloride.multidot.dihydrate and 100 .mu.l of concentrated
hydrochloric acid were added thereto. After heating under reflux
for 30 minutes, an aqueous saturated sodium bicarbonate was added
thereto and the insoluble matters were filtered off. After
extracting by adding ethyl acetate thereto, the extract was dried
over magnesium sulfate and concentrated. The residue was purified
by silica gel column chromatography, to give 490 mg of the title
compound.
[0321] The title compound was also obtained by hydrogenating
3-chloro-7-nitro-1H-indole at normal temperature under normal
pressure in the presence of a platinum-carbon catalyst.
[0322] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 5.14(2H, s),
6.36(1H, dd, J=7.5, 1.0 Hz), 6.68(1H, dd, J=7.9, 0.73 Hz), 6.81(1H,
dd, J=7.9, 7.5 Hz), 7.39(1H, d, J=2.7 Hz), 10.85(1H, br s)
PRODUCTION EXAMPLE 11a
[0323] 4-(2-Sulfamoylethyl)benzenesulfonyl Chloride
[0324] 1.3 g (7.3 mmol) of 2-phenylethanesulfonamide was added to
2.4 g (36.5 mmol) of chlorosulfonic acid under ice-cooling over 20
minutes, followed by stirring at room temperature for further 90
minutes. The reaction mixture solution was poured into ice-water,
and then extracted with ethyl acetate. The extract was successively
washed with an aqueous saturated sodium bicarbonate and brine, and
dried over magnesium sulfate. The solvent was evaporated, to give
1.6 g of the title compound.
[0325] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.97-3.02(2H, m),
3.21-3.26(2H, m), 7.21(2H, d, J=8.4 Hz), 7.53(2H, d, J=8.4 Hz)
[0326] The following raw material compounds were synthesized in the
same manner.
[0327] 4-[2-(methylsulfonyl)ethyl)benzenesulfonyl chloride
[0328] 4-[2-(N-methylmethanesulfonamide)ethyl)benzenesulfonyl
chloride
[0329] 4-[2-(methanesulfonamido)ethyl]benzenesulfonyl chloride
[0330] 4-(N-methylacetamido)benzenesulfonyl chloride
PRODUCTION EXAMPLE 12a
[0331] 5-Bromo-7-nitro-1H-indole
[0332] 5.05 g (17.7 mmol) of 1-acetyl-5-bromo-7-nitroindoline was
dissolved into a mixed solution of 6 ml of ethanol and 40 ml of 6 N
hydrochloric acid, followed by heating under reflux for 3 hours.
After neutralizing by adding sodium carbonate thereto, the mixture
was extracted with ethyl acetate. The extract was washed with
water, dried over magnesium sulfate and concentrated. Then, the
residue was purified by silica gel column chromatography, to give
4.13 g of 5-bromo-7-nitroindoline. 301 mg (1.24 mmol) of this
compound was added to 10 ml of toluene, and then 580 mg (2.55 mmol)
of 2,3-dichloro-5,6-dicyano- -1,4-benzoquinone was added thereto.
After heating under reflux for 3.5 hours while stirring, the
insoluble matters were filtered off and the filtrate was
concentrated. The residue was purified by silica gel column
chromatography, to give 252 mg of the title compound.
PRODUCTION EXAMPLE 13a
[0333] 5-Bromo-3-formyl-7-nitro-1H-indole
[0334] 210 mg (1.4 mmol) of phosphorous oxychloride was added to
1.0 g (14 mmol) of dimethylformamide at 0.degree. C. in nitrogen
atmosphere, followed by stirring for 30 minutes. 240 mg (1.0 mmol)
of the compound of Production Example 12a was added thereto at
0.degree. C., and the mixture was stirred at 0.degree. C. for 20
minutes and then at 100.degree. C. for 30 minutes. The reaction
mixture was ice-cooled and then poured into ice-water. The mixture
was stirred for 30 minutes, while it was kept at pH 7 to 8 by
adding a 1N aqueous sodium hydroxide. The resulting precipitates
were collected by filtration, washed with water and then purified
by silica gel column chromatography, to give 239 mg of the title
compound.
[0335] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 8.31(1H, d, J=1.8
Hz), 8.55(1H, s) 8.65(1H, d, J=1.8 Hz), 10.05(1H, s), 12.89(1H, br
s)
PRODUCTION EXAMPLE 14a
[0336] 7-Amino-5-bromo-3-cyano-1H-indole
[0337] 214 mg (0.8 mmol) of 5-bromo-3-cyano-7-nitro-1H-indole
obtained from the compound of Production Example 13a in the same
manner as in Production Example 7a was dissolved in a mixed
solution of 10 ml of methanol and 10 ml of tetrahydrofuran. The
mixture was hydrogenated at 3.0 kg/cm.sup.2 in the presence of
platinum oxide, then the catalyst was filtered off and the filtrate
was concentrated to dryness, to give 189 mg of the title
compound.
[0338] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 5.68-5.71(2H, m),
6.60(1H, d, J=2.0 Hz), 6.91(1H, d, J=2.0 Hz), 8.16(1H, s)
PRODUCTION EXAMPLE 15a
[0339] 3-Acetyl-7-amino-1H-indole
[0340] 11 ml (11 mmol) of a hexane solution containing 1.0 M
dimethylaluminum chloride was added to a dichloromethane solution
(50 ml) containing 1.2 g (7.5 mmol) of 7-nitro-1H-indole at
0.degree. C. in nitrogen atmosphere. Then, 2.1 ml (29.5 mmol) of
acetyl chloride was added thereto at 0.degree. C., followed by
stirring at room temperature for 4 hours. An aqueous saturated
ammonium chloride was added to the reaction system and the
resulting precipitates were collected by filtration. These
precipitates were washed sufficiently with hot ethanol. The washing
solution was combined with the filtrate and the combined solution
was concentrated. Water was added to the residue, and the mixture
was extracted with ethyl acetate. The extract was washed with
brine, and dried over magnesium sulfate. The solvent was
evaporated, and the residue was purified by silica gel column
chromatography, to give 3-acetyl-7-nitro-1H-indole. The product was
dissolved in 100 ml of methanol and hydrogenated at normal
temperature under normal pressure in the presence of
palladium-carbon. After filtering off the catalyst, the filtrate
was concentrated to dryness, to give 790 mg of the title
compound.
SYNTHETIC EXAMPLE 1a
[0341] N-(1H-Indole-7-yl)-4-nitrobenzenesulfonamide
[0342] 1.50 g (11.3 mmol) of the compound of Production Example 2a
was dissolved in 40 ml of pyridine, followed by adding 2.57 g (11.6
mmol) of 4-nitrobenzenesulfonyl chloride thereto at room
temperature under stirring. After stirring at room temperature
overnight, the solvent was evaporated, and to the residue were
added ethyl acetate and 0.2 N hydrochloric acid. The organic layer
was separated, washed with water, dried over magnesium sulfate.
Then, the solvent was evaporated, and the residue was purified by
silica gel column chromatography, to give 3.50 g of the title
compound.
[0343] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.42(1H, dd, J=2.8,
2.0 Hz), 6.66(1H, d, J=7.6 Hz), 6.83(1H, dd, J=8.0, 7.6 Hz),
7.31(1H, dd, J=3.2, 2.8 Hz), 7.36(1H, d, J=8.0 Hz), 7.94-8.02(2H,
m), 8.30-8.38(2H, m), 10.23(1H, s), 10.74-10.87(1H, m)
SYNTHETIC EXAMPLE 2a
[0344] N-(3-Chloro-1H-indole-7-yl)-4-nitrobenzenesulfonamide
[0345] 8.98 g (28.3 mmol) of the compound of Synthetic Example la
was dissolved in a mixed solution of 280 ml of dichloromethane and
7 ml of dimethylformamide, followed by adding 4.16 g (31.2 mmol) of
N-chlorosuccinimide under stirring in a nitrogen atmosphere. After
stirring at room temperature for 1.5 hours, 50 ml of water was
added thereto and the mixture was concentrated until the amount of
the mixture became about 80 ml. The organic layer was separated by
adding ethyl acetate and 0.2 N hydrochloric acid thereto,
successively washed with aqueous saturated sodium bicarbonate and
brine, and dried over magnesium sulfate. Then, the solvent was
evaporated, and the residue was purified by silica gel column
chromatography, to give 7.98 g of the title compound.
[0346] Melting point: 199.5 to 200.5.degree. C. (recrystallized
from chloroform)
[0347] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.72(1H, d, J=7.6
Hz), 6.96(1H, dd, J=8.0, 7.6 Hz), 7.31(1H, d, J=8.0 Hz),
7.47-7.53(1H, m), 7.92-8.02(2H, m), 8.30-8.41(2H, m), 10.33(1H, s),
11.07-11.22(1H, m)
SYNTHETIC EXAMPLE 3a
[0348] 4-Amino-N-(3-chloro-1H-indole-7-yl)benzenesulfonamide
[0349] 7.98 g (22.7 mmol) of the compound of Synthetic Example 2a
was dissolved in 220 ml of methanol, followed by heating under
reflux with stirring. 10 ml of concentrated hydrochloric acid and
7.40 g of a zinc powder were added thereto three times at intervals
of 10 minutes, followed by refluxing for further 10 minutes. After
cooling, the reaction mixture was neutralized by adding
significantly excess sodium bicarbonate and the insoluble matters
were filtered off. After concentrating the filtrate, the residue
was dissolved in ethyl acetate. The mixture was successively washed
with an aqueous saturated sodium bicarbonate, a 2N aqueous sodium
carbonate solution and brine, dried over magnesium sulfate, and
then the solvent was evaporated. The residue was purified by silica
gel column chromatography, to give 7.21 g of the title compound.
Melting point: 174.5 to 176.degree. C. (recrystallized from
ethanol-n-hexane)
[0350] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 5.97(2H, br s),
6.48(2H, d, J=8.8 Hz), 6.88(1H, d, J=7.6 Hz), 6.95(1H, dd, J=8.0,
7.6 Hz), 7.19(1H, d, J=8.0 Hz), 7.36(2H, d, J=8.8 Hz), 7.46(1H, d,
J=2.4 Hz), 9.56(1H, s), 10.86-10.98(1H, m)
SYNTHETIC EXAMPLE 4a
[0351]
N-(3-Chloro-1H-indole-7-yl)-4-(methanesulfonamide)benzenesulfonamid-
e
[0352] 68 mg (0.211 mmol) of the compound of Synthetic Example 3a
was dissolved in 1 ml of pyridine, followed by adding 15 .mu.l
(0.194 mmol) of methanesulfonyl chloride. After stirring at room
temperature overnight, an aqueous sodium bicarbonate was added
thereto, and the mixture was extracted with ethyl acetate. The
organic layer was successively washed with dilute hydrochloric acid
and water, dried over magnesium sulfate, and concentrated. Then,
the residue was purified by silica gel thin layer chromatography,
to give 76 mg of the title compound.
[0353] Melting point: 213.5 to214.degree. C. (decomposed)
(recrystallized from ethanol/n-hexane)
[0354] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.08(3H, s),
6.83(1H, d, J=7.5 Hz), 6.96(1H, dd, J=7.9, 7.7 Hz), 7.23(2H, d,
J=8.8 Hz), 7.24(1H, d, J=7.5 Hz), 7.47(1H, d, J=2.7 Hz), 7.68(2H,
d, J=8.8 Hz), 9.92(1H, br s), 10.38(1H, br s), 10.99(1H, br s)
SYNTHETIC EXAMPLE 5a
[0355] 4-Bromomethyl-N-(1H-indole-7-yl)benzenesulfonamide
[0356] 4-Bromomethylbenzenesulfonyl chloride and the compound of
Production Example 2a were reacted in tetrahydrofuran at room
temperature in the presence of an equivalent mol of pyridine and
treated in the same manner as in Synthetic Example 1am, to give the
title compound.
[0357] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 4.70(2H, s),
6.40(1H, dd, J=3.1, 1.1 Hz), 6.71(1H, ddd, J=7.4, 3.2, 0.92 Hz),
6.81(1H, ddd, J=8.1, 7.4, 0.92 Hz), 7.29-7.32 (2H, m), 7.57 (2H, d,
J=8.2 Hz), 7.73 (2H, d, J=8.4 Hz), 9.96(1H, br s), 10.75(1H, br
s)
SYNTHETIC EXAMPLE 6a
[0358]
N-(1,3-Dihydro-2H-indole-2-one-7-yl)-4-methylbenzenesulfonamide
[0359] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0360] Melting point: started decomposing gradually from a
temperature close to 246.degree. C. and decomposed rapidly at 267
to 269.degree. C. (recrystallized- from dioxane).
SYNTHETIC EXAMPLE 7a
[0361] 3-Chloro-N-(3-chloro-1H-indole-7-yl)benzenesulfonamide
[0362] 2.18 g (7.11 mmol) of
3-chloro-N-(1H-indole-7-yl)benzenesulfonamide synthesized in the
same manner as in Synthetic Example 1a was chlorinated in the same
manner as in Example 2a, to give 1.86 g of the title compound.
[0363] Melting point: 180 to 181.degree. C. (recrystallized from
dichloromethane/diisopropyl ether)
[0364] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.73(1H, d, J=7.6
Hz), 6.97(1H, dd, J=8.0, 7.6 Hz), 7.30(1H, d, J=8.0 Hz),
7.45-7.51(1H, m), 7.51-7.76(4H, m), 10.09(1H, s), 11.02-11.18(1H,
m)
SYNTHETIC EXAMPLE 8a
[0365]
4-Amino-N-(3,4-dichloro-1H-indole-7-yl)benzenesulfonamide
[0366] 2.03 g of the title compound was obtained from 2.43 g (6.29
mmol) of N-(3,4-dichloro-1H-indole-7-yl)-4-nitrobenzenesulfonamide
synthesized in the same manner as in Synthetic Example 1a in the
same manner as in Example 3a.
[0367] Melting point: 205 to 206.5.degree. C. (decomposed)
(recrystallized from ethanol/n-hexane)
[0368] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.00(2H, s),
6.50(2H, d, J=8.4 Hz), 6.77(1H, d, J=8.0 Hz), 6.94(1H, d, J=8.0
Hz), 7.35(2H, d, J=8.4 Hz), 7.51-7.58(1H, m), 9.57(1H, s),
11.20-11.38(1H, m)
SYNTHETIC EXAMPLE 9a
[0369] 4-[N-(1H-Indole-7-yl)sulfamoyl]benzoic Acid
[0370] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0371] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.40(1H, dd, J=2.9,
1.9 Hz), 6.67(1H, d, J=7.5 Hz), 6.82(1H, dd, J=7.9, 7.5 Hz),
7.31(1H, dd, J=2.9, 2.7 Hz), 7.33 (1H, d, J=7.9 Hz), 7.81-7.88 (2H,
m), 7.99-8.07 (2H, m), 10.07(1H, s), 10.73-10.83(1H, m),
13.30-13.58(1H, br)
SYNTHETIC EXAMPLE 10a
[0372] N-(3-Chloro-1H-indole-7-yl)-4-cyanobenzenesulfonamide
[0373] 76 mg of the title compound was obtained in the same manner
as in Example 2a, from 100 mg of
4-cyano-N-(1H-indole-7-yl)benzenesulfonamide synthesized in the
same manner as in Synthetic Example 1a.
[0374] Melting point: 210 to 211.degree. C. (recrystallized from
ethyl acetate/n-hexane)
[0375] .sup.1H-NMR(DMSO-d.sub.6) .delta.(ppm): 6.71(1H, dd, J=7.6,
0.8 Hz), 6.96(1H, dd, J=8.0, 7.6 Hz), 7.30(1H, d, J=8.0 Hz),
7.48(1H, dd, J=2.4, 0.8 Hz), 7.82-7.90(2H, m), 7.97-8.05(2H, m),
10.25(1H, s), 11.04-11.15(1H, m)
SYNTHETIC EXAMPLE 11a
[0376]
3-Chloro-N-(3-chloro-4-hydroxy-1H-indole-7-yl)benzenesulfonamide
[0377] 52 mg of the title compound was obtained in the same manner
as in Example 2a, from 100 mg of
3-chloro-N-(4-methoxy-1H-indole-7-yl)benzenesu- lfonamide
synthesized in the same manner as in Synthetic Example 1a.
[0378] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.79(3H, s),
6.37(1H, d, J=8.4 Hz), 6.45(1H, d, J=8.4 Hz), 7.24-7.31(1H, m),
7.48-7.77(4H, m), 9.76(1H, s), 11.06-11.17(1H, m)
SYNTHETIC EXAMPLE 12a
[0379]
3-Chloro-N-(3-chloro-4-hydroxy-1H-indole-7-yl)benzenesulfonamide
[0380] 220 mg (0.47 mmol) of
N-(4-tert-butyldimethylsilyloxy-3-chloro-1H-i-
ndole-7-yl)-3-chlorobenzenesulfonamide synthesized in the same
manner as in Synthetic Example 1a was added to a mixed solution (2
ml) of an aqueous 40% hydrogen fluoride solution/acetonitrile
(1:10). After stirred at room temperature overnight, water was
added thereto and the mixture was extracted with ethyl acetate. The
extract was dried over magnesium sulfate and concentrated. Then,
the residue was purified by silica gel column chromatography, to
give 141 mg of the title compound.
[0381] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.15(1H, dd, J=8.2,
1.5 Hz), 6.26(1H, d, J=8.2 Hz), 7.12(1H, s), 7.47-7.64(4H, m),
9.54(1H, s), 10.85(1H, s)
SYNTHETIC EXAMPLE 13a
[0382] N-(1H-Indazole-7-yl)-4-methoxybenzenesulfonamide
[0383] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0384] Melting point: 155 to 156.degree. C. (recrystallized from
ethyl acetate-n-hexane)
[0385] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.77(3H, s),
6.91-6.99(2H, m), 6.98-7.07(2H, m), 7.45-7.53(1H, m), 7.64-7.74(2H,
m), 8.01-8.07(1H, m), 9.97(1H, s), 12.61-12.72(1H, m)
SYNTHETIC EXAMPLE 14a
[0386]
6-Chloro-N-(3-chloro-1H-indole-7-yl)-3-pyridinesulfonamide
[0387] The title compound was obtained by chlorinating
6-chloro-N-(1H-indole-7-yl)-3-pyridinesulfonamide obtained by
reacting 6-chloro-3-pyridinesulfonyl chloride and the compound of
Production Example 2a in the same manner as in Example 1a.
[0388] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.73(1H, d, J=7.7
Hz), 6.97(1H, dd, J=7.9, 7.7 Hz), 7.30(1H, d, J=7.9 Hz), 7.46(1H,
d, J=2.6 Hz), 7.67(1H, d, J=8.4 Hz), 8.03(1H, dd, J=8.4, 2.6 Hz),
8.62(1H, d, J=2.6 Hz), 10.18-10.34(1H, br), 11.06-11.17(1H, m)
SYNTHETIC EXAMPLE 15a
[0389] N-(3-Chloro-1H-indole-7-yl)
-4-(methylthiomethyl)benzenesulfonamide
[0390] 1.97 g (5.37 mmol) of the compound of Synthetic Example 5a
was dissolved in 10 ml of tetrahydrofuran. To the mixture were
added 10 ml (39.4 mmol) of an aqueous 15% sodium methylthiolate
solution and a catalytic amount of methyltrioctylammonium chloride
at room temperature, followed by stirring over night. 20 ml of
water was added thereto, and the mixture was extracted with ethyl
acetate. The organic layer was washed with water, dried over
magnesium sulfate and concentrated. Then, the residue was purified
by silica gel column chromatography, to give 1.51 g of
N-(1H-indole-7-yl)-4(methylthiomethyl)benzenesulfonamide. The
product was chlorinated in the same manner as in Example 2a, to
give 839 mg of the title compound.
[0391] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.87(3H, s),
3.70(2H, s), 6.77(1H, dd, J=7.6, 2.1 Hz), 6.94(1H, dd, J=7.9, 7.7
Hz), 7.24(1H, d, J=7.9 Hz), 7.42(2H, d, J=8.2 Hz), 7.47(1H, d,
J=2.6 Hz), 7.67(2H, d, J=8.4 Hz), 9.96(1H, br s), 11.01(1H, br
s)
SYNTHETIC EXAMPLE 16a
[0392] 3-Chloro-N-(3-formyl-1H-indole-7-yl)benzenesulfonamide
[0393] 1.3 ml (13.9 mmol) of phosphorous oxychloride was added
dropwise to 14.5 ml of dimethylformamide at 10.degree. C. or less
under stirring in nitrogen atmosphere. After stirring at about
5.degree. C. for 30 minutes, 2.50 g (8.15 mmol) of
3-chloro-N-(1H-indole-7-yl)benzenesulfonamide synthesized in the
same manner as in Example 1 was added thereto in three portions.
After stirring at about 5.degree. C. for further 30 minutes, 200 ml
of cooled water was added thereto. The reaction mixture was
adjusted to pH about 14 by adding a 1N aqueous sodium hydroxide and
then to pH about 2 by adding 1N hydrochloric acid, and then
extracted by adding ethyl acetate thereto. The organic layer was
washed with brine, dried over magnesium sulfate and concentrated.
The residue was purified by silica gel column chromatography, to
give 1.45 g of the title compound.
[0394] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.70(1H, dd, J=7.6,
0.8 Hz), 7.06(1H, dd, J=8.0,7.6 Hz), 7.51-7.75(4H, m), 7.93(1H, d,
J=8.0 Hz), 8.22-8.28(1H, m), 9.93(1H, s), 10.17(1H, s),
11.86-11.98(1H, m)
SYNTHETIC EXAMPLE 17a
[0395] 3-Chloro-N-(3-cyano-1H-indole-7-yl)benzenesulfonamide
[0396] 274 mg (3.94 mmol) of hydroxylamine hydrochloride and 0.32
ml (3.96 mmol) of pyridine were added to a dimethylformamide
solution (18 ml) containing 1.20 g (3.58 mmol) of the compound of
Synthetic Example 16a at 70 to 80.degree. C. under stirring. After
stirring for 2.5 hours as it was, 437 mg (3.94 mmol) of selenium
dioxide and about 100 mg of magnesium sulfate powder were added
thereto. After stirring at the same temperature for further 2
hours, the solvent was evaporated. To the residue was added ethyl
acetate, and the insoluble matters were collected by filtration.
The filtrate was successively washed with 0.1 N hydrochloric acid
and brine, dried over magnesium sulfate and the solvent was
evaporated. The residue was purified by silica gel column
chromatography, to give 678 mg of the title compound. Melting
point: 204.5 to 205.degree. C. (recrystallized from ethyl
acetate/n-hexane)
[0397] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.71(1H, d, J=7.6
Hz), 7.08(1H, dd, J=8.0, 7.6 Hz), 7.47(1H, d, J=8.0 Hz),
7.50-7.76(4H, m), 8.17-8.25(1H, m), 10.21(1H, s), 11.92-12.09(1H,
m)
SYNTHETIC EXAMPLE 18a
[0398]
6-Chloro-N-(3-cyano-1H-indole-7-yl)-3-pyridinesulfonamide
[0399] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0400] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.77(1H, d, J=7.9
Hz), 7.12(1H, t, J=7.9 Hz), 7.50(1H, d, J=7.9 Hz), 7.72(1H, d,
J=8.4 Hz), 8.06(1H, dd, J=8.4, 2.6 Hz), 8.23(1H, d, J=2.6 Hz),
8.65(1H, d, J=2.6 Hz), 10.34-10.48(1H, br), 11.98-12.12(1H, m)
SYNTHETIC EXAMPLE 19a
[0401]
N-(3-Chloro-1H-indole-7-yl)-4-sulfamoylbenzenesulfonamide
[0402] 767 mg (3.0 mmol) of the compound of Production Example 5a
and 264 mg (2.0 mmol) of the compound of production Example 2a were
reacted and treated in the same manner as in Example 1a, to give
445 mg of N-(1H-indole-7-yl)-4-sulfamoylbenzenesulfonamide. The
product was chlorinated in the same manner as in Example 2a, to
give 349 mg of the title compound.
[0403] Melting point: started coloring partially in a black color
from a temperature close to 220.degree. C. and decomposed gradually
from a temperature close to 240.degree. C. (recrystallized from
ethanol/n-hexane).
[0404] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.75(1H, d, J=7.6
Hz), 6.96(1H, dd, J=8.0, 7.6 Hz), 7.29(1H, d, J=7.6 Hz), 7.50(1H,
d, J=2.8 Hz), 7.58(2H, s), 7.90-7.98(4H, m), 10.23(1H, s),
11.07-11.17(1H, m)
SYNTHETIC EXAMPLE 20a
[0405] 3-Chloro-N-(8-imidazo[1,2-a]pyridinyl)benzenesulfonamide
Hydrochloride
[0406] 1.97 g (18 mmol) of 2,3-diaminopyridine was dissolved in a
mixed solution of tetrahydrofuran and water, and a tetrahydrofuran
solution containing 1.90 g (9.0 mmol) of 3-chlorobenzenesulfonyl
chloride was added thereto. After stirring at room temperature
overnight, the mixture was concentrated, and water and
dichloromethane were added to the residue. The organic layer was
separated, and the wall of the reactor was rubbed. The resulting
crystals were collected by filtration, to give 1.41 g of
N-(2-amino-3-pyridiny)-3-chlorobenzenesulfonamide. 530 mg (1.87
mmol) of the crystals was dissolved in methanol and 367 mg (1.87
mmol) of an aqueous 40% chloroacetoaldehyde solution was added
thereto. After heating under reflux for 4 hours, the mixture was
concentrated to dryness. A small amount of methanol was added to
the residue and the crystals were collected by filtration, to give
373 mg of the title compound.
[0407] Melting point: gradually decomposed from a temperature close
to 210.degree. C. (recrystallized from ethanol)
SYNTHETIC EXAMPLE 21a
[0408]
N-(3,4-Dichloro-1H,-indole-7-yl)-4-sulfamoylbenzenesulfonamide
[0409] 429 mg (1.68 mmol) of the compound of Production Example 5a
and 250 mg (1.24 mmol) of the compound of Production Example 9a
were reacted and treated in the same manner as in Example 1a, to
give 200 mg of the title compound.
[0410] Melting point: started coloring from a temperature close to
282.degree. C. and gradually decomposed (recrystallized from
ethanol/ethyl ether).
[0411] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.62(1H, d, J=8.1
Hz), 6.95(1H, d, J=8.1 Hz), 7.53-7.62(3H, m), 7.87-7.99(4H, m),
10.17-10.33(1H, br), 11.44-11.56(1H, m)
SYNTHETIC EXAMPLE 22a
[0412]
N-(3-Chloro-1H-indole-7-yl)-4-(methylthio)benzenesulfonamide
[0413] The title compound was obtained in the same manner as in
Synthetic Examples 1a and 2a.
[0414] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.48(3H, s),
6.82(1H, dd, J=7.9, 1.5 Hz), 6.96(1H, dd, J=8.1, 7.5 Hz), 7.25(1H,
dd, J=7.9, 0.92 Hz), 7.33(2H, d, J=8.8 Hz), 7.49(1H, d, J=2.7 Hz),
7.62(2H, d, J=8.6 Hz), 9.96(1H, br s), 11.02(1H, br s)
SYNTHETIC EXAMPLE 23a
[0415]
N-(3-Chloro-1H-indole-7-yl)-4-(methylsulfonyl)benzenesulfonamide
[0416] 54.2 mg (0.154 mmol) of the compound of Synthetic Example
22a was dissolved in a mixed solution of 2 ml of methanol and 1.2
ml of water, to which were then added 30 mg of ammonium
molybdate.multidot.tetrahydrate and 0.6 ml of aqueous 30% hydrogen
peroxide at room temperature. After stirring overnight, water was
added thereto and the mixture was extracted with ethyl acetate. The
extract was washed with water, dried over magnesium sulfate and
concentrated. Then, the residue was purified by silica gel column
chromatography, to give 29.4 mg of the title compound.
[0417] Melting point: started coloring from a temperature close to
250.degree. C. and decomposed at 264 to 266.degree. C.
(recrystallized from ethanol/n-hexane)
[0418] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.28(3H, s),
6.75(1H, d, J=7.7 Hz), 6.97(1H, dd, J=7.9, 7.7 Hz), 7.30(1H, d,
J=8.1 Hz), 7.50(1H, d, J=2.7 Hz), 7.97(2H, d, J=8.2 Hz), 8.09(2H,
d, J=8.4 Hz), 10.29(1H, br s), 11.12(1H, br s)
SYNTHETIC EXAMPLE 24a
[0419]
N-(3-Chloro-1H-indole-7-yl)-4-(methylsulfinyl)benzenesulfonamide
[0420] 19.9 mg (0.056 mmol) of the compound of Synthetic Example
22a was dissolved in 2 ml of dichloromethane, followed by adding 10
mg (0.058 mmol) of m-chloroperbenzoate under stirring under
ice-cooling. After one hour, an aqueous saturated sodium
bicarbonate was added thereto, and the mixture was extracted with
ethyl acetate. The extract was washed with water, dried over
magnesium sulfate and concentrated. Then, the residue was purified
by silica gel thin layer chromatography, to give 14.4 mg of the
title compound.
[0421] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.76(3H, s),
6.78(1H, dd, J=7.5, 1.1 Hz), 6.96(1H, dt, Jd=0.55 Hz, Jt=7.8 Hz),
7.28(1H, dd, J=7.6, 0.82 Hz), 7.48(1H, d, J=2.7 Hz), 7.82(2H, d,
J=8.6 Hz), 7.89(2H, d, J=8.8 Hz), 10.15(1H, br s), 11.06(1H, br
s)
SYNTHETIC EXAMPLE 25a
[0422]
3-Chloro-N-(3-chloro-1H-pyrrolo[3,2-c]pyridine-7-yl)benzenesulfonam-
ide
[0423] The title compound was obtained in the same manner as in
Synthetic Examples 1a and 2a.
[0424] .sup.1H-NMR(DMSO-d6) .delta. (ppm): 7.41-7.65(2H, m),
7.65-7.77(2H, m), 7.74-7.86(2H, m), 8.40-8.62(1H, br m),
12.38-12.58(1H, br), 13.56-13.74(1H, br)
SYNTHETIC EXAMPLE 26a
[0425]
4-Acetamide-N-(3-chloro-4-methyl-1H-indole-7-yl)benzenesulfonamide
[0426] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0427] Melting point: decomposed gradually from a temperature close
to 225.degree. C. (recrystallized from ethanol/n-hexane)
[0428] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.03(3H, s),
2.56(3H, s), 6.54-6.60(2H, m), 7.33(1H, d, J=2.6 Hz), 7.60(2H, d,
J=9.0 Hz), 7.64(2H, d, J=9.0 Hz), 9.63(1H, br s), 10.24(1H, br s),
10.92(1H, br s)
SYNTHETIC EXAMPLE 27a
[0429]
4-Amino-N-(3-chloro-4-methyl-1H-indole-7-yl)benzenesulfonamide
[0430] 3.75 g (9.9 mmol) of the compound of Synthetic Example 26a
was dissolved in 25 ml of an aqueous 2 N sodium hydroxide, followed
by stirring at 100.degree. C. for 2 hours. After returnign to room
temperature, the mixture was adjusted to pH 6 by adding acetic
acid. The resulting precipitates were collected by filtration and
purified by silica gel column chromatography, to give 1.1 g of the
title compound.
[0431] Melting point: decomposed gradually from a temperature close
to 230.degree. C. (recrystallized from ethanol/n-hexane)
[0432] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.56(3H, s),
5.93(2H, br s), 6.46(2H, d, J=8.8 Hz), 6.59(1H, d, J=7.8 Hz),
6.64(1H, d, J=7.8 Hz), 7.31(2H, d, J=8.8 Hz), 7.36(1H, d, J=2.9
Hz), 9.34(1H, br s), 10.88(1H, br s)
SYNTHETIC EXAMPLE 28a
[0433] 4-Cyano-N-(3-cyano-1H-indole-7-yl)benzenesulfonamide.
[0434] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0435] Melting point: 250.5 to 252.degree. C. (recrystallized from
ethyl acetate/n-hexane)
[0436] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.67(1H, d, J=7.7
Hz), 7.05(1H, t, J=7.9 Hz), 7.44(1H, d, J=7.7 Hz), 7.78-7.87(2H,
m), 7.97-8.05(2H, m), 8.16-8.23(1H, m), 10.28-10.43(1H, br),
11.92-12.09(1H, m)
SYNTHETIC EXAMPLE 29a
[0437]
4-Carbamoyl-N-(3-chloro-1H-indole-7-yl)benzenesulfonamide
[0438] To a solution of 1.0 g (3.01 mmol) of the compound of
Synthetic Example 10a added to 4.8 ml of ethanol 2.4 ml were added
a 30% aqueous hydrogen peroxide and 360 .mu.l of an aqueous 6 N
sodium hydroxide were respectively added in three portions under
stirring. (reaction temperature: about 50.degree. C.). After
stirring at at 50.degree. C. for further 30 minutes, the reaction
mixture was acidified by adding dilute hydrochloric acid and then
extracted with ethyl acetate. The organic layer was collected by
fractionation, washed with water, dried over magnesium sulfate and
concentrated. The residue was purified by silica gel column
chromatography, to give 600 mg of the title compound. Melting
point: started coloring and decomposing from a temperature close to
248.degree. C. and rapidly decomposed at 252.5 to 253.5.degree. C.
(recrystallized from ethanol/n-hexane)
[0439] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.76(1H, d, J=7.5
Hz), 6.95(1H, dd, J=8.1, 7.5 Hz), 7.27(1H, d, J=8.1 Hz), 7.49(1H,
d, J=2.6 Hz), 7.59 (1H, br s), 7.76-7.83(2H, m), 7.91-7.98 (2H, m),
8.12 (1H, br s), 10.10(1H, s), 11.01-11.12(1H, m)
SYNTHETIC EXAMPLE 30a
[0440] N-(4-Bromo-1H-indole-7-yl)-4-nitrobenzenesulfonamide
[0441] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0442] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.35-6.41(1H, m),
6.56(1H, d, J=8.4 Hz), 7.06(1H, dd, J=8.4, 0.8 Hz), 7.41-7.48(1H,
m), 7.92-8.02(2H, m), 8.30-8.41(2H, m), 10.34(1H, s),
11.18-11.32(1H, m)
SYNTHETIC EXAMPLE 31a
[0443]
N-(3-Chloro-4-cyano-1H-indole-7-yl)-4-nitrobenzenesulfonamide
[0444] 200 mg (0.505 mmol) of the compound of Synthetic Example 30a
was dissolved in 0.8 ml of N-methylpyrrolidone, followed by adding
83 mg (0.91 mmol) of cuprous cyanide. After stirring at 180 to
19.degree. C. for3 hours, 40 ml of ice-water was added thereto. The
insoluble matters were collected by filtration, washed with water,
and extracted with hot ethanol and hot chloroform. The extract was
concentrated and the residue was purified by silica gel thin layer
chromatography, to give 65 mg of
N-(4-cyano-1H-indole-7-yl)-4-nitrobenzenesulfonamide. This product
was chlorinated in the same manner as in Example 2, to give 42 mg
of the title compound.
[0445] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.98(1H, d, J=8.0
Hz), 7.51(1H, d, J=8.0 Hz), 7.79(1H, d, J=2.8 Hz), 7.99-8.08(2H,
m), 8.31-8.40(2H, m), 10.75-10.95(1H, br), 11.62-11.73(1H, m)
SYNTHETIC EXAMPLE 32a
[0446]
4-Amino-N-(3-chloro-4-cyano-1H-indole-7-yl)benzenesulfonamide
[0447] The title compound was obtained from the compound of
Synthetic Example 31a in the same manner as in synthetic Example
3a.
[0448] Melting point: started decomposing from a temperature close
to 232.degree. C. and rapidly decomposed at 249.5 to 255.degree. C.
(recrystallized from ethanol-n-hexane)
[0449] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.09(2H, s),
6.52(2H, d, J=8.8 Hz), 7.10(1H, d, J=8.4 Hz), 7.46(2H, d, J=8.8
Hz), 7.50(1H, d, J=8.4 Hz), 7.72-7.79(1H, m), 10.20(1H, s),
11.40-11.59(1H, m)
SYNTHETIC EXAMPLE 33a
[0450]
6-Amino-N-(3-chloro-1H-indole-7-yl)-3-pyridinesulfonamide
[0451] 2.48 g (7.25 mmol) of the compound of Synthetic Example 14a
and 679 mg (5.07 mmol) of lithium iodide were added to 25 ml of
ethanol. 10 ml of liquid ammonia was added thereto, and the mixture
was heated at 120.degree. C. for 26 hours in a sealed tube and then
concentrated. The residue was dissolved in ethyl acetate, and the
mixture was successively washed with an aqueous saturated sodium
bicarbonate and water, dried over magnesium sulfate and
concentrated. Then, the residue was purified by silica gel column
chromatography, to give 982 mg of the title compound.
[0452] Melting point: 206 to 207.degree. C. (recrystallized from
ethyl-n-hexane)
[0453] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.37(1H, d, J=8.8
Hz), 6.83-6.94(1H, m) 6.88(2H, br s), 6.99(1H, dd, J=7.9, 7.7 Hz),
7.25(1H, dd, J=7.9, 0.7 Hz), 7.48(1H, d, J=2.7 Hz), 7.56(1H, dd,
J=8.8, 2.4 Hz), 8.14(1H, d, J=2.4 Hz), 9.70(1H, s), 10.92-11.03(1H,
m)
SYNTHETIC EXAMPLE 34a
[0454]
N-(3-Chloro-1H-indole-7-yl)-4-(methylsulfinylmethyl)benzenesulfonam-
ide
[0455] The title compound was obtained by oxidizing the compound of
Synthetic Example 15a in the same manner as in Example 24a.
[0456] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.41(3H, s),
3.98(1H, d, J=12.6 Hz), 4.18(1H, d, J=12.8 Hz), 6.77(1H, d, J=7.5
Hz), 6.94(1H, dd, J=7.9, 7.7 Hz), 7.25(1H, d, J=7.9 Hz), 7.43(2H,
d, J=8.1 Hz), 7.47(1H, d, J=2.8 Hz), 7.73(2H, d, J=8.1 Hz),
10.01(1H, br s), 11.03(1H, br s)
SYNTHETIC EXAMPLE 35a
[0457]
N-(3-Chloro-1H-indole-7-yl)-4-(2-sulfamoylethyl)benzenesulfonamide
[0458] 865 mg (3.05 mmol) of the compound of Production Example 11a
was reacted with 376 mg (2.84 mmol) of the compound of Production
Example 2a and treated in the same manner as in Example 1a. The
resulting 957 mg of
N-(1H-indole-7-yl)-4-(2-sulfamoylethyl)benzenesulfonamide was
chlorinated in the same manner as in Example 2a, to give 980 mg of
the title compound.
[0459] Melting point: 217 to 219.degree. C. (decomposed)
(recrystallized from ethanol-n-hexane)
[0460] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.01-3.06(2H, m),
3.23-3.28(2H, m), 6.81(1H, dd, J=7.5, 0.37 Hz), 6.88(2H, br s),
6.95(1H, dd, J=8.1, 7.5 Hz), 7.24(1H, dd, J=7.8, 0.37 Hz), 7.42(2H,
d, J=8.4 Hz), 7.49(1H, d, J=2.6 Hz), 7.68(2H, d, J=8.2 Hz),
9.99(1H, br s), 11.02(1H, br s)
SYNTHETIC EXAMPLE 36a
[0461]
N-(3-Chloro-1H-indole-7-yl)-4-[2-(methylsulfonyl)ethyl]benzenesulfo-
namide
[0462] The title compound was obtained in the same manner as in
Synthetic Examples 1a and 2a.
[0463] Melting point: started coloring from a temperature close to
180.degree. C. and decomposed at 201 to 203.degree. C.
(recrystallized from ethanol-n-hexane)
[0464] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.92(3H, s),
3.01-3.07(2H, m), 3.40-3.46(2H, m), 6.81(1H, d, J=7.9 Hz), 6.94(1H,
dd, J=7.9, 7.7 Hz), 7.24(1H, d, J=7.7 Hz), 7.45(2H, d, J=8.2 Hz),
7.49(1H, d, J=2.7 Hz), 7.68(2H, d, J=8.2 Hz), 9.99(1H, br s),
11.03(1H, br s)
SYNTHETIC 37a
[0465] 6-Amino-N-(3-cyano-1H-indole-7-yl)-3-pyridinesulfonamide
[0466] The compound of Synthetic Example 18a was aminated in the
same manner as in Example 33a, to give the title compound.
[0467] Melting point: 300.degree. C. or more (recrystallized from
ethanol-n-hexane)
[0468] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.39(1H, d, J=9.0
Hz), 6.88(1H, d, J=7.7 Hz), 6.89(2H, s), 7.11(1H, dd, J=7.9, 7.7
Hz), 7.41(1H, dd, J=7.9, 0.7 Hz), 7.55(1H, dd, J=9.0, 2.6 Hz),
8.12(1H, d, J=2.6 Hz), 8.19(1H, s), 9.72-9.90(1H, br),
11.78-11.92(1H, m)
SYNTHETIC EXAMPLE 38a
[0469]
4-Acetamido-3-chloro-N-(3-chloro-1H-indole-7-yl)benzenesulfonamide
[0470] The title compound was obtained in the same manner as in
Synthetic Examples 1a and 2a.
[0471] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.14(3H, s),
6.77(1H, d, J=7.7 Hz), 6.98(1H, dd, J=7.9, 7.7 Hz), 7.29(1H, d,
J=7.9 Hz), 7.50(1H, d, J=2.7 Hz), 7.64(1H, dd, J=8.6, 2.2 Hz),
7.75(1H, d, J=2.2 Hz), 8.04 (1H, d, J=8.6 Hz), 9.69 (1H, br s),
10.04 (1H, br s), 11.11 (1H, br s)
SYNTHETIC EXAMPLE 39a
[0472] N-(3-cyano-1H-indole-7-yl)-8-quinolinesulfonamide
[0473] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0474] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.68(1H, d, J=7.3
Hz), 6.89(1H, dd, J=7.9, 7.7 Hz), 7.25(1H, d, J=8.1 Hz),
7.69-7.74(2H, m), 8.21(1H, d, J=2.9 Hz), 8.30(1H, dd, J=8.2, 1.3
Hz), 8.35(1H, dd, J=7.4, 1.4 Hz), 8.54(1H, dd, J=8.3, 1.7 Hz),
9.15(1H, dd, J=4.3, 1.7 Hz), 10.04(1H, br s), 12.14(1H, br s)
SYNTHETIC EXAMPLE 40a
[0475]
5-Chloro-N-(3-cyano-1H-indole-7-yl)-2-thiophenesulfonamide
[0476] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0477] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.88(1H, ddd,
J=7.7, 2.2, 0.73 Hz), 7.16(1H, dd, J=7.9, 7.7 Hz), 7.20(1H, d,
J=4.0 Hz), 7.36(1H, d, J=4.2 Hz), 7.51(1H, d, J=8.1 Hz), 8.23(1H,
d, J=3.1 Hz), 10.42(1H, br s), 12.01(1H, br s)
SYNTHETIC EXAMPLE 41a
[0478]
N-(3-Chloro-1H-indole-7-yl)-4-(methoxycarbonylamino)benzenesulfonam-
ide
[0479] 170 mg (1.8 mmol) of methyl chloroformate was added to a
pyridine solution (1 ml) containing 38 mg (0.18 mmol) of the
compound of Synthetic Example 3a, followed by stirring at room
temperature overnight. The reaction mixture was concentrated and
the residue was purified by silica gel column chromatography, to
give 20 mg of the title compound.
[0480] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.65(3H, s),
6.80(1H, d, J=7.7 Hz), 6.93(1H, t, J=7.9 Hz), 7.21(1H, dd, J=7.7,
0.37 Hz), 7.45(1H, d, J=2.7 Hz), 7.51(2H, d, J=9.0 Hz), 7.63 (2H,
d, J=8.8 Hz), 9.85(1H, br s), 10.07(1H, s), 10.97(1H, br s)
SYNTHETIC EXAMPLE 42a
[0481] 4-Acetyl-N-(3-cyano-1H-indole-7-yl)benzenesulfonamide
[0482] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0483] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.60(3H, s),
6.74(1H, d, J=7.7 Hz), 7.05(1H, dd, J=7.9, 7.7 Hz), 7.42(1H, d,
J=7.9 Hz), 7.81-7.88(2H, m), 8.03-8.10(2H, m), 8.21(1H, s),
10.18-10.50(1H, br), 11.92-12.07(1H, m)
SYNTHETIC EXAMPLE 43a
[0484]
N-(3-Chloro-1H-indole-7-yl)-4-(N-methoxysulfamoyl)benzenesulfonamid-
e
[0485] The title compound was obtained in the same manner as in
Synthetic Examples 1a and 2a.
[0486] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.65(3H, s),
6.73(1H, d, J=7.6 Hz), 6.96(1H, dd, J=8.0, 7.6 Hz), 7.30(1H, d,
J=8.0 Hz), 7.50(1H, d, J=2.4 Hz), 7.98(4H, s), 10.29(1H, br s),
10.76(1H, br s), 11.12(1H, br s)
SYNTHETIC EXAMPLE 44a
[0487] N-(3-Cyano-1H-indole-7-yl)-.beta.-styrenesulfonamide
[0488] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0489] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.14-7.20(2H, m),
7.32(2H, s), 7.35-7.47 (4H, m), 7.60-7.68 (2H, m), 8.23 (1H, s),
9.70-10.03 (1H, br), 11.85-12.12(1H, br)
SYNTHETIC EXAMPLE 45a
[0490]
3-Chloro-N-(3-cyano-1H-indole-7-yl)-2-methylbenzenesulfonamide
[0491] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0492] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.61(3H, s),
6.69(1H, d, J=7.7 Hz), 7.04(1H, t, J=7.9 Hz), 7.36(1H, dd, J=8.1,
7.9 Hz), 7.42(1H, d, J=7.9 Hz), 7.73(1H, dd, J=8.1, 1.1 Hz),
7.77(1H, dd, J=8.0, 0.82 Hz), 8.25(1H, d, J=3.1 Hz), 10.37(1H, s),
l1.99(1H, br s)
SYNTHETIC EXAMPLE 46a
[0493]
N-(3-Chloro-1H-indole-7-yl)-6-isopropylamino-3-pyridinesulfonamide
[0494] 400 mg (1.17 mmol) of the compound of Synthetic Example 14a
and 0.80 ml (9.39 mmol) of isopropylamine were added to 5 ml of
dioxane, followed by heating at 100.degree. C. for 7.5 hours in a
sealed tube. After concentrating, the mixture was dissolved in
ethyl acetate, which was then successively washed with aqueous
dilute citric acid, an aqueous saturated sodium bicarbonate and
water. The mixture was dried over magnesium sulfate, and then
concentrated. The residue was purified by silica gel thin layer
chromatography, to give 235 mg of the title compound.
[0495] Melting point: started coloring from the temperature close
to 210.degree. C. and decomposed at 213 to 215.degree. C.
(recrystallized from ethyl acetate/n-hexane).
[0496] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.09(6H, d, J=6.6
Hz), 3.90-4.08(1H, m), 6.39(1H, d, J=9.0 Hz), 6.90-7.05(2H, m),
7.24(1H, d, J=7.9 Hz), 7.33(1H, d, J=7.7 Hz), 7.48(1H, d, J=2.4
Hz), 7.54(1H, dd, J=9.0, 2.6 Hz), 8.22(1H, d, J=2.6 Hz),
9.65-9.84(1H, br), 10.88-11.04(1H, m)
SYNTHETIC EXAMPLE 47a
[0497]
N-(3-Chloro-1H-indole-7-yl)-6-[[2-(dimethylamino)ethyl]amino]-3-pyr-
idinesulfonamide
[0498] The title compound was obtained from the compound of
Synthetic Example 14a and N,N-dimethylethylenediamine in the same
manner as in Synthetic Example 46a.
[0499] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.14(6H, s),
2.35(2H, t, J=6.6 Hz), 3.24-3.44(2H, m), 6.48(1H, d, J=9.0 Hz),
6.92(1H, d, J=7.7 Hz), 6.99(1H, dd, J=7.9, 7.7 Hz),7.22(1H, d,
J=7.9 Hz),7.27-7.39(1H, m), 7.47(1H, d, J=2.4 Hz), 7.54(1H, dd,
J=9.0, 2.6 Hz), 8.21(1H, d, J=2.6 Hz), 10.91-11.03(1H, m)
SYNTHETIC EXAMPLE 48a
[0500] N-(3-Cyano-1H-indole-7-yl)-2-furansulfonamide
[0501] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0502] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.62(1H, ddd,
J=3.7, 1.8, 0.37 Hz), 6.78(1H, d, J=7.5 Hz), 7.04(1H, d, J=3.5 Hz),
7.12(1H, t, J=7.9 Hz), 7.49(1H, d, J=8.1 Hz), 7.99-8.00(1H, m),
8.23(1H, d, J=3.1 Hz), 10.49(1H, br s), 12.04(1H, br s)
SYNTHETIC EXAMPLE 49a
[0503]
N-(3-Chloro-1H-indole-7-yl)-4-[(dimethylaminosulfonyl)amino]benzene-
sulfonamide
[0504] The title compound was obtained from the compound of
Synthetic Example 3a and dimethylsulfamoyl chloride in the same
manner as in Synthetic Example 1a.
[0505] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.66(6H, s),
6.81(1H, dd, J=7.7, 0.92 Hz), 6.95(1H, dd, J=7.9, 7.7 Hz), 7.20(2H,
d, J=8.8 Hz), 7.23(1H, d, J=8.1 Hz), 7.47(1H, d, J=2.7 Hz),
7.64(2H, d, J=8.8 Hz), 10.98(1H, br s)
SYNTHETIC EXAMPLE 50a
[0506]
N-(3-Methyl-1H-indole-7-yl)-4-(methylsulfonyl)benzenesulfonamide
[0507] 580 mg (15.3 mmol) of sodium borohydride and 150 mg of 10%
palladium-carbon were added to a 2-propanol suspension (25 ml)
containing 300 mg (1.58 mmol) of 3-formyl-7-nitro-1H-indole,
followed by refluxing for 6 hours. After water was added to the
reaction system, the catalyst was filtered off. The filtrate was
extracted with ethyl acetate, and the extract was washed with brine
and then dried over magnesium sulfate. The solvent was evaporated,
and the residue was dissolved in 5 ml of pyridine. The mixture was
reacted and treated with 170 mg (0.67 mmol) of
4-(methylsulfonyl)benzenesulfonyl chloride in the same manner as in
Example 1a, to give 149 mg of the title compound.
[0508] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.18(3H, s),
3.24(3H, s), 6.69(1H, d, J=7.7 Hz), 6.81(1H, t, J=7.7 Hz), 7.06(1H,
br s), 7.25(1H, d, J=7.8 Hz), 7.95(2H, d, J=8.8 Hz), 8.04(2H, d,
J=8.2Hz), 10.14(1H, br s), 10.40(1H, br s)
SYNTHETIC EXAMPLE 51a
[0509] 3-Cyano-N-(3-cyano-1H-indole-7-yl)benzenesulfonamide
[0510] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0511] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.71(1H, d, J=7.2
Hz), 7.09(1H, dd, J=8.0, 7.6 Hz), 7.49(1H, d, J=8.0 Hz), 7.74(1H,
dd, J=8.0, 7.6 Hz), 7.94(1H, d, J=8.0 Hz), 8.11-8.14(2H, m),
8.23(1H, d, J=2.8 Hz) 10.30(1H, br s), 12.05(1H, br s)
SYNTHETIC EXAMPLE 52a
[0512]
N-(3-Chloro-1H-indole-7-yl)-4-(N-methylmethanesusulfonamide)benzene-
sulfonamide
[0513] The title compound was obtained in the same manner as in
Synthetic Examples 1a and 2a.
[0514] Melting point: 199 to 201.degree. C. (decomposed)
(recrystallized from ethanol-n-hexane)
[0515] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.98(3 H, s),
3.24(3H, s), 6.83(1H, dd, J=7.7, 0.37 Hz), 6.96(1H, dd, J=7.9, 7.7
Hz), 7.26(1H, dd, J=7.9, 0.55 Hz), 7.48(1H, d, J=2.7 Hz),
7.50-7.54(2H, m), 7.72-7.76(2H, m), 10.04(11H, br s), 11.02(1H, br
s)
SYNTHETIC EXAMPLE 53a
[0516]
N-(3-Chloro-1H-indole-7-yl)-4-[(methanesulfonamide)methyl]benzenesu-
lfonamide
[0517] The title compound was obtained in the same manner as in
Synthetic Examples 1a and 2a.
[0518] Melting point: started coloring from the temperature close
to 180.degree. C. and decomposed at 189 to 191.degree. C.
(recrystallized from ethanol-n-hexane)
[0519] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.81(3H, s),
4.19(2H, d, J=6.0 Hz), 6.79(1H, d, J=7.7 Hz), 6.94(11H, dd, J=7.9,
7.7 Hz), 7.24(1H, d, J=7.9 Hz), 7.47(2H, d, J=8.8 Hz),
7.47-7.49(1H, m), 7.64(1H, t, J=6.4 Hz), 7.72(2H, d, J=8.4 Hz),
10.00(1H, s), 11.03(1H, br s)
SYNTHETIC EXAMPLE 54a
[0520]
N-(3-Chloro-1H-indole-7-yl)-4-(1-pyrrolidinylsulfonyl)benzenesulfon-
amide
[0521] The title compound was obtained from
4-(1-pyrrolidinylsulfonyl)benz- enesulfonyl chloride and the
compound of Production Example 10a in the same manner as in
Synthetic Example 1a.
[0522] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.55-1.59(4H, m),
3.07-3.11(4H, m), 6.71(1H, d, J=7.6 Hz), 6.95(1H, ddd, J=8.2, 7.4,
1.2 Hz), 7.30(1H, d, J=8.0 Hz), 7.46(1H, d, J=2.4 Hz), 7.89(2H, d,
J=8.8 Hz), 7.92(2H, d, J=8.4 Hz), 10.18(1H, br s), 11.03(1H, br
s)
SYNTHETIC EXAMPLE 55a
[0523]
N-(3-Cyano-1H-indole-7-yl)-1-methyl-4-imidazolesulfonamide
[0524] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0525] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.61(3H, s),
7.00(1H, dd, J=7.7, 0.92 Hz), 7.07(1H, dd, J=7.9, 7.7 Hz), 7.35(1H,
d, J=7.9 Hz), 7.75-7.76(2H, m), 8.19(1H, d, J=3.1 Hz), 10.03(1H, br
s), 11.92(1H, br s)
SYNTHETIC EXAMPLE 56a
[0526]
N-(3-Chloro-1H-indole-7-yl)-6-[(2-hydroxyethyl)amino]-3-pyridinesul-
fonamide
[0527] The title compound was obtained from the compound of
Synthetic Example 14a and 2-aminoethanol in the same manner as in
Synthetic Example 46a.
[0528] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.24-3.40(2H, m),
3.42-3.52(2H, m), 4.66-4.77(1H, m), 6.48(1H, d, J=9.3 Hz), 6.92(1H,
d, J=7.7 Hz), 7.00(1H, t, J=7.7 Hz), 7.24(1H, d, J=7.7 Hz),
7.40-7.62(2H, m), 7.48(1H, d, J=2.2 Hz), 8.22(1H, d, J=2.6 Hz),
9.63-9.90(1H, br), 10.90-11.07(1H, m)
SYNTHETIC EXAMPLE 57a
[0529]
N-(3-Chloro-1H-indole-7-yl)-6-mercapto-3-pyridinesulfonamide
[0530] 340 mg (0.99 mmol) of the compound of Synthetic Example 14a
and 151 mg (1.98 mmol) of thiourea were added to 5 ml of ethanol,
followed by heating under reflux for 2 hours. After concentrating,
1.6 ml of water and 57 mg of sodium carbonate were added to the
residue and the resulting mixture was stirred at room temperature
for 10 minutes. 85 mg of sodium hydroxide was added thereto and the
mixture was further stirred for 10 minutes, followed by filtering
off the insoluble matters. The filtrate was acidified with
hydrochloric acid, and the resulting precipitates were collected by
filtration, washed with water, then dissolved in tetrahydrofuran
and dried over magnesium sulfate. After concentrating, the residue
was purified by silica gel thin layer chromatography, to give 121
mg of the title compound.
[0531] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.84(1H, d, J=7.6
Hz), 7.03(1H, t, J=7.6 Hz), 7.28(1H, d, J=9.2 Hz), 7.31(1H, d,
J=7.6 Hz), 7.44(1H, dd, J=9.2, 2.4 Hz), 7.48(1H, d, J=2.6 Hz),
7.68(1H, d, J=2.4 Hz), 9.58-9.80(1H, br), 11.08-11.19(1H, m)
SYNTHETIC EXAMPLE 58a
[0532] 7-(4-Chlorobenzenesulfonamide)-1H-indole-2-carboxylic
Acid
[0533] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0534] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.65(1H, d, J=7.6
Hz), 6.87(1H, dd, J=8.0, 7.6 Hz), 7.00(1H, s), 7.26(1H, d, J=8.0
Hz), 7.56-7.65(2H, m), 7.68-7.77(2H, m), 9.62-10.00(1H, br),
11.40-11.74(1H, br)
SYNTHETIC EXAMPLE 59a
[0535]
N-(3-Chloro-1H-indole-7-yl)-6-cyclopropylamino-3-pyridinesulfonamid-
e
[0536] The title compound was obtained in the same manner as in
Synthetic Example 46a.
[0537] Melting point: started coloring from a temperature close to
228.degree. C. and decomposed at 233.5 to 235.degree. C.
(recrystallized from ethyl acetate-n-hexane)
[0538] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 0.36-0.46(2H, m),
0.63-0.75(2H, m), 2.44-2.64(1H, m), 6.45-6.64(1H, m), 6.93(1H, d,
J=7.7 Hz), 7.00(1H, dd, J=7.9, 7.7 Hz), 7.24(1H, d, J=7.9 Hz),
7.49(1H, d, J=2.7 Hz), 7.57-7.73(2H, m), 8.25(1H, d, J=2.6 Hz),
9.68-9.90(1H, br), 10.92-11.04(1H, m)
SYNTHETIC EXAMPLE 60a
[0539]
N-(3-Cyano-1H-indole-7-yl)-5-methyl-3-pyridinesulfonamide
[0540] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0541] Melting point: gradually decomposed at a temperature close
to 288.degree. C. (recrystallized from ethanol-n-hexane)
[0542] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.33(3H, s),
6.75(1H, d, J=7.7 Hz), 7.09(1H, dd, J=7.9, 7.7 Hz), 7.48(1H, d,
J=7.9 Hz), 7.87-7.91(1H, m), 8.22(1H, d, J=3.1 Hz), 8.58-8.67(2H,
m), 10.28(1H, br s), 11.95-12.08(1H, m)
SYNTHETIC EXAMPLE 61a
[0543]
N-(3-Chloro-1H-indole-7-yl)-4-(N-methylsulfamoyl)benzenesulfonamide
[0544] The title compound was obtained in the same manner as in
Synthetic Examples 1a and 2a.
[0545] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.39(3H, d, J=5.2
Hz), 6.71(1H, dd, J=7.8, 2.0 Hz), 6.96(1H, dd, J=8.0, 7.6 Hz),
7.30(1H, d, J=8.0 Hz), 7.48(1H, d, J=2.8 Hz), 7.68(1H, q, J=4.9
Hz), 7.87-7.93(4H, m) 10.20(1H, br s), 11.08(1H, br s)
SYNTHETIC EXAMPLE 62a
[0546]
N-(3-Chloro-1H-indole-7-yl)-4-[2-(methanesulfonamide)ethyl]benzenes-
ulfonamide
[0547] The title compound was obtained in the same manner as in
Synthetic Examples 1a and 2a.
[0548] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.73-2.81(5H,
m),3.13-3.19(2H, m), 6.82(1H, d, J=7.7 Hz), 6.95(1H, dd, J=8.1, 7.7
Hz), 7.09(1H, t, J=5.9 Hz), 7.24(1H, d, J=8.1 Hz), 7.39(2H, d,
J=8.2 Hz), 7.48(1H, d, J=2.7 Hz), 7.68(2H, d, J=8.4 Hz), 9.97(1H,
br s), 11.02(1H, br s)
SYNTHETIC EXAMPLE 63a
[0549]
N-(3-Chloro-1H-indole-7-yl)-4-(sulfamoylmethyl)benzenesulfonamide
[0550] 389 mg (1.44 mmol) of the compound of Production Example 6a
was reacted with 159 mg (1.2 mmol) of the compound of Production
Example 2a and the reaction product was treated in the same manner
as in Example 1a, to give 233 mg of
N-(1H-indole-7-yl)-4-(sulfamoylmethyl)benzenesulfonamid- e. The
compound was chlorinated in the same manner as in Example 2a, to
give 160 mg of the title compound.
[0551] Melting point: 237 to 238.5.degree. C. (decomposed)
(recrystallized from ethanol/n-hexane)
[0552] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 4.33(2H, s),
6.84(1H, dd, J=7.7, 0.73 Hz), 6.93(2H, s), 6.92-6.97(1H, m),
7.24(1H, dd, J=7.9, 0.37 Hz), 7.48 (1H, d, J=2.7 Hz), 7.48-7.52
(2H, m), 7.75-7.79 (2H, m), 10.08(1H, br s), 11.04(1H, br s)
SYNTHETIC EXAMPLE 64a
[0553]
N-(3-Chloro-1H-indole-7-yl)-4-thiocarbamoylbenzenesulfonamide
[0554] 400 mg (1.21 mmol) of the compound of Synthetic Example 10a
was dissolved in 10 ml of dimethylformamide, to which was then
added 0.5 ml of triethylamine. Hydrogen sulfide was made to pass
through the mixture at a bath temperature of 60 to 70.degree. C.
for 45 minutes. After concentrating, the residue was dissolved in
ethyl acetate, successively washed with dilute hydrochloric acid,
an aqueous saturated sodium bicarbonate and water, and dried over
magnesium sulfate. After evaporating the solvent, the residue was
purified by silica gel column chromatography, to give 355 mg of the
title compound.
[0555] Melting point: 223 to 225.degree. C. (decomposed)
(recrystallized from ethanol/n-hexane)
[0556] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.81(1H, d, J=7.7
Hz), 6.96(1H, dd, J=7.9, 7.7 Hz), 7.27(1H, d, J=7.9 Hz), 7.50(1H,
d, J=2.7 Hz), 7.73-7.80(2H, m), 7.86-7.93(2H, m), 9.58-9.73(1H, br
m), 10.02-10.18(1H, br m), 10.15(1H, s), 11.03-11.12(1H, m)
SYNTHETIC EXAMPLE 65a
[0557] 5-Bromo-N-(3-cyano-1H-indole-7-yl)-2-pyridinesulfonamide
[0558] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0559] Melting point: 245.5 to 246.5.degree. C. (decomposed)
(recrystallized from ethyl acetate/n-hexane)
[0560] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.82(1H, d, J=7.7
Hz), 7.07(1H, dd, J=7.9, 7.7 Hz), 7.44(1H, d, J=7.9 Hz), 7.80(1H,
d, J=8.2 Hz), 8.23(1H, d, J=2.2 Hz), 8.29(1H, dd, J=8.2, 2.2 Hz),
8.92(1H, d, J=2.2 Hz), 10.42-10.67(1H, br), 11.93-12.08(1H, m)
SYNTHETIC EXAMPLE 66a
[0561] N-(3-Cyano-1H-indole-7-yl)-2-naphthalenesulfonamide
[0562] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0563] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.74(1H, dd, J=7.6,
2.8 Hz), 7.00(1H, dd, J=7.9, 7.7 Hz), 7.39(1H, dd, J=8.0, 0.46 Hz),
7.61-7.72(2H, m), 7.80 (1H, dd, J=8.6, 1.8 Hz), 8.01 (1H, d, J=8.1
Hz), 8.08 (1H, s), 8.10(1H, s), 8.21(1H, d, J=2.9 Hz), 8.34(1H, d,
J=1.6 Hz), 10.23(1H, br s), 12.01(1H, br s)
SYNTHETIC EXAMPLE 67a
[0564] N-(3-Acetyl-1H-indole-7-yl)-3-chlorobenzenesulfonamide
[0565] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0566] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.44(3H, s),
6.65(1H, d, J=7.5 Hz), 7.01(1H, dd, J=7.9, 7.7 Hz), 7.53-7.63(2H,
m), 7.69-7.73(2H, m), 8.01(1H, dd, J=8.1, 0.73 Hz), 8.26(1H, d,
J=2.9 Hz), 10.l0(1H, s), 11.75(1H, br s)
SYNTHETIC EXAMPLE 68a
[0567]
4-Amino-N-(5-bromo-3-cyano-1H-indole-7-yl)benzenesulfonamide
[0568] The title compound was obtained by hydrogenating
N-(5-bromo-3-cyano-1H-indole-7-yl)-4-nitrobenzenesulfonamide,
obtained from 4-nitrobenzenesulfonyl chloride and the compound of
Production Example 14a in the same manner as in Example 1a, at
normal temperature under normal pressure in the presence of
platinum oxide.
[0569] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.07(2H, br s),
6.52(2H, d, J=8.4 Hz), 6.97-6.99(1H, m), 7.36(2H, dd, J=8.7, 1.6
Hz), 7.51(1H, br s), 8.25(1H, s), 9.93(1H, d, J=5.5 Hz), 11.97(1H,
br s)
SYNTHETIC EXAMPLE 69a
[0570]
N-(3-Chloro-1H-indole-7-yl)-4-(N-ethylsulfamoyl)benzenesulfonamide
[0571] The title compound was obtained in the same manner as in
Synthetic Examples 1a and 2a.
[0572] Melting point: 213.5 to 215.degree. C. (recrystallized from
ethanol/n-hexane)
[0573] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 0.90(3H, t, J=7.2
Hz), 2.76(2H, dq, Jd=5.8 Hz, Jq=7.2 Hz), 6.70(1H, d, J=7.4 Hz),
6.95(1H, dd, J=8.0, 7.6 Hz), 7.29(1H, d, J=8.0 Hz), 7.47(1H, d,
J=2.8 Hz), 7.78(1H, t, J=5.6 Hz), 7.90(4H, s), 10.18(1H, br s),
11.06(1H, br s)
SYNTHETIC EXAMPLE 70a
[0574]
N-(3-Chloro-1H-indole-7-yl)-4-(ethanesulfonamide)benzenesulfonamide
[0575] The title compound was obtained in the same manner as in
Synthetic Example 4a.
[0576] Melting point: 214 to 215.degree. C. (decomposed)
(recrystallized from ethanol/n-hexane)
[0577] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.14(3H, t, J=7.3
Hz), 3.16(2H, q, J=7.3 Hz), 6.82(1H, d, J=7.5 Hz), 6.96(1H, dd,
J=7.9, 7.7 Hz), 7.23(2H, d, J=8.8 Hz), 7.24(1H, d, J=7.5 Hz),
7.47(1H, d, J=2.6 Hz), 7.66(2H, d, J=8.8 Hz), 9.90(1H, br s),
10.37(1H, br s), 10.96(1H, br s)
SYNTHETIC EXAMPLE 71a
[0578]
N-(3-Chloro-1H-indole-7-yl)-6-[(2-cyanoethyl)amino]-3-pyridinesulfo-
namide
[0579] The title compound was obtained in the same manner as in
Synthetic Example 46a.
[0580] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.72(2H, t, J=6.4
Hz), 3.46-3.55(2H, m), 6.53(1H, d, J=9.0 Hz), 6.90(1H, d, J=7.7
Hz), 6.99(1H, dd, J=7.9, 7.7 Hz), 7.25(1H, d, J=7.9 Hz), 7.48(1H,
d, J=2.6Hz), 7.61(1H, dd, J=9.0, 2.4 Hz), 7.78-7.87(1H, m),
8.25(1H, d, J=2.4 Hz), 9.70-9.95(1H, br), 10.92-11.04(1H, m)
SYNTHETIC EXAMPLE 72a
[0581]
N-(3-Chloro-1H-indole-7-yl)-4-(N-methylcarbamoyl)benzenesulfonamide
[0582] 533 mg (1.68 mmol) of the compound of Synthetic Example 9a
was dissolved in a mixed solution of 5 ml of dimethylformamide and
2.5 ml of dimethyl sulfoxide, to which were then added 171 mg (2.53
mmol) of methylamine hydrochloride and 705 .mu.l (5.06 mmol) of
triethylamine. 436 .mu.l (2.02 mmol) of diphenylphosphrylazide was
added thereto, followed by stirring at room temperature overnight.
Then, the mixture was concentrated and extracted with ethyl
acetate. The extract was successively washed with dilute
hydrochloric acid, an aqueous saturated sodium bicarbonate and
water, and dried over magnesium sulfate. After concentrating, the
residue was purified by silica gel column chromatography, to give
465 mg of N-(1H-indole-7-yl)-4-(N-methylcarbamoyl-
)benzenesulfonamide. The obtained compound was chlorinated in the
same manner as in Synthetic Example 2a, to give 413 mg of the title
compound.
[0583] Melting point: 252 to 253.degree. C. (decomposed)
(recrystallized from ethanol/n-hexane)
[0584] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.76(3H, d, J=4.6
Hz), 6.74(1H, d, J=7.7 Hz), 6.94(1H, dd, J =7.9, 7.7 Hz), 7.27(1H,
d, J=7.9 Hz), 7.49(1H, d, J=2.7 Hz), 7.76-7.83(2H, m),
7.87-7.94(2H, m), 8.61(1H, q, J=4.6 Hz), 10.10(1H, s),
11.03-11.13(1H, m)
SYNTHETIC EXAMPLE 73a
[0585] N-(3-chloro-1H-indole-7-yl)
-4-(methylsulfonylmethyl)benzenesulfona- mide
[0586] 510 mg of the compound of Synthetic Example 34a was oxidized
using aqueous 30% hydrogen peroxide in the same manner as in
Example 23a, to give 307 mg of the title compound.
[0587] Melting point: started coloring from a temperature close to
225.degree. C. and decomposed gradually from a temperature close to
235.degree. C. (recrystallized from ethanol/n-hexane)
[0588] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.88(3H, s),
4.57(2H, s), 6.77(1H, d, J=7.6 Hz), 6.94(1H, dd, J=7.9, 7.7 Hz),
7.25(1H, d, J=8.0 Hz), 7.47(1H, d, J=2.7 Hz), 7.51-7.56(2H, m),
7.73-7.78(2H, m), 10.05(1H, br s), 11.04(1H, br s)
SYNTHETIC EXAMPLE 74a
[0589]
N-(3-Chloro-1H-indole-7-yl)-4-(N,N-dimethylsulfamoyl)benzenesulfona-
mide
[0590] The title compound was obtained in the same manner as in
Synthetic Examples 1a and 2a.
[0591] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.57 (6H, s), 6.71
(1H, dd, J=7.4, 0.6 Hz), 6.97(1H, dd, J=8.0, 7.6 Hz), 7.31(1H, d,
J=8.0 Hz), 7.47(1H, d, J=2.8 Hz), 7.86(2H, d, J=8.4 Hz), 7.91(2H,
d, J=8.4 Hz), 10.19(1H, br s), 11.04(1H, br s)
SYNTHETIC EXAMPLE 75a
[0592]
N-(3-Chloro-1H-indole-7-yl)-4-(1-pyrrolidinylcarbonyl)benzenesulfon-
amide
[0593] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0594] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.79(2H, dt,
Jd=12.8 Hz, Jt=6.4 Hz) 1.85(2H, dt, Jd=13.6 Hz, Jt=6.8 Hz),
3.22(2H, t, J=6.4 Hz), 3.44(2H, t, J=6.8 Hz), 6.78(1H, d, J=7.2
Hz), 6.96(1H, dd, J=8.0, 7.2 Hz), 7.28(1H, d, J=8.0 Hz), 7.47(1H,
d, J=2.4 Hz), 7.60(2H, d, J=8.0 Hz), 7.74 (2H, d, J=8.4 Hz), 10.06
(1H, br s), 11. 01 (H, br s)
SYNTHETIC EXAMPLE 76a
[0595]
3-Chloro-N-(3-chloro-1H-indole-7-yl)-N-methylbenzenesulfonamide
[0596] 120 mg (0.352 mmol) of the compound of Synthetic Example 7a
was dissolved in 10 ml of dimethylformamide, to which was then
added 19.2 mg (0.479 mmol) of sodium hydride (60%). After stirring
at room temperature for 30 minutes, 30 .mu.l (0.482 mmol) of methyl
iodide was added thereto. After two hours, water was added thereto,
followed by extracting with ethyl acetate. The organic layer was
washed with water and dried over magnesium sulfate. After
concentrating, the residue was purified by silica gel thin layer
chromatography, to give 87 mg of the title compound.
[0597] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.26 (3H, s), 6.51
(1H, dd, J=7.6, 0.64 Hz), 7.00(1H, dd, J=7.9, 7.7 Hz), 7.47(1H, d,
J=8.1 Hz), 7.53(1H, d, J=2.7 Hz), 7.54-7.59(2H, m), 7.65(1H, t,
J=7.9 Hz), 7.84(1H, ddd, J=8.1, 2.1, 1.1 Hz), 11.62(1H, br s)
SYNTHETIC EXAMPLE 77a
[0598]
N-(3,4-Dichloro-1H-indole-7-yl)-4-(sulfamoylmethyl)benzenesulfonami-
de
[0599] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0600] Melting point: decomposed gradually from a temperature close
to 297.degree. C. (recrystallized from ethanol/n-hexane)
[0601] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 4.34(2H, s),
6.72(1H, d, J=8.1 Hz), 6.93(2H, s), 6.94(1H, d, J=8.1 Hz), 7.51(2H,
d, J=8.1 Hz), 7.57(1H, dd, J=2.7, 0.55 Hz), 7.75(2H, d, J=8.2 Hz),
10.10(1H, br s), 11.44(1H, br s)
SYNTHETIC EXAMPLE 78a
[0602]
N-(3-Cyano-1H-indole-7-yl)-4-[2-(methylsulfonyl)ethyl]benzenesulfon-
amide
[0603] The title compound was obtained in the same manner as in
Synthetic Example 1a.
[0604] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.94(3H, s),
3.03-3.08(2H, m), 3.42-3.47(2H, m), 6.77(1H, dd, J=7.7, 0.37 Hz),
7.05(1H, t, J=7.9 Hz), 7.41(1H, d, J=8.1 Hz), 7.46(2H, d, J=8.2
Hz), 7.66(2H, d, J=8.2 Hz), 8.20(1H, s), 10.09(1H, br s), 11.92(1H,
br s)
SYNTHETIC EXAMPLE 79a
[0605]
N-(3-Chloro-1H-indole-7-yl)-4-(N-methylacetamido)benzenesulfonamide
[0606] The title compound was obtained in the same manner as in
Synthetic Examples 1a and 2a.
[0607] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.84(3H, br s),
3.16(3H, s), 6.81(1H, d, J=7.7 Hz), 6.96(1H, dd, J=8.0, 7.6 Hz),
7.27(1H, d, J=7.9 Hz), 7.45-7.49(2H, m), 7.47(1H, d, J=2.7 Hz),
7.70-7.75(2H, m), 10.02(1H, br s), 11.01(1H, br s)
SYNTHETIC EXAMPLE 80a
[0608]
N-(3-Chloro-1H-indole-7-yl)-6-hydroxy-3-pyridinesulfonamide
[0609] Under ice-cooling, into a solution of the compound of
Example 33a (100 mg, 0.31 mmol) dissolved in 2 ml of glacial acetic
acid was added dropwise 1 ml of an aqueous solution containing 32
mg (0.46 mmol) of sodium nitrite. After stirring for one hour, the
mixture was adjusted to about pH 8 by adding an aqueous sodium
bicarbonate and further stirred for 10 minutes. The reaction
mixture was extracted with ethyl acetate, and the extract was
washed with water, dried over magnesium sulfate and concentrated.
Then, the residue was purified by silica gel thin layer
chromatography, to give 54 mg of the title compound.
[0610] Melting point: 244-245.degree. C. (decomposed)
(recrystallized from ethyl acetate/n-hexane)
[0611] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.39(1H, d, J=9.5
Hz), 6.88(1H, d, J=7.7 Hz), 7.04(1H, dd, J=7.9, 7.7 Hz), 7.32(1H,
d, J=7.9 Hz), 7.50(1H, d, J=2.7 Hz), 7.58(1H, dd, J=9.5, 3.1 Hz),
7.64(1H, d, J=3.1 Hz), 9.76-9.94(1H, br), 11.01-11.13(1H, m),
11.98-12.15(1H, br)
SYNTHETIC EXAMPLE 81a
[0612]
N-(3-Chloro-1H-indole-7-yl)-4-[2-(N-methylmethanesulfonamido)ethyl]-
benzenesulfonamide
[0613] The title compound was obtained in the same manner as in
Synthetic Examples 1a and 2a.
[0614] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.69(3H, s),
2.76(3H, s), 2.86(2H, t, J=7.5 Hz), 3.26(2H, t, J=7.5 Hz), 6.78(1H,
dd, J=7.4, 0.55 Hz), 6.94(1H, t, J=7.7 Hz), 7.24(1H, dd, J=7.7,
0.37 Hz), 7.39(2H, d, J=8.2 Hz), 7.48 (1H, d, J=2.6 Hz), 7.66 (2H,
d, J=8.2 Hz), 9.94 (1H, br s), 11.02(1H, br s)
SYNTHETIC EXAMPLE 82a
[0615]
N-(3-Chloro-1H-indole-7-yl)-4-(trifluoromethanesulfonamido)benzenes-
ulfonamide
[0616] 128 .mu.l (0.76 mmol) of trifluoromethanesulfonic acid
anhydride was added to a pyridine solution (5 ml) containing 62 mg
(0.19 mmol) of the compound of Synthetic Example 3a at 0.degree.
C., followed by stirring as it was overnight. The reaction solution
was evaporated. A phosphoric acid buffer solution having a pH of 7
was added thereto, followed by extracting with ethyl acetate. Then,
the extract was washed with brine and dried over magnesium sulfate.
The solvent was evaporated and the residue was purified by silica
gel column chromatography, to give 20 mg of the title compound.
[0617] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.79(1H, d, J=7.7
Hz), 6.94(1H, dd, J=7.9, 7.7 Hz), 7.16(2H, d, J=8.6 Hz), 7.23(1H,
d, J=7.9 Hz), 7.46(1H, d, J=2.7 Hz), 7.58(2H, d, J=8.1 Hz),
9.84(1H, br s), 10.98(1H, br s)
SYNTHETIC EXAMPLE 83a
[0618]
N-(3-Chloro-1H-indole-7-yl)-4-[(N-methylmethanesulfonamido)methyl]b-
enzenesulfonamide
[0619] The title compound was obtained in the same manner as in
Synthetic examples 1a and 2a.
[0620] Melting point: 200.5 to 202.degree. C. (recrystallized from
ethanol)
[0621] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.63 (3H, s), 2.94
(3H, s), 4.27 (2H, s), 6.80(1H, d, J=7.3 Hz), 6.95(1H, dd, J=8.1,
7.5 Hz), 7.25(1H, d, J=7.9 Hz), 7.45(2H, d, J=8.2 Hz), 7.47(1H, d,
J=2.7 Hz), 7.74(2H, d, J=8.2 Hz), 10.00(1H, s), 10.00(1H, br s)
SYNTHETIC EXAMPLE 84a
[0622]
3-Chloro-N-(3-chloro-1H-pyrrolo[2,3-c]pyridine-7-yl)benzenesulfonam-
ide
[0623] To 84 ml of aqueous concentrated ammonia were added 600 mg
(3.05 mmol) of 7-bromo-1H-pyrrolo[2,3-c]pyridine synthesized from
2-bromo-3-nitropyridine in the same manner as in Production Example
la, 194 mg of a copper powder and 603 mg of cuprous chloride. The
mixture was heated in a sealed tube at 120.degree. C. for 15 hours
and then treated, to give 170 mg of
7-amino-1H-pyrrolo[2,3-c]pyridine. The resulting product was
reacted and treated in the same manner as in Examples 1a and 2a, to
give 57 mg of the title compound.
[0624] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.93(1H, d, J=6.6
Hz), 7.45(1H, dd, J=6.6, 5.8 Hz), 7.53(1H, dd, J=8.0, 7.6 Hz),
7.61(1H, d, J=7.6 Hz), 7.73(1H, d, J=2.8 Hz), 7.85(1H, d, J=8.0
Hz), 7.96(1H, d, J=1.2 Hz), 11.90-12.10(1H, m), 12.72(1H, br s)
SYNTHETIC EXAMPLE 85a
[0625]
N-(3-Chloro-1H-indole-7-yl)-4-[3-(1-imidazolyl)propyl]benzenesulfon-
amide
[0626] To
4-(3-bromopropyl)-N-(3-chloro-1H-indole-7-yl)benzenesulfonamide
(213 mg, 0.5 mmol) were added 170 mg (2.5 mmol) of imidazole and 6
ml of dimethylformamide, followed by heating at 80.degree. C. for 3
hours in a nitrogen atmosphere. Then, the reaction mixture was
poured into water and extracted with chloroform. The extract was
dried over magnesium sulfate and concentrated. Then, the residue
was purified by silica gel column chromatography, to give 160 mg of
the title compound.
[0627] Melting point: 86 to 90.degree. C.
[0628] .sup.1H-NMR(DMSO-d.sub.6) .delta.(ppm): 1.95-2.04(2H, m),
2.55(2H, t, J=7.9 Hz), 3.92(2H, t, J=7.1 Hz), 6.81(1H, dd, J=7.7,
0.9 Hz), 6.88(1H, t, J=1.1 Hz), 6.94(1H, dd, J=7.9, 7.7 Hz),
7.16(1H, t, J=1.2 Hz), 7.23(1H, d, J=7.7 Hz), 7.32(2H, d, J=8.4
Hz), 7.47(1H, d, J=2.7 Hz), 7.60(1H, br s), 7.65(2H, d, J=8.4 Hz),
9.91-10.00(1H, m), 10.98-11.02(1H, m)
SYNTHETIC EXAMPLE 86a
[0629]
N-(3-Chloro-1H-indole-7-yl)-4-(N-[2-(2-pyridinyl)ethyl]carbamoyl]be-
nzenesulfonamide
[0630] 2.82 g (12.8 mmol) of 4-(chlorosulfonyl)benzoic acid and
1.42 g (8.54 mmol) of 7-amino-3-chloro-1H-indole were reacted with
each other in pyridine at room temperature under stirring
overnight, to give 2.33 g of
4-[N-(3-chloro-1H-indole-7-yl)sulfamoyl]benzoic acid. To 303 mg
(0.86 mmol) of the product were successively added 260 .mu.l of
dimethylformamide, 204 .mu.l (0.95 mmol) of
diphenylphosphorylazide, 132 .mu.l (0.95 mmol) of triethylamine and
113 .mu.l (0.94 mmol) of 2-(2-aminoethyl)pyridine, followed by
stirring at room temperature overnight. After concentrating, ethyl
acetate and an aqueous saturated sodium bicarbonate were added
thereto. The organic layer was separated and washed with brine.
After evaporating the solvent, the residue was purified by silica
gel column chromatography, to give 175 mg of the title
compound.
[0631] Melting point: 220.5 to 222.degree. C.
[0632] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.95-2.99(2H, m),
3.56-3.62(2H, m), 6.75(1H, d, J=7.5 Hz), 6.94(1H, dd, J=7.9, 7.7
Hz), 7.19-7.28(3H, m), 7.48(1H, d, J=2.8 Hz), 7.69(1H, dt, Jd=1.8
Hz, Jt=7.7 Hz), 7.79(2H, d, J=8.6 Hz), 7.88(2H, d, J=8.6 Hz),
8.48-8.51(1H, m), 8.75(1H, t, J=5.2 Hz), 10.09-10.12(1H, m),
11.06-11.09(1H, m)
SYNTHETIC EXAMPLE 87a
[0633] 4-Amidino-N-(3-chloro-1H-indole-7-yl)benzenesulfonamide
[0634] 3.3 ml (3.3 mmol) of a hexane solution containing 1.0 M
trimethylaluminum and 10 ml of toluene were added to 162 mg (3.0
mmol) of ammonium chloride. After the generation of gas was ceased,
the mixture was evaporated until the amount of the solution became
about 3 ml. While stirring, 97 mg (0.30 mmol) of the compound of
Production Example 4a was added thereto and the mixture was heated
at 80.degree. C. for 4 hours. After cooling, a concentrated ammonia
was added thereto, the insoluble matters were filtered off and the
filtrate was concentrated. Ethyl acetate was added thereto, the
insoluble matters were filtered off and the filtrate was
concentrated. The residue was purified by silica gel column
chromatography, to give 35 mg of the title compound.
[0635] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.93(1H, dd, J=7.7,
1.5 Hz), 6.96(1H, dd, J=7.7, 7.5 Hz), 7.24(1H, dd, J=7.5, 1.3 Hz),
7.50(1H, d, J=2.7 Hz), 7.90(2H, d, J=8.6 Hz), 8.01(2H, d, J=8.6
Hz), 9.16-9.62(2H, br), 10.40-10.75(1H, br), 11.50(1H, s)
SYNTHETIC EXAMPLE 88a
[0636]
N-(3-Chloro-1H-indole-7-yl)-4-[N-[2-(1-imidazolyl)ethyl]sulfamoyl]b-
enzenesulfonamide
[0637] 557 mg (1.13 mmol) of
4-[N-(2-bromoethyl)sulfamoyl]-N-(3-chloro-1H--
indole-7-yl)benzenesulfonamide and 820 mg (12.0 mmol) of imidazole
were added to 10 ml of dimethylformamide and the mixture was
stirred at 80.degree. C. for 2 days. After concentrating, the
residue was dissolved in ethyl acetate. The mixture was washed with
water, dried over sodium sulfate and concentrated. The residue was
purified by silica gel column chromatography, to give 324 mg of the
title compound.
[0638] Melting point: started coloring gradually from a temperature
close to 200.degree. C. and decomposed at 218 to 221.degree. C.
(recrystallized from ethanol/n-hexane)
[0639] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.05(2H, ddd,
J=6.2, 6.0, 5.9 Hz), 3.96(2H, dd, J=6.0, 5.9 Hz), 6.69-6.72(1H, m),
6.84(1H, brs), 6.92(1H, dd, J=7.9, 7.7 Hz), 7.08(1H, brs), 7.26(1H,
d, J=7.5 Hz), 7.44(1H, d, J=2.7 Hz), 7.55(1H, brs), 7.82-7.88(4H,
m), 8.06(1H, t, J=5.9 Hz), 10.18-10.36(1H, br), 11.09(1H, d, J=2.4
Hz)
SYNTHETIC EXAMPLE 89a
[0640]
3-(5-Bromonicotinamido)-N-(3-cyano-1H-indole-7-yl)benzenesulfonamid-
e
[0641] 785 mg (3.54 mmol) of 3-nitrobenzenesulfonyl chloride was
reacted with 506 mg (3.22 mmol) of the compound of Production
Example 3a in the same manner as in Production Example 4a and
treated, to give 950 mg of
N-(3-cyano-1H-indole-7-yl)-3-nitrobenzenesulfonamide. The product
was reduced using zinc powder/concentrated hydrochloric acid in 30
ml of methanol according to a conventional method, to give 459 mg
of 3-amino-N-(3-cyano-1H-indole-7-yl)benzenesulfonamide. 109 mg
(0.35 mmol) of the product was dissolved in 2 ml of pyridine and
179 mg (0.70 mmol) of 5-bromonicotinoyl chloride hydrochloride was
added thereto. After stirring at room temperature overnight, the
mixture was concentrated. An aqueous diluted citric acid was added
to the residue. The resulting precipitates were collected by
filtration, and successively washed with water, an aqueous diluted
sodium bicarbonate, water and ether. The precipitates were
dissolved in tetrahydrofuran, and the mixture was dried over
magnesium sulfate and concentrated. Crystals precipitated by adding
ether and n-hexane were collected by filtration, to give 108 mg of
the title compound.
[0642] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.81(1H, dd, J=7.7,
0.7 Hz), 7.07(1H, t, J=7.9 Hz), 7.42(1H, dd, J=7.9, 0.7 Hz),
7.47-7.51(1H, m), 7.55(1H, t, J=7.9 Hz), 7.93-7.97(1H, m),
8.21-8.23(1H, m), 8.31(1H, t, J=1.8 Hz), 8.55(1H, dd, J=2.4, 2.0
Hz), 8.93(1H, d, J=2.4 Hz), 9.06(1H, d, J=2.0 Hz), 10.23-10.25(1H,
m), 10.75(1H, br s), 11.94-11.96(1H, m)
SYNTHETIC EXAMPLE 90a
[0643]
N-(3-Chloro-1H-indole-7-yl)-4-(N-(2-thiazolyl)sulfamoyl]benzenesulf-
onamide
[0644] 5.2 g (20.4 mmol) of sulfathiazole was added to a mixed
solution of 14 ml of water and 3.4 ml of concentrated hydrochloric
acid and the mixture was stirred. To the mixture was added dropwise
an aqueous saturated solution of 2.1 g (30.4 mmol) of sodium
nitrite at 0.degree. C. or less. Then, 5 ml of acetic acid was
added thereto, followed by stirring at 5.degree. C. for about 10
minutes. An acetic acid solution saturated with sulfur dioxide
(solution prepared by saturating 18 ml of acetic acid with sulfur
dioxide and then adding 830 mg of cupric chloride dihydrate
thereto) was added dropwise to the reaction solution at 0.degree.
C. under stirring. After 5 minutes, the reaction solution was
poured into ice-water. The precipitates were collected by
filtration, washed with water and dried, to give 2.9 g of
4-chlorosulfonyl-N-(2-thiaz- olyl)benzenesulfonamide. 570 mg (1.68
mmol) of the product was reacted with 200 mg (1.2 mmol) of the
compound of Production Example 1a in the same manner as in
Production Example 4a and treated, to give 456 mg of the title
compound.
[0645] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.68(1H, dd, J=7.5,
0.73 Hz), 6.87(1H, d, J=4.6 Hz), 6.93(1H, dd, J=8.1, 7.5
Hz),7.26-7.30(1H, m), 7.28(1H, d, J=4.6 Hz), 7.46(1H, d, J=2.7 Hz),
7.82-7.88(2H, m), 7.88-7.94(2H, m), 10.10-10.26(1H, br),
11.04-11.10(1H, m), 12.83-13.01 (1H, br)
SYNTHETIC EXAMPLE 91a
[0646]
5-Chloro-N-(3-chloro-1H-indole-7-yl)-4-(5-methyl-3-pyridinesulfonam-
ido)-2-thiophenesulfonamide
[0647] 645 mg (2.46 mmol) of 5-chloro-4-nitro-2-thiophenesulfonyl
chloride was reacted with 410 mg (2.46 mmol) of the compound of
Production Example 1a in the same manner as in Production Example
4a and treated, to give 194 mg of
5-chloro-N-(3-chloro-1H-indole-7-yl)-4-nitro-2-thiophenesulfona-
mide. The product was reduced using zinc powder/concentrated
hydrochloric acid in 10 ml of methanol according to a conventional
method, to give 75 mg of
4-amino-5-chloro-N-(3-chloro-1H-indole-7-yl)-2-thiophenesulfonamide-
. 72 mg (0.20 mmol) of the product was dissolved in 2 ml of
tetrahydrofuran, and 18 .mu.l of pyridine and 38 mg (0.2 mmol) of
5-methyl-3-pyridinesulfonyl chloride were added thereto. After
stirring at room temperature overnight, the organic layer was
separated by adding ethyl acetate and 1N hydrochloric acid thereto.
It was successively washed with water, an aqueous sodium
bicarbonate and water, dried over magnesium sulfate and
concentrated. Then, the residue was purified by silica gel column
chromatography, to give 82 mg of the title compound.
[0648] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.33(3H, s),
6.76(1H, d, J=7.7 Hz), 7.03(1H, dd, J=7.9, 7.7 Hz), 7.35(1H, s),
7.38(1H, d, J=7.9 Hz), 7.51(1H, d, J=2.7 Hz), 7.80(1H, dd, J=2.0,
1.5 Hz), 8.60(1H, dd, J=2.0, 0.4 Hz), 8.71(1H, dd, J=1.5, 0.4 Hz),
10.35-10.40(1H, m), 10.73-10.80(1H, br), 11.16-11.19(1H, m)
PRODUCTION EXAMPLE 1b
[0649] 2-Amino-5-bromoquinoline
[0650] 2-Bromo-6-nitrobenzaldehyde (30.4 g), magnesium oxide (75 g)
and dimethyl sulfoxide (11.3 ml) were sufficiently stirred for one
minute. Then, to the mixture was added diethyl
(cyanomethyl)phosphonate (25.8 ml) and the mixture was stirred for
further 2 hours. The stirring was stopped and the reaction mixture
was allowed to stand overnight. Thereafter, ethyl acetate was added
thereto and the resulting mixture was stirred, followed by
filtering. The filtrate was concentrated and the residue was
purified by silica gel column chromatography (ethyl acetate), to
give 32 g of 3-(2-bromo-6-nitrophenyl)-2-propenenitrile (E isomer:Z
isomer=3:1).
[0651] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 5.63(d, J=16.5 Hz,
E-isomer1H), 5.81(d, J=10.8 Hz, Z-isomer 1H), 7.42-7.52(m, E-isomer
1H,Z-isomer 2H), 7.56(d, J=16.5 Hz, E-isomer 1H), 7.90-8.16(m,
E-isomer 2H, Z-isomer 2H).
[0652] Next, ethanol (250 ml), tin (60 g) and distilled water (150
ml) were added to 32 g of
3-(2-bromo-6-nitrophenyl)-2-propenenitrile (E isomer:Z isomer=3:1),
followed by heating under stirring at 90.degree. C. To the mixture
was added dropwise concentrated hydrochloric acid (256 ml),
followed by stirring at the same temperature for 3 hours. After
returning to room temperature, the liquid layer was decanted and
cooled to 0.degree. C. The resulting solid was collected by
filtration. An aqueous ammonia was added thereto, and the mixture
was extracted by ethyl acetate. The extract was concentrated and
the residue was purified by silica gel column chromatography (ethyl
acetate), to give 5.0 g of the title compound.
[0653] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 4.88 (2H, bs),
6.79(1H, d, J=9.3 Hz), 7.39 (1H, t, J=8.9 Hz), 7.51(1H, d, J=8.9 Hz
), 7.61(1H, d, J=8.9 Hz), 8.27 (1H, d, J=9.3 Hz).
PRODUCTION EXAMPLE 2b
[0654] 2-Amino-5-chloroquinoline
[0655] The title compound was obtained from
2-chloro-6-nitrobenzaldehyde in the same manner as in Production
Example 1b.
[0656] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 5.25(2H, bs),
6.80(1H, d, J=9.7 Hz), 7.32(1H, dd, J=7.5 Hz, 1.5 Hz), 7.46(1H, t,
J=7.5 Hz), 7.57(1H, m), 8.30(1H, d, J=9.7 Hz, 1.0 Hz).
PRODUCTION EXAMPLE 3b
[0657] 3-Carbethoxy-4-hydroxy-8-bromoquinoline
[0658] A mixture of 50 g (0.291 mol) of 2-bromoaniline and 63 g
(0.291 mol) of diethylethoxymethylene malonate was heated at
100.degree. C. under reduced pressure for 3 hours and further at
200.degree. C. for 12 hours. After the reaction was completed, the
reaction mixture solid was washed with ethyl acetate and the
crystals were collected by filtration and dried, to give 50 g of
the title compound.
[0659] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.26(3H, t, J=7.2
Hz), 4.21(2H, q, J=7.2 Hz), 7.34(1H, t, J=7.6 Hz), 8.03(1H, dd,
J=1.6 Hz, 7.6 Hz), 8.15(1H, dd, J=1.6 Hz, 7.6 Hz), 8.43(1H, s),
11.56(1H, s).
PRODUCTION EXAMPLE 4b
[0660] 3-Carbethoxy-8-bromoquinoline
[0661] A mixture of 2.5 g (8.4 mmol) of
3-carbethoxy-4-hydroxy-8-bromoquin- oline and 10 ml of phosphorous
oxychloride was heated under reflux for one hour. After the
reaction was completed, phosphorous oxychloride was removed and the
residue was purified by NH silica gel, to give 2.6 g of a
chloro-compound. Next, 500 mg (1.6 mmol) of the chloro-compound was
dissolved in 20 ml of dioxane, 1 g of zinc powder and 3 ml of
acetic acid were adaded thereto, followed by heating at 65.degree.
C. for 30 minutes. Ethyl acetate was added to the reaction
solution, and the mixture was filtered through Celite. The filtrate
was washed with brine, dried over magnesium sulfate and
concentrated. To the residue was added 1 ml of acetic acid, and the
mixture was allowed to stand for 12 hours and then acetic acid was
removed. The residue was subjected to silica gel column
chromatography, and eluted with the solvent (ethyl
acetate/n-hexane=1/7), to give obtaining 180 mg of the title
compound.
[0662] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.47(3H, t, J=7.2
Hz), 4.50(2H, q, J=7.2 Hz), 7.50(1H, t, J=7.6 Hz), 7.93(1H, dd,
J=1.2 Hz, 7.6Hz), 8.18(1H, dd, J=1.2 Hz, 7.6 Hz), 8.85(1H, d, J=2
Hz), 9.57 (1H, d, J=2Hz).
PRODUCTION EXAMPLE 5b
[0663] 3-Amino-8-bromoquinoline
[0664] 500 mg (1.8 mmol) of 3-carbethoxy-8-bromoquinoline was added
to an aqueous ethanol (10ml)/1 N NaOH solution (10 ml) and the
mixture was stirred at room temperature for 3 hours. Ethanol was
removed and the residue was neutralized with 1N HCl. The resulting
solid was collected by filtration, washed with water and dried, to
give 450 mg of a carboxylic acid. Next, 450 mg (1.8 mmol) of the
carboxylic acid was added to 25 ml of tert-butanol. Further, to the
mixture were added 0.58 ml (2.7 mmol) of DPPA and 0.37 ml (2.7
mmol) of triethylamine, followed by heating under reflux for 12
hours. The reaction solution was concentrated, and the residue was
subjected to silica gel chromatography and eluted with the solvent
(ethyl acetate-n-hexane=1-4), to give 352 mg of an amide compound.
Next, 350 mg (1.1 mmol) of the amide compound was added to a mixed
solution of 4 ml of methanol/2 ml of conc. HCl, and the mixture was
stirred at room temperature for one hour. The reaction solution was
basified with an aqueous ammonia and extracted with ethyl acetate.
The organic layer was washed with brine, dried over magnesium
sulfate and then concentrated, to give 240 mg of the title
compound.
[0665] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 5.88(2H, s), 7.13
(1H, d, J=2.8 Hz), 7.24(1H, dd, J=7.6 Hz, 8.4 Hz), 7.59-7.65(2H,
m), 8.49(1H, d, J=2.8 Hz).
PRODUCTION EXAMPLE 6b
[0666] 3-Amino-8-isoquinoline
[0667] The title compound was obtained from 2-iodoaniline in the
same manner as in Production Examples (3b-5b).
[0668] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 5.85(2H, s),
7.07(1H, d, J=2.8 Hz), 7.10(1H, t, J=7.6 Hz), 7.62(1H, dd, J=1.2
Hz, 7.6Hz), 7.90(1H, dd, J=1.2 Hz, 7.6 Hz), 8.45(1H, d, J=2.8
Hz).
PRODUCTION EXAMPLE 7b
[0669] 3-Amino-8-cyanoquinoline
[0670] The title compound was obtained from 2-cyanoaniline the same
manner as in Production Examples (3b-5b).
[0671] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.03(2H, br s),
7.22(1H, d, J=2.8 Hz), 7.48(1H, dd, J=7.2 Hz, 8.4 Hz), 7.84(1H, dd,
J=1.2 Hz, 8.4 Hz), 7.94(1H, dd, J=1.2 Hz, 8.4 Hz), 8.57(1H, d,
J=2.8 Hz).
PRODUCTION EXAMPLE 8b
[0672] 3-Amino-8-(methylsulfonyl)quinoline
[0673] The title compound was obtained in the same manner as in
Production Examples (3b-5b).
[0674] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 6.00(2H, s), 7.26(1H,
d, J=2.4 Hz), 7.53(1H, t, J=7.2 Hz), 7.91(1H, dd, J=1.6 Hz, 7.2
Hz), 7.96(1H, dd, J=1.2 Hz, 8.4 Hz), 8.58(1H, d, J=2.8 Hz).
PRODUCTION EXAMPLE 9b
[0675] 3-Amino-8-chloroquinoline
[0676] The title compound was obtained in the same manner as in
Production Examples (3b-5b).
[0677] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 5.90(2H, s),
7.17(1H, d, J=2.8 Hz), 7.33(1H, t, J=7.6 Hz), 7.46(1H, d, J=7.6
Hz), 7.58(1H, d, J=7.6 Hz), 8.52(1H, d, J=2.8 Hz).
PRODUCTION EXAMPLE 10b
[0678] 3-Amino-8-trifluoromethylquinoline
[0679] The title compound was obtained in the same manner as in
Production Examples (3b-5b).
[0680] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 5.94(2H, s),
7.23(1H, d, J=2.8 Hz), 7.48(1H, t, J=7.6 Hz), 7.69(1H, d, J=7.6
Hz), 7.91(1H, d, J=7.6 Hz), 8.55(1H, d, J=2.8 Hz).
PRODUCTION EXAMPLE 11b
[0681] Ethyl-8-chloro-4-vinylquinoline-3-carboxylate
[0682] Tributylvinyltin (2.8 ml) and
tetrakistriphenylphosphinepalladium (171 mg) were added to a
toluene solution (20 ml) containing 2.0 g (7.4 mmol) of
ethyl-4,8-dichloroquinoline-3-carboxylate obtained in the same
manner as in Production Example 4b, followed by stirring for 2
hours under heating under reflux. The reaction solution was
filtered through Celite and the filtrate was concentrated. Then,
the residue was purified by silica gel chromatography, to give 1.92
g of the title compound.
[0683] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.36(3H, t, J=7.6
Hz), 4.37(2H, d, J=7.6 Hz), 5.52(1H, d, J=18.0 Hz), 5.58(1H, d,
J=16.4 Hz), 7.40(1H, dd, J=16.4, 18.0 Hz), 7.70(1H, t, J=8.0 Hz),
8.11(1H, d, J=8.0 Hz), 8.25(1H, d, J=8.0 Hz), 9.24(1H, s).
PRODUCTION EXAMPLE 12b
[0684] 3-Amino-8-chloro-4-vinylquinoline
[0685] The title compound was obtained from
ethyl-4-vinyl-8-chloroquinolin- e-3-carboxylate in the same manner
as in Production Example 5b.
[0686] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 5.69(1H, dd, J=1.6,
18.0 Hz), 5.81(2H, s), 5.84(1H, dd, J=1.6, 11.6 Hz), 6.91(1H, dd,
J=11.6, 18.0 Hz), 7.38(1H, t, J=8.0 Hz), 7.52(1H, dd, J=1.2, 8.0
Hz), 7.85(1H, dd, J=1.2, 8.0 Hz), 8.60(1H, s).
PRODUCTION EXAMPLE 13b
[0687] Ethyl-7-amino-2-chloroquinoline-4-carboxylate
[0688] 43 g (231 mmol) of diethyl oxaloacetate was added to 25 g
(231 mmol) of methaphenylenediamine and the mixture was stirred at
160.degree. C. for one hour. After cooling as it was, the crystals
were washed with methanol. Phosphorous oxychloride (3.6 ml) was
added to a chloroform solution (30 ml) containing 3.0 g (13 mmol)
of the crystals, followed by heating under reflux for one hour.
After cooling as it was, the mixture was poured into ice-water and
basified with a 1 N aqueous sodium hydroxide. Then, crystals were
collected by filtration and washed with tetrahydrofuran, and the
filtrate was evaporated, to give 4.85 g of the title compound.
[0689] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.31-1.42(3H, m),
4.34-4.46(2H, m), 6.92(1H, d, J=2.4 Hz), 7.12(1H, dd, J=2.4, 9.2
Hz), 7.40(1H, s), 8.21(1H, d, J=9.2 Hz).
PRODUCTION EXAMPLE 14b
[0690] 2-Benzylthio-4-methoxypyridazine
[0691] 843 mg (21 mmol, 55% oily) of sodium hydride was suspended
in dimethyl sulfoxide (30 ml). Under ice-cooling, 2.0 ml (16.7
mmol) of benzylmercaptan was added thereto, followed by stirring
for 10 minutes. To the reaction mixture was added 2.5 g (17.6 mmol)
of 4-methoxy-2-chloropyridazine, followed by stirring at room
temperature overnight. To the reaction mixture was added an aqueous
saturated ammonium chloride, followed by extracting with ethyl
acetate. The organic layer was washed with brine, dried over
magnesium sulfate and concentrated. Then, the residue was purified
by silica gel chromatography, to give 1.63 g of the title
compound.
[0692] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.98(3H, s),
4.48(2H, s), 7.12(1H, d, J=8.8 Hz), 7.22-7.26(1H, m), 7.29-7.37(2H,
m), 7.41-7.44(2H, m), 7.57(1H, d, J=8.8 Hz).
PRODUCTION EXAMPLE 15b
[0693] 2-Benzylthio-4-carboxyamidopyridine
[0694] Thionyl chloride (120 ml) was added to 25 g (159 mmol) of
2-chloroisonicotinic acid, and the mixture was stirred while
heating under reflux for 3 hours. After cooling as it was, the
mixture was evaporated, to give the residue. A tetrahydrofuran
solution (200 ml) containing the reside was poured into a mixed
solution of an aqueous ammonium (200 ml) and a tetrahydrofuran (200
ml) under ice-cooling. After stirring under ice-cooling for 15
minutes, the mixture was evaporated. Crystals were collected by
filtration and washed with water, to give 22.6 g of white crystals.
4.2 ml (36 mmol) of benzylthiomercaptan and 10 g (77 mmol) of
potassium carbonate were added to a dimethylformamide solution
containing 5.13 g (32 mmol) of the white crystals, and the mixture
was stirred while heating under reflux for 3 hours. Water was added
to the reaction solution, and the mixture was extracted with ethyl
acetate. The organic layer was washed with brine, dried over
magnesium sulfate and evaporated. Then, the residue was purified by
silica gel chromatography, and the resulting crystals were washed
with hexane, to give 6.3 g of the title compound.
[0695] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 4.46(2H, s),
7.22-7.33(3H, m),7.41(2H, d, J=7.22 Hz), 7.49(1H, dd, J=1.6, 5.2
Hz), 7.67(1H, s), 7.73(1H, s), 8.21(1H, s), 8.58(1H, d, J=5.2
Hz).
PRODUCTION EXAMPLE 16b
[0696] 7-Amino-2-chloro-4-methylquinoline
[0697] 32 ml (251 mmol) of ethyl acetoacetate was added to 27 g
(251 mmol) of methaphenylenediamine and the mixture was stirred at
200.degree. C. for one hour. After cooling as it was, crystals were
washed with hexane. 15 ml of phosphorous oxychloride was added to
9.5 g (54 mmol) of the crystals, followed by heating under reflux
for 2 hours. After cooling as it was, the reaction mixture was
poured into ice-water and basified with an aqueous saturated
ammonium. The resulting crystals were collected by filtration and
washed with water. The crystals were washed with methanol and the
filtrate was evaporated, to give 4.85 g of the title compound.
[0698] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.18(3H, s),
5.95(2H, s), 6.82(1H, d, J=2.4 Hz), 6.98(1H, s), 7.01(1H, dd,
J=2.4, 8.8 Hz), 7.76(1H, d, J=8.8 Hz).
PRODUCTION EXAMPLE 17b
[0699] 3,4-Dihydroisoquinoline
[0700] N-Bromosuccinimide (39.2 g) was added to a methylene
chloride solution (300 ml) containing 26.67 g (0.2 mol) of
1,2,3,4-tetrahydroisoqu- inoline under ice-cooling over 20 minutes.
After stirring for 40 minutes, an aqueous 30% sodium hydroxide
solution (130 ml) was added to the reaction solution. The organic
layer was washed with water and then extracted with a 10% aqueous
hydrochloric acid (200 ml). The aqueous layer was washed with
methylene chloride, basified with an aqueous ammonia, and then
extracted with methylene chloride. The extract was dried over
magnesium sulfate and then evaporated. The resulting residue was
distilled (about 16 mmHg, 120.degree. C.), to give 21.5 g of the
title compound as an oil.
[0701] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.66 (2H, t, J=8
Hz), 3.62 (2H, td, J=2 Hz, 8 Hz), 7.19-7.21 (1H, m), 7.29-7.33 (1H,
m), 7.35-7.40 (1H, m), 8.31 (1H, t, J=2 Hz).
PRODUCTION EXAMPLE 18b
[0702] 7-Nitroisoquinoline
[0703] 15 g of potassium nitrite was added to a concentrated
sulfuric acid (70 ml) solution containing 18 g (0.14 mol) of
3,4-dihydroisoquinoline was added thereto at -15.degree. C. over 20
minutes. After stirring at room temperature for one hour, the
mixture was heated at 60.degree. C. for 40 minutes. The reaction
solution was poured into ice-water and basified with an aqueous
ammonia. The mixture was extracted with ethyl acetate, and the
organic layer was washed with brine and dried over magnesium
sulfate. After concentrating, decaline (100 ml), nitrobenzene (100
ml) and 2 g of Pd-Black were added to the residue, and the mixture
was heated at 200.degree. C. overnight in nitrogen stream. The
reaction solution was washed with ethyl acetate and then extracted
with 2N hydrochloric acid. The aqueous layer was washed with ethyl
acetate and then an aqueous sodium hydroxide was added thereto. The
resulting precipitates were collected by filtration and washed with
water, to give 14.4 g of the title compound.
[0704] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 7.79 (1H, d, J=5.6
Hz), 8.00 (1H, d, J=9.2 Hz), 8.48 (1H, dd, J=2.4 Hz, 9.2 Hz), 8.75
(1H, d, J=5.6 Hz), 8.96 (1H, d, J=2 Hz), 9.48 (1H, s).
PRODUCTION EXAMPLE 19b
[0705] 4-Bromo-7-nitroisoquinoline
[0706] 1.2 ml of aqueous HBr and 3 ml of bromine were added to 1.6
g (9.19 mmol) of 7-nitroquinoline and the mixture was heated at
180.degree. C. for 5.5 hours. The reaction solution was extracted
with ethyl acetate. The extract was successively washed with an
aqueous sodium hydroxide, an aqueous sodium thiosulfate and brine,
dried over magnesium sulfate and concentrated. Then, the resulting
residue was purified by silica gel column chromatography (eluted
with hexane-hexane:ethyl acetate=4:1), to give 500 mg of the title
compound.
[0707] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 8.36(1H, d, J=9.2
Hz), 8.58(1H, d, J=2.4 Hz, 9.2 Hz), 8.93(1H, s), 8.96(1H, d,
J=3.2Hz), 9.38(1H, s).
PRODUCTION EXAMPLE 20b
[0708] 7-Amino-4-bromoisoquinoline
[0709] 66 mg (0.26 mmol) of 7-nitro-4-bromoisoquinoline was
dissolved in 1 ml of ethanol, 2 ml of tetrahydrofuran and 1 ml of
water. To the mixture were added 70 mg of an iron powder and 140 mg
of ammonium chloride, followed by heating at 50.degree. C. for 3
hours. A 1N aqueous sodium hydroxide was added to the reaction
solution, and the mixture was extracted with chloroform. The
organic layer was dried over magnesium sulfate and concentrated.
The resulting residue was crystallized from isopropyl ether, to
give 33 mg of the title compound.
[0710] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 5.98 (2H, s), 6.97
(1H, d, J=2.4 Hz), 7.31 (1H, dd, J=2.4 Hz, 8.8 Hz), 8.28 (1H, s),
8.89 (1H, s).
PRODUCTION EXAMPLE 21b
[0711] 6-(4-Toluenesulfonylamino)isoquinoline
[0712] 6-Aminoisoquinoline (3.348 g, Synthesis, 733 (1975)) was
dissolved in pyridine (30 ml). To the mixture was added
4-toluenesulfonyl chloride (5.13 g), followed by stirring at room
temperature overnight. Water was added thereto, and the mixture was
extracted with ethyl acetate. The extract was washed with brine and
dried over anhydrous magnesium sulfate. The solvent was evaporated
and the residue was recrystallized from ethanol, to give the title
compound (5.958 g, 85%) as pale yellow crystals.
[0713] .sup.1H-NMR (DMSO-d.sub.6) .delta. (ppm): 2.28(3H, s),
7.32(2H, d, J=8.2 Hz), 7.40(1H, dd, J=1.6, 9.2 Hz), 7.55(1H, brs),
7.67(1H, d, J=5.6 Hz), 7.74(2H, d, J=8.2 Hz), 7.97(1H, d, J=9.2
Hz), 8.36(1H, d, J=5.6 Hz), 9.10(1H, s).
PRODUCTION EXAMPLE 22b
[0714] 1-Chloro-6-(4-toluenesulfonylamino)isoquinoline
[0715] 6-(4-Toluenesulfonylamino)isoquinoline (3.0 g, Production
Example 21b) was dissolved in chloroform (100 ml). Under
ice-cooling, m-chloroperbenzoic acid (2.57 g) was added thereto,
followed by stirring at room temperature overnight. The solvent was
evaporated, and the resulting crystals were washed with diethyl
ether, collected by filtration and dried, to give pale yellow
crystals. The crystals were suspended in chloroform (83 ml) and
phosphorous oxychloride (19 ml) was added thereto, followed by
heating under ref lux for 5 hours. After cooling, the solvent was
evaporated. The residue was basified by adding an aqueous saturated
sodium bicarbonate in an ice bath, and then the mixture was
extracted with ethyl acetate. The extract was washed with brine and
dried over anhydrous magnesium sulfate, and the solvent was
evaporated. The residue was purified by silica gel column, to give
crude crystals of the title compound (1.630 g, 49.40%). The
crystals were recrystallized from ethanol, to give the title
compound as colorless crystals.
[0716] .sup.1H-NMR (DMSO-d.sub.6) .delta. (ppm): 2.29(3H, s),
7.34(2H, d, J=8.0 Hz), 7.52 (1H, dd, J=2.0, 9.0 Hz), 7.65 (1H, d,
J=2.0 Hz), 7.76 (1H, d, J=5.6 Hz), 7.77 (2H, d, J=8.0 Hz), 8.14
(1H, d, J=9.0 Hz), 8.16 (1H, d, J=5.6 Hz).
PRODUCTION EXAMPLE 23b
[0717] 6-Amino-1-chloroisoquinoline
[0718] 1-Chloro-6-(4-toluenesulfonylamino)isoquinoline (3.323 g,
Production Example 22b) was dissolved in sulfuric acid (30 ml),
followed by stirring at room temperature overnight. The reaction
solution was poured into ice, and basified by adding an aqueous
sodium hydroxide solution and then potassium carbonate thereto,
followed by extracting with ethyl acetate. The extract was washed
with brine and dried over anhydrous magnesium sulfate. The solvent
was evaporated, to give the title compound (1.37 g, 76.81%) as
yellowish brown crystals.
[0719] .sup.1H-NMR (DMSO-d.sub.6) .delta. (ppm): 6.23 (2H, brs),
6.76 (1H, s), 7.09 (1H, d, J=9.6 Hz), 7.37 (1H, d, J=6.4 Hz), 7.89
(1H, d, J=9.6 Hz), 7.90 (1H, d, J=6.4 Hz).
PRODUCTION EXAMPLE 24b
[0720] 2-Chloro-1,6-naphthyridine
[0721] 1,6-Naphthyridine-2-one (1.0 g, J. Org. Chem. 4744 (1990))
was dissolved in phosphorous oxychloride (19 ml), followed by
heating under reflux at 120.degree. C. for 2 hours. After cooling,
the solvent was evaporated, and the residue was basified with water
and potassium carbonate. Then, the mixture was extracted with ethyl
acetate, and the extract was washed with brine and dried over
anhydrous magnesium sulfate. The solvent was evaporated, to give
the title compound (0.658 g, 58.45%) as orange crystals.
[0722] .sup.1H-NMR (CDCl.sub.3) .delta. (ppm): 7.55 (1H, d, J=8.8
Hz), 7.86 (1H, d, J=6.0 Hz), 8.28 (1H, d, J=8.8 Hz), 8.80 (1H, d,
J=6.0 Hz), 9.29 (1H, s).
PRODUCTION EXAMPLE 25b
[0723] 2-Amino-1,6-naphthyridine
[0724] 2-Chloro-1,6-naphthyridine (0.628 g, Production Example 22b)
and an aqueous ammonia (40 ml) were heated at 130.degree. C. for 11
hours in a sealed tube. After cooling, the mixture was extracted
with ethyl acetate, and the extract was washed with brine and dried
over anhydrous magnesium sulfate. The solvent was evaporated and
the residue was purified by silica gel column, to give the title
compound (0.497 g, 89.73%) as pale yellow crystals.
[0725] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.81 (1H, d, J=8.8
Hz), 7.24 (1H, d, J=5.8 Hz), 7.97 (1H, d, J=8.8 Hz), 8.34 (1H, d,
J=5.8 Hz), 8.80 (1H, s).
PRODUCTION EXAMPLE 26b
[0726] N-(3-Nitrophenethyl)phthalimide
[0727] 3-Nitrophenethyl alcohol (15 g) was dissolved in
tetrahydrofuran (225 ml). After adding triphenylphosphine (26 g)
and phthalimide (13.9 g) thereto, the mixture was ice-cooled and
diethylazodicarboxylate (15.5 ml) was added dropwise thereinto.
After stirring at room temperature for one hour, the resulting
crystals were collected by filtration, washed with diethyl ether
and dried, to give N-(3-nitrophenethyl)phthalimide as colorless
crystals.
[0728] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 3.12 (2H, t, J=7.4
Hz), 3.98 (2H, t, J=7.4 Hz), 7.47 (1H, dd, J=8.0, 8.0 Hz), 7.60
(1H, d, J=8.0 Hz), 7.72 (2H, m), 7.83 (2H, m), 8.09 (1H, d, J=8.0
Hz), 8.12 (1H, s).
PRODUCTION EXAMPLE 27b
[0729] 3-Nitrophenethylamine
[0730] N-(3-Nitrophenethyl)phthalimide obtained in Production
Example 26b was suspended in ethanol (150 ml). To the mixture was
added hydrazine (5.7 ml), followed by heating under reflux for one
hour. The reaction solution was once dissolved completely, but
crystals again precipitated. The crystals were filtered off and
washed with cooled ethanol. Then, the solvent was evaporated, to
give the title compound (5.559 g, 99%) as a yellow oil.
[0731] .sup.1H-NMR (CDCl.sub.3) .delta. (ppm): 2.87(2H, t, J=6.8
Hz), 3.04(2H, t, J=6.8 Hz), 7.48(1H, dd, J=7.6, 8.4 Hz), 7.55(1H,
ddd, J=1.2, 1.6, 7.6 Hz), 8.08(2H, m).
PRODUCTION EXAMPLE 28b
[0732] N-Acetyl-N-(3-nitrophenethyl)amine
[0733] 3-Nitrophenethylamine (5.559 g, Production Example 25b) was
dissolved in pyridine (33 ml), and acetyl chloride (2.5 ml) was
added dropwise thereinto under ice-cooling. After stirring at room
temperature for 0.5 hr, the mixture was ice-cooled again. Water was
added thereto, and the mixture was extracted with ethyl acetate.
The extract was washed with brine and dried over anhydrous
magnesium sulfate. The solvent was evaporated, to give the title
compound (6.323 g, 91%) as a yellow oil.
[0734] .sup.1H-NMR (CDCl.sub.3) .delta. (ppm): 1.97(3H, s),
2.95(2H, t, J=7.0 Hz), 3.55(2H, dt, J=6.0, 7.0 Hz), 5.60(1H, brs),
7.49(1H, dd, J=7.2, 8.0 Hz), 7.55(1H, d, J=7.2 Hz), 8.07(1H, s),
8.12(1H, d, J=8.0 Hz).
PRODUCTION EXAMPLE 29b
[0735] N-Acetyl-N-(3-aminophenethyl)amine
[0736] N-Acetyl-N-(3-nitrophenethyl)amine (2.1 g, Production
Example 28b) was dissolved in ethanol (40 ml). To the mixture were
added an iron powder (2.25 g), ammonium acetate (4.3 g) and water
(20 ml), followed by heating under reflux for 1.5 hours. Solid was
filtered off and washed with ethanol, and then the filtrate was
partially evaporated. The residue was extracted with ethyl acetate,
washed with brine and dried over anhydrous magnesium sulfate. The
solvent was evaporated, to give the title compound (1.723 g, 96%)
as a yellow oil.
[0737] .sup.1H-NMR (CDCl.sub.3) .delta.(ppm): 1.94(3H, s), 2.72(2H,
t, J=6.8 Hz), 3.50(2H, dt, J=6.0, 6.8 Hz), 6.53(1H, s), 6.57(1H, d,
J=8.0 Hz), 6.59(1H, d, J=7.2 Hz), 7.10(1H, dd, J=7.2, 8.0 Hz).
PRODUCTION EXAMPLE 30 b
[0738] N-Acetyl-N-(3-ethoxycarbonylaminophenethyl)amine
[0739] N-Acetyl-N-(3-aminophenethyl)amine (1.7 g, Production
Example 29b) was dissolved in pyridine (5 ml). Under ice-cooling,
ethyl chloroformate (1.4 ml) was added dropwise thereinto, followed
by stirring at room temperature for one hour. Then, the mixture was
ice-cooled again and water was added thereto. The mixture was
extracted with ethyl acetate, and the extract was washed with brine
and dried over anhydrous magnesium sulfate. The solvent was
evaporated, to give the title compound (2.358 g, 97%) as a yellow
oil.
[0740] .sup.1H-NMR (CDCl.sub.3) .delta. (ppm): 1.29 (3H, t, J=7.2
Hz), 1.93 (3H, s), 2.76 (2H, t, J=7.0 Hz), 3.47 (2H, dt, J=6.0, 7.0
Hz), 4.20 (2H, q, J=7.2 Hz), 5.57 (1H, brs), 6.86 (1H, d, J=7.2
Hz), 7.21 (1H, dd, J=7.2, 8.0 Hz), 7.28 (1H, d, J=8.0 Hz), 7.29
(1H, s).
PRODUCTION EXAMPLE 31b
[0741] 6-Ethoxycarbonylamino-1-methyl-3,4-dihydroisoquinoline
[0742] Using N-acetyl-N-(3-ethoxycarbonylaminophenethyl)amine (1.0
g, Production Example30b), a cyclization reaction was run according
to the method described in Heterocycles 31 (2), 341 (1990). After
the reaction was completed, the reaction solution was poured into
ice and basified with potassium carbonate. Then, the solution was
extracted with ethyl acetate, and the extract was washed with brine
and dried over anhydrous magnesium sulfate. The solvent was
evaporated, to give the title compound as a brown oil.
[0743] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.19(3H, t, J=7.2
Hz), 2.23(3H, s), 2.60(2H, t, J=7.4 Hz), 3.55(2H, t, J=7.4 Hz),
4.13(2H, q, J=7.2 Hz), 7.31(1H, d, J=6.8 Hz), 7.32(1H, s), 7.34(1H,
d, J=6.8 Hz).
PRODUCTION EXAMPLE 32b
[0744] 6-Ethoxycarbonylamino-1-methylisoquinoline
[0745] p-Cymene (100 ml) and palladium carbon (0.9 g) were added to
6-ethoxycarbonylamino-1-methyl-3,4-dihydroisoquinoline, followed by
heating under stirring at 195.degree. C. for one hour in a nitrogen
atmosphere. The catalyst was filtered off and washed with ethanol,
and then the filtrate was partially evaporated. After extracting
with 1N hydrochloric acid, the extract was basified with potassium
carbonate and then extracted with ethyl acetate. The extract was
washed with brine and dried over anhydrous magnesium sulfate
anhydride. The solvent was evaporated, to give the title compound
(0.629 g, 69%, 2 steps) as pale yellow crystals.
[0746] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.30(3H, t, J=7.2
Hz), 2.89(3H, s), 4.26(2H, q, J=7.2 Hz), 7.40(1H, d, J=5.8 Hz),
7.56(1H, dd, J=1.6, 8.8 Hz), 7.99(1H, d, J=8.8 Hz), 8.05(1H, d,
J=1.6 Hz), 8.30(1H, d, J=5.6 Hz), 8.37(1H, s).
PRODUCTION EXAMPLE 33b
[0747] 6-Amino-1-methylisoquinoline
[0748] 6-Ethoxycarbonylamino-1-methylisoquinoline (0.629 g,
Production Example 32b) was dissolved in ethanol (20 ml), to which
was then added an aqueous 8 N sodium hydroxide solution (6.8 ml),
followed by heating under reflux for 1.5 hours. After cooling as it
was to room temperature, an aqueous saturated ammonium chloride was
added thereto and the mixture was extracted with ethyl acetate. The
extract was washed with brine and dried over anhydrous magnesium
sulfate. The solvent was evaporated, to give the title compound
(0.311 g, 72%) as pale yellow crystals.
[0749] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 2.81(3H, s), 4.24(2H,
brs), 6.60(1H, d, J=2.0 Hz), 6.91(1H, ddd, J=1.6, 2.0, 8.8 Hz),
7.18(1H, d, J=5.6 Hz), 7.84(1H, d, J=8.8 Hz), 8.16(1H, dd, J=1.6,
5.6 Hz).
PRODUCTION EXAMPLE 34b
[0750] N-t-Butoxycarbonyl-3-nitrophenethylamine
[0751] 3-Nitrophenethylamine (4.559 g, Production Example 27b) was
dissolved in tetrahydrofuran (130 ml), to which were then added
triethylamine (8.4 ml) and di-t-butyl dicarbonate (6.6 g), followed
by stirring at room temperature for 2 hours. After evaporating the
solvent, brine was added thereto and the mixture was then extracted
with ethyl acetate. The extract was washed with brine and dried
over anhydrous magnesium sulfate. The solvent was evaporated, to
give the title compound (8.789 g, including impurities) as a yellow
oil. It was used in the next reaction without being further
purified.
[0752] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.53(9H, s), 2.92(2H,
t, J=7.6 Hz), 3.42 (2H, dt, J=6.4, 6.8 Hz), 4.58 (1H, brs), 7.48
(1H, dd, J=7.2, 8.0 Hz), 7.54 (1H, d, J=8.0 Hz), 8.07 (1H, s), 8.10
(1H, d, J=7.2 Hz).
PRODUCTION EXAMPLE 35b
[0753] 3-(2-t-Butoxycarbonylaminoethyl)-aniline
[0754] The title compound (5.521 g, 76%) was obtained as a yellow
oil by using N-t-butoxycarbonyl-3-nitrophenethylamine (8.789 g,
including impurities, Production Example 34b) in the same manner as
in Production Example 170b.
[0755] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.44 (9H, s), 2.70
(2H, t, J=7.4 Hz), 3.36 (2H, brq), 4.54 (1H, brs), 6.54 (1H, s),
6.57 (1H, d, J=8.0 Hz), 6.60 (1H, d, J=7.2 Hz), 8.10 (1H, dd,
J=7.2, 8.0 Hz).
PRODUCTION EXAMPLE 36b
[0756] 3-(2-Butoxycarbonylaminoethyl)ethoxycarbonylaminobenzene
[0757] The title compound (0.320 g) was obtained as a yellow oil by
using 3-(2-t-butoxycarbonylaminoethyl)aniline (5.521 g, Production
Example 35b) in the same manner as in Production Example 29b. It
was used in the next reaction without being further purified.
[0758] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.31 (3H, t, J=7.2
Hz), 1.43 (9H, s), 2.77 (2H, t, J=7.4 Hz), 3.67 (2H, brq), 4.22
(2H, q, J=7.4 Hz), 4.55 (1H, brs), 6.52 (1H, brs), 6.89 (1H, m),
7.24 (1H, m).
PRODUCTION EXAMPLE 37b
[0759] 3-Ethoxycarbonylaminophenethylamine Hydrochloride
[0760] 3-(2-t-Butoxycarbonylaminoethyl)-ethoxycarbonylaminobenzene
(14.96 g, Production Example 36b) was dissolved in ethanol (15 ml),
to which was then added hydrochloric acid (15 ml) under
ice-cooling, followed by stirring at room temperature for 20
minutes. Hydrochloric acid (12 ml) and ethanol (15 ml) were added
thereto, followed by stirring at room temperature for 20 minutes.
Then, hydrochloric acid (20 ml) and ethanol (30 ml) were further
added thereto, followed by stirring at room temperature for 30
minutes. After evaporating (subjecting azeotropic distillation
together with toluene) the solvent, the title compound (11.99 g)
was obtained as pale yellow crystals.
[0761] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.22 (3H, t, J=7.2
Hz), 2.82 (2H, m), 2.95 (2H, m), 4.10 (2H, q, J=7.2 Hz), 6.86 (1H,
d, J=7.6 Hz), 7.20 (1H, dd, J=7.6, 8.4 Hz), 7.31 (1H, d, J=8.4 Hz),
7.36 (1H, s), 8.05 (2H, brs), 9.61 (1H, s).
PRODUCTION EXAMPLE 38b
[0762] 6-Aminoethyl-1,2.3,4-tetrahydroisoquinoline
[0763] The title compound (4.226 g, including impurities) was
obtained as a yellow oil by using
3-ethoxycarbonylaminophenethylamine hydrochloride (4.7 g) obtained
in Production Example 39b according to the method described in
Chem. Pharm. Bull. 42 (8), 1676 (1994).
[0764] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.29 (3H, t, J=7.2
Hz), 2.68 (1H, brs), 2.83 (3H, m), 3.73 (2H, m), 4.20 (2H, q, J=7.2
Hz), 6.77 (1H, s), 6.94 (1H, d, J=8.4 Hz), 7.07 (1H, d, J=8.4 Hz),
7.18 (1H, brs).
PRODUCTION EXAMPLE 39b
[0765] 6-Ethoxycarbonylaminoisoquinoline
[0766] p-Cymene (100 ml) and palladium carbon (0.9 g) were added to
6-aminoethyl-1,2,3,4-tetrahydroisoquinoline (10 g, Production
Example 38b), followed by heating under stirring at 195.degree. C.
for one hour in a nitrogen atmosphere. The catalyst was filtered
off, and the reaction mixture was washed with ethanol. Then, the
filtrate was evaporated, and the resulting crystals were washed
with diethyl ether and dried. The solvent was evaporated, to give
the title compound (6.51 g, 66%) as pale yellow crystals.
[0767] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.36(3H, t, J=7.2
Hz), 3.74(1H, m), 4.29(2H, q, J=7.2 Hz), 6.70(1H, d, J=2.0 Hz),
7.46(1H, dd, J=2.0, 8.8 Hz), 7.58(1H, d, J=6.0 Hz), 7.90(1H, d,
J=8.8 Hz), 8.04(1H, brs), 8.46(1H, d, J=6.0 Hz), 9.13(1H, s).
PRODUCTION EXAMPLE 40b
[0768] 6-Ethoxycarbonylaminoisoquinoline-N-oxide
[0769] The title compound (293 mg) was obtained as pale yellow
crystals by using 6-ethoxycarbonylaminoisoquinoline (250 mg,
Production Example 39b) in the same manner as in Production Example
22b.
[0770] .sup.1H-NMR(DMSO-d6) .delta. (ppm): 1.25(3H, t, J=7.2 Hz),
4.26(2H, q, J=7.2 Hz), 7.61(1H, dd, J=2.0, 8.8 Hz), 7 79(1H, d,
J=8.8 Hz), 7.81(1H, d, J=7.2 Hz), 8.04(1H, dd, J=2.0, 7.2 Hz),
8.79(1H, s), 8.46(1H, d, J=6.0 Hz), 9.13(1H, s).
PRODUCTION EXAMPLE 41b
[0771] 1-Chloro-6-ethoxycarbonylaminoisoqinoline
[0772] The title compound (173 mg, 60%, 2 steps) was obtained as
pale yellow crystals by using
6-ethoxycarbonylaminoisoquinoline-N-oxide (250 mg) in the same
manner as in Production Example 22b.
[0773] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.34(3H, t, J=7.2
Hz), 4.29(2H, q, J=7.2 Hz), 7.36(1H, brs),7.50 (1H, d, J=5.6 Hz),
7.52(1H, dd, J=2.4, 9.2 Hz), 8.11(1H, m), 8.19(1H, d, J=5.6 Hz),
8.22(1H, d, J=9.2 Hz).
PRODUCTION EXAMPLE 42b
[0774] 1-Methoxy-6-methoxycarbonylaminoisoquinoline
[0775] 1-Chloro-6-ethoxycarbonylaminoisoquinoline (2.27 g,
Production Example 41b) was dissolved in dimethyl sulfoxide (45
ml), to which was then added a 28% sodium methoxide solution (8.7
ml), followed by heating under stirring at 110.degree. C. for 1.5
hours. After cooling as it was to room temperature, an aqueous
saturated ammonium chloride was added thereto and the mixture was
extracted with ethyl acetate. The extract was washed with brine and
dried over anhydrous magnesium sulfate. The solvent was evaporated,
to give the title compound (1.75 g, 84%) as a brown oil.
[0776] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 3.74 (3H, s), 4.03
(3H, s), 7.05 (1H, d, J=5.8 Hz), 7.41 (1H, dd, J=2.0, 9.2 Hz), 7.86
(1H, d, J=5.8 Hz), 7.90 (1H, brs), 8.06 (1H, d, J=9.2 Hz), 8.08
(1H, brs).
PRODUCTION EXAMPLE 43b
[0777] 6-Amino-1-methoxyisoquinoline
[0778] The title compound (1.04 g, 99%) was obtained as pale brow
crystals by using 1-methoxy-6-methoxycarbonylaminoisoquinoline
(1.75 g, Production Example 42b) and also methanol as the solvent
in the same manner as in Production Example 41b.
[0779] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 4.07(3H, s), 4.07(2H,
brs), 6.78(1H, d, J=2.2 Hz), 6.88(1H, dd, J=2.2, 8.8 Hz), 6.95(1H,
d, J=6.0 Hz), 7.84(1H, d, J=6.0 Hz), 8.03(1H, d, J=8.8 Hz).
PRODUCTION EXAMPLE 44b
[0780] N-Propinyl-(3-nitrophenethyl)amine
[0781] The title compound (3.070 g, 77%, including impurities) was
obtained as a yellow oil by using 3-nitrophenethylamine (3.0 g,
Production Example 27b) and propionyl chloride (2.5 ml) in the same
manner as in Production Example 28b.
[0782] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.14 (3H, t, J=7.6
Hz), 2.19 (2H, q, J=7.6 Hz), 2.96 (2H, t, J=6.8 Hz), 3.56 (2H, dt,
J=6.4, 6.8 Hz), 7.49 (1H, dd, J=7.6, 8.0 Hz), 7.55 (1H, d, J=7.6
Hz), 8.07 (1H, s), 8.10 (1H, d, J=8.0 Hz).
PRODUCTION EXAMPLE 45b
[0783] N-Propinyl-(3-aminophenethyl)amine
[0784] N-Propinyl-(3-nitrophenethyl)amine (3.070 g, Production
Example 44b) was used to run a reaction in the same manner as in
Production Example 29b. The resulting residue was purified by
silica gel column, to give the title compound (0.857 g, 32%) as a
pale yellow oil.
[0785] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.12 (3H, t, J=7.6
Hz), 2.19 (2H, q, J=7.6 Hz), 2.71 (2H, t, J=6.8 Hz), 3.49 (2H, dt,
J=6.0, 6.8 Hz), 5.56 (1H, brs), 6.52 (1H, s), 6.56 (1H, d, J=7.6
Hz), 6.56 (1H, d, J=7.6 Hz), 7.09 (1H, dd, J=7.6, 7.6 Hz).
PRODUCTION EXAMPLE 46b
[0786] N-Propinyl-(3-ethoxycarbonylaminophenethyl)amine
[0787] N-Propinyl-(3-aminophenethyl)amine (0.857 g, Production
Example 44b) was used to run a reaction in the same manner as in
Production Example 30b. The resulting residue was purified by
silica gel column, to give the title compound (0.747 g, 61%) as a
pale yellow oil.
[0788] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.12 (3H, t, J=7.6
Hz), 1.30 (3H, t, J=7.0 Hz), 2.16 (2H, q, J=7.6 Hz), 2.78 (2H, t,
J=6.8 Hz), 3.50 (2H, dt, J=6.0, 6.8 Hz), 4.21 (2H, q, J=7.0 Hz),
6.67 (1H, brs), 6.87 (1H, d, J=6.8 Hz), 7.00 (1H, brs), 7.22 (1H,
dd, J=6.8, 8.4 Hz), 7.26 (1H, d, J=8.4 Hz), 7.28 (1H, s).
PRODUCTION EXAMPLE 47b
[0789] 6-Ethoxycarbonylamino-1-ethylisoquinoline
[0790] 6-Ethoxycarbonylamino-1-ethyl-3,4-dihydroisoquinoline was
obtained as brown crystals by using
N-propynyl-(3-ethoxycarbonylaminophenethyl)ami- ne (0.747 g,
Production Example 46b) in the same manner as in Production
Examples 31b-32b, and then the title compound (0.516 g, 75%, 2
steps) was obtained as a yellow oil.
[0791] The data of the intermediate and the title compound are as
follows.
[0792] 6-Ethoxycarbonylamino-1-ethyl-3,4-dihydroisoquinoline
[0793] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.21 (3H, t, J=7.6
Hz), 1.30 (3H, t, J=7.0 Hz), 2.66 (2H, t, J=7.4 Hz), 2.74 (2H, q,
J=7.6 Hz), 3.64 (2H, t, J=7.4 Hz), 4.23 (2H, q, J=7.0 Hz), 7.32
(1H, d, J=8.4 Hz), 7.37 (1H, s), 7.43 (1H, d, J=8.4 Hz), 7.79 (1H,
s).
[0794] 6-Ethoxycarbonylamino-1-ethylisoquinoline
[0795] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.32 (3H, t, J=7.0
Hz), 1.41 (3H, t, J=7.6 Hz), 3.27 (2H, q, J=7.6 Hz), 4.27 (2H, q,
J=7.0 Hz), 7.40 (1H, d, J=6.0 Hz), 7.52 (1H, dd, J=2.0, 8.8 Hz),
7.89 (1H, s), 8.02 (1H, d, J=2.0 Hz), 8.25 (1H, d, J=8.8 Hz), 8.34
(1H, J=6.0 Hz).
PRODUCTION EXAMPLE 48b
[0796] 6-Amino-1-ethylisoquinoline
[0797] The title compound (0.320 g, 88%) was obtained as pale
yellow crystals by using 6-ethoxycarbonylamino-1-ethylisoquinoline
(0.516 g, Production Example 47b) in the same manner as in
Production Example 33b.
[0798] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.31 (3H, t, J=7.2
Hz), 3.21 (2H, q, J=7.2 Hz), 4.20 (2H, brs), 6.82 (1H, d, J=2.4
Hz), 6.95 (1H, dd, J=2.4, 8.8 Hz), 7.21 (1H, d, J=6.0 Hz), 7.94
(1H, d, J=8.8 Hz), 8.24 (1H, d, J=6.0 Hz).
PRODUCTION EXAMPLE 49b
[0799] 1-Methoxy-4-(3-nitrophenyl)propane-1-ene
[0800] Methoxymethylphosphonium chloride (31.1 g) was suspended in
tetrahydrofuran (200 ml), to which was then added potassium
t-butoxide (10.2 g) under ice-cooling. When the reaction solution
was changed to red in color, a solution obtained by dissolving
3-nitroacetophenone (10 g) in tetrahydrofuran (100 ml) was added
thereto little by little by using a pipette. After stirring at room
temperature for 2.5 hours, an aqueous saturated ammonium chloride
was added thereto under ice-cooling. The mixture was extracted with
ethyl acetate, and the extract was washed with brine and dried over
magnesium sulfate anhydride. The solvent was evaporated, and the
resulting residue was purified by silica gel column, to give the
title compound (8.010 g) as a yellow oil.
PRODUCTION EXAMPLE 50b
[0801] 2-(3-Nitrophenyl)propanal
[0802] 2 N hydrochloric acid (150 ml) was added to
1-methoxy-4-(3-nitrophe- nyl)propane-1-ene (8.010 g), followed by
heating under stirring at 80.degree. C. for 4 hours. Then,
hydrochloric acid (5 ml) was added thereto, followed by heating
under reflux for 2.5 hours. After cooling, the mixture was
neutralized by an aqueous sodium hydroxide solution and extracted
with ethyl acetate. The extract was washed with brine and dried
over anhydrous magnesium sulfate. The solvent was evaporated, to
give the title compound (7.531 g) as a yellow oil.
PRODUCTION EXAMPLE 51b
[0803] 2-(3-Nitrophenyl)propane-1-ol
[0804] 2-(3-Nitrophenyl)propanal (7.531 g) was dissolved in ethanol
(100 ml), to which was then added sodium borohydride (1.9 g) under
ice-cooling, followed by stirring at room temperature for one hour.
Brine was added thereto, followed by extracting with ethyl acetate.
The extract was washed with brine and dried over anhydrous
magnesium sulfate. A residue obtained by evaporating the solvent
was purified by silica gel column, to give the title compound
(6.275 g, 57.19% in 3 steps) as a brown oil.
[0805] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.34(3H, d, J=6.8
Hz), 1.51(1H, brs), 3.09(1H, tq, J=6.8, 6.8 Hz), 3.78(2H, d, J=6.8
Hz), 7.50(1H, dd, J=7.6, 8.4 Hz), 7.60(1H, ddd, J=1.2, 1.6, 7.6
Hz), 8.10(1H, ddd, J=1.2, 2.4, 8.4 Hz), 8.13(1H, dd, J=1.6, 2.4
Hz).
PRODUCTION EXAMPLE 52b
[0806] 2-(3-Nitrophenyl)propylamine
[0807] The title compound was obtained as a yellow oil by using
2-(3-nitrophenyl)propane-1-ol (1.908 g, Production Example 51b) in
the same manner as in Production Examples 26b-27b.
PRODUCTION EXAMPLE 53b
[0808] 1-t-Butoxycarbonylamino-2-(3-nitrophenyl)propane
[0809] The reaction was conducted using
2-(3-nitrophenyl)propylamine obtained in Production Example 52b in
the same manner as in Production Example 35b. The resulting residue
was purified by silica gel column, to give the title compound
(2.626 g) as a yellow oil.
[0810] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.31 (3H, d, J=6.8
Hz), 1.40 (9H, s), 3.10 (1H, m), 3.26 (1H, m), 3.38 (1H, m), 7.49
(1H, dd, J=7.6, 8.4 Hz), 7.56 (1H, d, J=7.6 Hz), 8.08 (1H, s), 8.10
(1H, d, J=8.4 Hz).
PRODUCTION EXAMPLE 54b
[0811] 2-(3-Aminophenyl)-1-t-butoxycarbonylaminopropane
[0812] The title compound was obtained as a yellow oil by using the
obtained 1-t-butoxycarbonylamino-2-(3-nitrophenyl)propane (2.626 g)
in the same manner as in Production Examples 29b.
PRODUCTION EXAMPLE 55b
[0813]
1-t-Butoxycarbonylamino-2-(3-ethoxycarbonylaminophenyl)propane
[0814] The reaction was conducted using the obtained
2-(3-aminophenyl)-1-t-butoxycarbonylaminopropane in the same manner
as in Production Example 30b. The resulting residue was purified by
silica gel column, to give the title compound (2.960 g, 77.56% in 3
steps) as a brown oil.
[0815] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.25(3H, d, J=7.6
Hz), 1.31(3H, t, J=7.2 Hz), 1.41(9H, s), 2.90(1H, m), 3.18(1H, ddd,
J=4.2, 7.6, 9.2 Hz), 3.39(1H, m), 4.42(2H, q, J=7.6 Hz), 4.45(1H,
brs), 6 87(1H, brs), 6.94(1H, m), 7.22(3H, m).
PRODUCTION EXAMPLE 56b
[0816]
6-Ethoxycarbonylamino-4-methyl-1,2,3,4-tetrahydroisoquinoline
[0817] The title compound (2.967 g, crude) was obtained as a yellow
solid by using
1-t-butoxycarbonylamino-2-(3-ethoxycarbonylaminophenyl)propane
(2.960 g, Production Example 55b) in the same method as in
Production Examples 38b-39b.
PRODUCTION EXAMPLE 57b
[0818] 6-Ethoxycarbonylamino-4-methylisoquinoline
[0819] The title compound (2.061 g, crude) was obtained as pale
yellow crystals by using the obtained
6-ethoxycarbonylamino-4-methyl-1,2,3,4-tet- rahydroisoquinoline
(2.967 g, crude) in the same manner as in Production Example
40b.
[0820] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.36(3H, t, J=7.2
Hz), 2.59(3H, s), 4.30(2H, q, J=7.2 Hz), 7.12(1H, d, J=2.0 Hz),
7.49(1H, dd, J=2.0, 8.8 Hz), 7.91(1H, d, J=8.8 Hz), 8.12(1H, s),
8.32(1H, s), 9.00(1H, s).
PRODUCTION EXAMPLE 58b
[0821] 6-Amino-4-methylisoquinoline
[0822] The reaction was conducted using the obtained
6-ethoxycarbonylamino-4-methylisoquinoline (2.061 g, crude) in the
same manner as in Production Example 30b. The resulting crystals
were washed with diethyl ether and dried, to give the title
compound (0.403 g, 27.75% in 4 steps) as pale yellow crystals.
[0823] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 2.48(3H, s), 4.18(2H,
brs), 6.95(1H, d, J=2.0 Hz), 7.00(1H, dd, J=2.0, 8.8 Hz), 7.76(1H,
d, J=8.8 Hz), 8.19(1H, s), 8.86(1H, s).
PRODUCTION EXAMPLE 59b
[0824] 2-(3-Nitrophenyl)butane-1-ol
[0825] The title compound (5.456 g, 50.08% in 3 steps) was obtained
as a yellow oil by using 3-nitropropiophenone (10 g) in the same
method as in Production Examples 52b-55b.
[0826] 1H-NMR(CDCl.sub.3) .delta. (ppm): 0.86 (3H, t, J=7.4 Hz),
1.63 (1H, m), 1.85 (1H, m), 3.24 (1H, m), 3.83 (2H, m), 7.50 (1H,
dd, J=7.2, 8.0 Hz), 7.57 (1H, d, J=8.0 Hz), 8.10 (1H, s), 8.13 (1H,
d, J=7.2 Hz).
PRODUCTION EXAMPLE 60b
[0827] 2-(3-Nitrophenyl)butylamine
[0828] The title compound (5.247 g) was obtained as a yellow oil by
using 2-(3-nitrophenyl)butane-1-ol (5.456 g, Production Example
59b) in the same manner as in Production Examples 26b-27b.
PRODUCTION EXAMPLE 61b
[0829] 1-t-Butoxycarbonylamino-2-(3-nitrophenyl)butane
[0830] Successively, the reaction was conducted using the obtained
2-(3-nitrophenyl)butylamine (5.247 g) in the same manner as in
Production Example 27b. The resulting residue was purified by
silica gel column, to give the title compound (7.679 g) as a pale
yellow oil.
[0831] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 0.83(3H, t, J=7.4
Hz), 1.39(9H, s), 1.63(1H, m), 1.79(1H, m), 2.84(1H, m), 3.21(1H,
m), 3.52(1H, m), 4.42(1H, brs), 7.49(1H, d, J=7.6 Hz), 7.52(1H, dd,
J=6.8, 7.6 Hz), 8.04(1H, s), 8.10(1H, d, J=6.8 Hz).
PRODUCTION EXAMPLE 62b
[0832] 2-(3-Aminophenyl)-1-t-butoxycarbonylaminobutane
[0833] The title compound (6.311 g, 85.40% in 4 steps) was obtained
as a yellow oil by using
1-t-butoxycarbonylamino-2-(3-nitrophenyl)butane (7.679 g) in the
same method as in Production Example 29b.
PRODUCTION EXAMPLE 63b
[0834]
1-t-Butoxycarbonylamino-2-(3-ethoxycarbonylaminophenyl)butane
[0835] The title compound (8.230 g, crude) was obtained as an
orange solid by using the obtained compound in the same method as
in Production Example 30b.
[0836] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 0.81 (3H, t, J=7.4
Hz), 1.31 (3H, t, J=7.2 Hz), 1.40 (9H, s), 1.55 (1H, m), 1.68 (1H,
m), 2.63 (1H, m), 3.14 (1H, ddd, J=4.8, 8.8, 13.6 Hz), 3.52 (1H,
m), 4.22 (2H, q, J=7.2 Hz), 4.38 (1H, brs), 6 63 (1H, brs), 6.87
(1H, m), 7.23 (3H, m).
PRODUCTION EXAMPLE 64b
[0837]
6-Ethoxycarbonylamino-4-ethyl-1,2,3,4-tetrahydroisoquinoline
[0838] The title compound was obtained as a brown oil by using
1-t-butoxycarbonylamino-2-(3-ethoxycarbonylaminophenyl)butane
(8.230 g, crude, Production Example 63b) in the same method as in
Production Examples 38b-39b.
PRODUCTION EXAMPLE 65b
[0839] 6-Ethoxycarbonylamino-4-ethylisoquinoline
[0840] A reaction was run using the obtained
6-ethoxycarbonylamino-4-ethyl- -1,2,3,4-tetrahydroisoquinoline (3.0
g) in the same manner as in Production Example 40b. The resulting
crude crystals were washed with ethanol/diethyl ether and dried, to
give the title compound as orange crystals.
[0841] .sup.1H-NMR (DMSO-d.sub.6) .delta. (ppm): 1.27 (3H, t, J=7.2
Hz), 1.28 (3H, t, J=7.2 Hz), 2.91 (2H, q, J=7.2 Hz), 4.18 (2H, q,
J=7.2 Hz), 7.64 (1H, d, J=8.8 Hz), 8.00 (1H, d, J=8.8 Hz), 8.25
(1H, s), 8.27 (1H, s), 8.98 (1H, s), 10.12 (1H, s).
PRODUCTION EXAMPLE 66b
[0842] 6-Amino-4-ethylisoquinoline
[0843] The reaction was conducted using
6-ethoxycarbonylamino-4-ethylisoqu- inoline in the same manner as
in Production Example 30b. The resulting residue was purified by
NH-silica gel column, and the resulting crude crystals were washed
with diethyl ether and dried, to give the title compound (0.637 g)
as orange crystals.
[0844] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.35 (3H, t, J=7.6
Hz), 2.92 (2H, q, J=7.6 Hz), 4.17 (2H, brs), 6.99 (1H, d, J=8.4
Hz), 7.00 (1H, s), 7.77 (1H, d, J=8.4 Hz), 8.21 (1H, s), 8.86 (1H,
s).
PRODUCTION EXAMPLE 67b
[0845] Diethyl methyl-(3-nitrobenzyl)malonate
[0846] Sodium (0.7 g) was dissolved in ethanol (45 ml), to which
were then added diethylmethyl malonate (5.26 ml) and 3-nitrobenzyl
chloride (5 g), followed by heating under reflux for 2 hours. The
mixture was ice-cooled and an aqueous ammonium chloride was added
thereto, followed by extracting with ethyl acetate. The extract was
washed with brine and dried over anhydrous magnesium sulfate. The
solvent was evaporated, to give the title compound (9.724 g) as a
pale yellow oil.
[0847] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.27 (6H, t, J=7.2
Hz), 1.37 (3H, s), 3.32 (2H, s), 4.21 (4H, q, J=7.2 Hz), 7.44 (1H,
d, J=7.6 Hz), 7.48 (1H, dd, J=7.6, 7.6 Hz), 8.03 (1H, s), 8.11 (1H,
d, J=7.6 Hz).
PRODUCTION EXAMPLE 68b
[0848] Ethyl 1-methyl-2-(3-nitrophenyl)propionate
[0849] The obtained diethyl methyl-(3-nitrobenzyl)malonate (9.724
g) was dissolved in dimethyl sulfoxide (30 ml), to which were then
added water (0.54 ml) and lithium chloride (2.54 g), followed by
stirring under heating at 190.degree. C. for 3.5 hours. After
cooling as it was, water was added thereto, followed by extracting
with ethyl acetate. The extract was washed with brine and dried
over anhydrous magnesium sulfate. The solvent was evaporated, to
give the title compound (5.071 g, 73.35% in 2 steps) as a brown
oil.
[0850] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.20 (3H, t, J=7.2
Hz), 1.21 (3H, d, J=7.2 Hz), 2.79 (2H, m), 3.10 (1H, m), 4.10 (2H,
q, J=7.2 Hz), 7.45 (1H, dd, J=7.6, 8.0 Hz), 7.52 (1H, d, J=7.6 Hz),
8.06 (1H, s), 8.08 (1H, d, J=8.0 Hz).
PRODUCTION EXAMPLE 69b
[0851] 1-Methyl-2-(3-nitrophenyl)propionic Acid
[0852] Ethyl 1-methyl-2-(3-nitrophenyl)propionate (5.071 g,
Production Example 68b) was dissolved in ethanol (50 ml), to which
was then added an aqueous 5 N sodium hydroxide solution (43 ml),
followed by heating under reflux for 2.5 hours. After cooling as it
was, diethyl ether and water were added thereto, and the aqueous
layer was separated. The organic layer was extracted with aqueous
saturated sodium bicarbonate. The aqueous layers were combined,
acidified by adding dilute hydrochloric acid, and then extracted
with diethyl ether. The extract was washed with brine and dried
over anhydrous magnesium sulfate. The solvent was evaporated, and
the resulting residue was purified by silica gel column, to give
the title compound (2.918 g, 65.27%) as a red oil.
[0853] .sup.1H-NMR (CDCl.sub.3) .delta. (ppm): 1.24 (3H, d, J=6.0
Hz), 2.83 (2H, s), 3.16(1H, m), 7.47 (1H, dd, J=7.2, 8.0 Hz),
7.54(1H, d, J=7.2 Hz), 8.08(1H, s), 8.10(1H, d, J=8.0 Hz).
PRODUCTION EXAMPLE 70b
[0854] N-Boc-1-methyl-2-(3-nitrophenyl)ethylamine
[0855] 1-Methyl-2-(3-nitrophenyl)propionic acid (2.918 g,
Production Example 69b) was dissolved in t-butanol (36 ml), to
which were then added triethylamine (4.09 ml) and
diphenylphosphorylazide, followed by heating under reflux for 2.5
hours. After cooling as it was, the solvent was evaporated. An
aqueous saturated sodium bicarbonate was added thereto, followed by
extracting with ethyl acetate. The extract was washed with brine
and dried over anhydrous magnesium sulfate. The solvent was
evaporated, and the resulting residue was purified by silica gel
column, to give the title compound (2.117 g, 54.14%) as yellow
crystals.
[0856] .sup.1H-NMR (CDCl.sub.3) .delta. (ppm): 1.13 (3H, d, J=6.8
Hz), 2.82 (1H, m), 2.92(1H, m), 3.94(1H, brs), 7.47(1H, dd, J=7.2,
8.0 Hz), 7.54 (1H, d, J=7.2 Hz), 8.05(1H, s), 8.09(1H, d, J=8.0
Hz).
PRODUCTION EXAMPLE 71b
[0857] N-Boc-2-(3-aminophenyl)-1-methylethylamine
[0858] A reaction was conducted using
N-Boc-1-methyl-2-(3-nitrophenyl)ethy- lamine (2.117 g, Production
Example 70b) in the same manner as in Production Example 29b. After
extracting, the resulting residue was purified by silica gel
column, to give the title compound (0.976 g, 51.63%) as a yellow
oil.
PRODUCTION EXAMPLE 72b
[0859] N-Boc-1-methyl-2-(3-ethoxycarbonylaminophenyl)ethylamine
[0860] The title compound (1.173 g, crude) was obtained as a yellow
oil by using N-Boc-2-(3-aminophenyl)-1-methylethylamine (0.976 g)
in the same method as in Production Example 30b. It was used in the
next reaction without carrying out a further purification.
[0861] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.09 (3H, d, J=6.4
Hz), 1.31 (3H, t, J=7.2 Hz), 1.43 (9H, s), 2.62 (1H, dd, J=6.8 Hz,
13.2 Hz), 2.82 (1H, m), 3.88 (1H, m), 4.22 (2H, q, J=7.2 Hz), 4.38
(1H, m), 6.56 (1H, m), 6.89 (1H, d, J=6.8 Hz), 7.18 (1H, s), 7.22
(1H, dd, J=6.8, 8.0 Hz), 7.23 (1H, d, J=8.0 Hz).
PRODUCTION EXAMPLE 73b
[0862] 2-(3-Ethoxycarbonylaminophenyl)-1-methylethylamine
Hydrochloride
[0863] N-Boc-1-methyl-2-(3-ethoxycarbonylaminophenyl)ethylamine
(1.173 g, crude) was dissolved in ethanol (5.0 ml), to which was
then added hydrochloric acid (5 ml), followed by stirring at room
temperature for 1.5 hours. Then, hydrochloric acid (2.5 ml) was
further added thereto, followed by stirring at room temperature for
2 hours. The solvent was evaporated, to give the title compound
(1.148 g, crude) as a yellow oil. It was used in the next reaction
without carrying out a further purification.
[0864] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.03 (3H, d, J=6.8
Hz), 1.22 (3H, t, J=7.2 Hz), 2.55 (1H, m), 2.95 (1H, m), 3.32 (1H,
m), 4.10 (2H, q, J=7.2 Hz), 6.84 (1H, d, J=7.2 Hz), 7.21 (1H, dd,
J=7.2, 7.2 Hz), 7.29 (1H, d, J=7.2 Hz), 7.35 (1H, s), 8.00 (1H,
brs), 9.60 (1H, s).
PRODUCTION EXAMPLE 74b
[0865]
6-Ethoxycarbonylamino-3-methyl-1,2,3,4-tetrahydroisoquinoline
[0866] The reaction was conducted using
2-(3-ethoxycarbonylaminophenyl)-1-- methylethylamine hydrochloride
(1.148 g, Production Example 73b) according to the method of Chem.
Pharm. Bull. 42 (8), 1676 (1994). The product was purified by
NH-silica gel column, to give the title compound (0.441 g).
[0867] .sup.1H-NMR(CDCl.sub.3) .delta.(ppm): 1.24 (3H, d, J=6.4
Hz), 1.30 (3H, t, J=7.2 Hz), 2.48 (1H, dd, J=10.0 Hz, 16.4 Hz),
2.75 (1H, dd, J=3.6 Hz, 16.4 Hz), 3.01 (1H, m), 4.03 (2H, brq),
4.21 (2H, q, J=7.2 Hz), 6.66 (1H, s), 6.95 (1H, d, J=8.4 Hz), 7.09
(1H, d, J=8.4 Hz), 7.14 (1H, s).
PRODUCTION EXAMPLE 75b
[0868] 6-Ethoxycarbonylamino-3-methylisoquinoline
[0869] The title compound (0.356 g) was obtained using the obtained
6-ethoxycarbonylamino-3-methyl-1,2,3,4-tetrahydroisoquinoline
(0.441 g) in the same method as in Production Example 39b.
[0870] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.34(3H, t, J=7.2
Hz), 2.67 (3H, s), 4.28(2H, q, J=7.2 Hz), 7.08(1H, brs), 7.39(1H,
dd, J=2.0, 8.8 Hz), 7.40(1H, s), 7.85(1H, d, J=8.8 Hz), 7.94(1H,
brs), 9.05(1H, s).
PRODUCTION EXAMPLE 76b
[0871] 6-Amino-3-methylisoquinoline
[0872] Crude crystals (0.182 g) obtained using the obtained
6-ethoxycarbonylamino-3-methylisoquinoline (0.356 g) in the same
method as in Production Example 33b were washed with diethyl ether
and dried, to give the title compound (93 g) as pale yellow
crystals.
[0873] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 2.63(3H, s), 4.14(2H,
brs), 6.77(1H, d, J=2.0 Hz), 6.93 (1H, dd, J=2.0, 8.8 Hz), 7.18(1H,
s), 7.72(1H, d, J=8.8 Hz), 8.9
SYNTHETIC EXAMPLE 1b
[0874] N-(8-Bromoquinoline-3-yl)-3-pyridinesulfonamide
[0875] 3-Amino-8-bromoquinoline (300 mg, Production Example 5b) was
dissolved in pyridine (5 ml), to which was then added
3-pyridinesulfonyl chloride (254 mg), followed by stirring at room
temperature for 30 minutes. After the reaction was completed, the
reaction solution was poured into brine and extracted with ethyl
acetate. The organic layer was dried over magnesium sulfate and
then concentrated. The resulting crude crystals were washed with
ethyl acetate and IPA, to give the title compound (270 mg).
[0876] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.47(1H, t, J=8.0
Hz), 7.52-7.60(1H, m), 7.99-8.03(2H, m), 8.10(1H, d, J=2.4 Hz),
8.18-8.22(1H, m), 8.71(1H, d, J=2.4 Hz), 8.78(1H, dd, J=1.6 Hz,
4.8Hz), 8.98(1H, d, J=2.4 Hz), 11.23(1H, br s).
SYNTHETIC EXAMPLE 2b
[0877] N-(5-Bromoquinoline-2-yl)-5-methyl-3-pyridinesulfonamide
[0878] The title compound was obtained from
2-amino-5-bromoquinoline (Production Example 1b) and
5-methyl-3-pyridinesulfonyl chloride in the same manner as in
Synthetic Example 1b.
[0879] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.37(3H, s),
7.58-7.72(4H, m), 8.11(1H, br s), 8.37(1H, d, J=9.6 Hz), 8.59(1H,
d, J=1.2 Hz), 8.86(1H, br s).
SYNTHETIC EXAMPLE 3b
[0880] 6-Amino-N-(8-bromoquinoline-3-yl)-3-pyridinesulfonamide
[0881] The title compound was obtained from
3-amino-8-bromoquinoline (Production Example 5b) and
6-amino-3-pyridinesulfonyl chloride in the same manner as in
Synthetic Example 1b.
[0882] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.40(1H, d, J=8.8
Hz), 6.93(2H, br s), 7.44(1H, t, J=8.0 Hz), 7.65(1H, dd, J=2.4 Hz,
8.8Hz), 7.96-7.99(2H, m), 8.01(1H, d, J=2.4 Hz), 8.31(1H, d, J=2.4
Hz), 8.70(1H, d, J=2.4 Hz), 10.73(1H, br s).
SYNTHETIC EXAMPLE 4b
[0883] N-(8-Bromoquinoline-3-yl)-4-cyanobenzenesulfonamide
[0884] The title compound was obtained from
3-amino-8-bromoquinoline (Production Example 5b) and
4-cyanobenzenesulfonyl chloride in the same manner as in Synthetic
Example 1b.
[0885] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.46(1H, t, J=8.0
Hz), 7.96-8.07(7H, m), 8.70(1H, d, J=2.4 Hz), 11.27(1H, br s).
SYNTHETIC EXAMPLE 5b
[0886] 6-Chloro-N-(8-bromoquinoline-3-yl)-3-pyridinesulfonamide
[0887] The title compound was obtained from
3-amino-8-bromoquinoline (Production Example 5b) and
6-chloro-3-pyridinesulfonyl chloride in the same manner as in
Synthetic Example 1b.
[0888] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.47(1H, t, J=8.0
Hz), 7.71(1H, d, J=8.4 Hz), 7.99-8.03(2H, m), 8.10(1H, d, J=2.4
Hz), 8.20(1H, dd, J=8.4 Hz), 8.71(1H, d, J=2.4 Hz), 8.83(1H, d,
J=2.4 Hz), 10.73(1H, br s).
SYNTHETIC EXAMPLE 6b
[0889]
N-(8-Bromoquinoline-3-yl)-4-(N-ethylsulfamoyl)benzenesulfonamide
[0890] The title compound was obtained from
3-amino-8-bromoquinoline (Production Example 5b) and
4-(N-ethylsulfamoyl)benzenesulfonyl chloride in the same manner as
in Synthetic Example 1b.
[0891] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 0.82(3H, t, J=7.2
Hz), 2.69-2.76(2H, m), 7.45(1H, t, J=8.4 Hz), 7.75(1H, t, J=5.6
Hz), 7.90-8.04(7H, m), 8.70(1H, d, J=2.8 Hz), 11.18(1H, br s).
SYNTHETIC EXAMPLE 7b
[0892] N-(8-Bromoquinoline-3-yl)-5-cyano-2-pyridinesulfonamide
[0893] The title compound was obtained from
3-amino-8-bromoquinoline (Production Example 5b) and
5-cyano-3-pyridinesulfonyl chloride in the same manner as in
Synthetic Example 1b.
[0894] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.46(1H, t, J=8.0
Hz), 7.95(1H, d, J=8.0 Hz), 8.01(1H, d, J=8.0 Hz), 8.11(11H, d,
J=2.4 Hz), 8.21(1H, d, J=8.4 Hz), 8.57(1H, dd, J=2.0 Hz, 8.4Hz),
8.79(1H, d, J=2.4 Hz), 9.14(1H, d, J=2.0 Hz), 11.49(1H, br s).
SYNTHETIC EXAMPLE 8b
[0895] N-(8-Cyanoquinoline-3-yl)-3-pyridinesulfonamide
[0896] The title compound was obtained from
3-amino-8-cyanoquinoline (Production Example 7b) and
3-pyridinesulfonyl chloride in the same manner as in Synthetic
Example 1b.
[0897] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.59(1H, dd, J=4.8
Hz, 8.0 Hz), 7.70(1H, t, J=8.0 Hz), 8.21-8.25(3H, m), 8.33(1H, d,
J=8.0 Hz), 8.77-8.79(2H, m), 9.01(1H, d, J=2.8 Hz), 11.34(1H, br
s).
SYNTHETIC EXAMPLE 9b
[0898] N-(8-Cyanoquinoline-3-yl)-4-cyanobenzenesulfonamide
[0899] The title compound was obtained from
3-amino-8-cyanoquinoline (Production Example 7b) and
4-cyanobenzenesulfonyl chloride in the same manner as in Synthetic
Example 1b.
[0900] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.71(1H, t, J=8.0
Hz), 7.96-8.07(4H, m), 8.18(1H, d, J=2.8 Hz), 8.24(1H, d, J=8.0
Hz), 8.31(1H, d, J=8.0 Hz), 8.78(1H, d, J=2.8 Hz), 11.37(1H, br
s).
SYNTHETIC EXAMPLE 10b
[0901] N-(5-Bromoquinoline-2-yl)-3-pyridinesulfonamide
[0902] The title compound was obtained from
2-amino-5-bromoquinoline (Production Example 1b) and
3-pyridinesulfonyl chloride in the same manner as in Synthetic
Example 1b.
[0903] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.57-7.61(3H, m),
7.70-7.72(2H, m), 8.28(1H, br), 8.38(1H, d, J=9.6 Hz), 8.75(1H, dd,
J=1.2 Hz, 4.8Hz), 9.07(1H, br).
SYNTHETIC EXAMPLE 11b
[0904] N-(8-Bromoquinoline-3-yl)-5-indanesulfonamide
[0905] The title compound was obtained from
3-amino-8-bromoquinoline (Production Example 5b) and
5-indanesulfonyl chloride in the same manner as in Synthetic
Example 1b.
[0906] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.92-2.01(2H, m),
2.81-2.86(4H, m), 7.34(1H, d, J=8.0 Hz), 7.44(1H, t, J=8.0 Hz),
7.60(1H, dd, J=1.6 Hz, 8.0 Hz), 7.70(1H, d, J=1.6 Hz), 7.95(1H, d,
J=8.0 Hz), 7.97(1H, d, J=8.0 Hz), 8.03(1H, d, J=2.4 Hz), 8.71(1H,
d, J=2.4 Hz), 10.93 (1H, br s).
SYNTHETIC EXAMPLE 12b
[0907] N-(8-Iodoquinoline-3-yl)
-N*-acetyl-5-indolinesulfonamide
[0908] The title compound was obtained from 3-amino-8-iodoquinoline
(Production Example 6b) and N-acetyl-6-indolinesulfonyl chloride in
the same manner as in Synthetic Example 1b.
[0909] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.11(3H, s),
3.11(2H, t, J=8.4 Hz), 4.06(2H, t, J=8.4 Hz), 7.28(1H, t, J=8.0
Hz), 7.65-7.68(2H, m), 7.93-7.96(2H, m), 8.05(1H, d, J=9.2 Hz),
8.22(1H, dd, J=1.2 Hz, 7.6Hz), 8.64(1H, d, J=2.4 Hz), 10.87(1H, br
s).
SYNTHETIC EXAMPLE 13b
[0910] N-(8-Bromoquinoline-3-yl)-3-quinolinesulfonamide
[0911] The title compound was obtained from
3-amino-8-bromoquinoline (Production Example 5b) and
3-quinolinesulfonyl chloride in the same manner as in Synthetic
Example 1b.
[0912] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.38(1H, t, J=8.0
Hz), 7.70-7.74(1H, m), 7.90-8.00 (3H, m), 8.07 (1H, d, J=8.0 Hz),
8.13 (1H, d, J=2.4 Hz), 8.19(1H, dd, J=0.8 Hz, 8.4 Hz), 8.75(1H, d,
J=2.4 Hz), 9.00-9.01(1H, m), 9.19(1H, d, J=2.4 Hz), 11.31(1H, br
s).
SYNTHETIC EXAMPLE 14b
[0913]
N-(8-Bromoquinoline-3-yl)-N*-acetyl-1,2,3,4-tetrahydroquinoline-6-s-
ulfonamide
[0914] The title compound was obtained from
3-amino-8-bromoquinoline (Production Example 5b) and
N-acetyl-1,2,3,4-tetrahydroquinoline-6-sulfon- yl chloride in the
same manner as in Synthetic Example 1b.
[0915] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.86-2.01(2H, m),
2.77(2H, t, J=6.4 Hz), 3.65-3.76(2H, m),
SYNTHETIC EXAMPLE 15b
[0916] N-(8-Iodoquinoline-3-yl)-4-isoquinolinesulfonamide
[0917] The title compound was obtained from 3-amino-8-iodoquinoline
(Production Example 6b) and 4-isoquinolinesulfonyl chloride in the
same manner as in Synthetic Example 1b.
[0918] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.26(1H, t, J=8.0
Hz), 7.82-7.86(1H, m), 7.93-7.95(1H, m), 7.98(1H, d, J=2.4 Hz),
8.02-8.06(1H, m), 8.19(1H, dd, J=1.2 Hz, 7.6 Hz), 8.27(1H, d, J=8.4
Hz), 8.59(1H, d, J=2.4 Hz), 8.67(1H, d, J=8.4 Hz), 9.12(1H, s),
9.52(1H, s), 11.57(1H, br s).
SYNTHETIC EXAMPLE 16b
[0919] 4-Cyano-N-(8-iodoquinoline-3-yl)-benzenesulfonamide
[0920] The title compound was obtained from 3-amino-8-iodoquinoline
(Production Example 6b) and 4-cyanobenzenesulfonyl chloride in the
same manner as in Synthetic Example 1b.
[0921] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.31(1H, t, J=8.0
Hz), 7.96-8.04(6H, m), 8.26(1H, dd, J=1.2 Hz, 7.2 Hz), 8.65(1H, d,
J=2.8 Hz), 11.24(1H, br s).
SYNTHETIC EXAMPLE 17b
[0922] N-(8-Isoquinoline-3-yl)-3-pyridinesulfonamide
[0923] The title compound was obtained from 3-amino-8-iodoquinoline
(Production Example 6b) and 3-pyridinesulfonyl chloride in the same
manner as in Synthetic Example 1b.
[0924] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.31(1H, t, J=8.0
Hz), 7.57-7.60(1H, m), 7.99(1H, d, J=1.2 Hz, 8.4 Hz), 8.04(1H, d,
J=2.8 Hz), 8.18-8.21(1H, m), 8.26(1H, dd, 1.2Hz, 7.2Hz), 8.66(1H,
d, J=2.8 Hz), 8.77(1H, dd, J=1.6 Hz, 4.8 Hz), 8.98(1H, d, J=2.8
Hz), 11.20(1H, br s).
SYNTHETIC EXAMPLE 18b
[0925] N-(5-Bromoquinoline-2-yl)-4-cyanobenzenesulfonamide
[0926] The title compound was obtained from
2-amino-5-bromoquinoline (Production Example 1b) and
4-cyanobenzenesulfonyl chloride in the same manner as in Synthetic
Example 1b.
[0927] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.57-7.73(4H, m),
8.00-8.08(4H, m), 8.38(1H, d, J=8.8 Hz).
SYNTHETIC EXAMPLE 19b
[0928] N-(8-Bromoquinoline-3-yl)-6-ethyl-3-pyridinesulfonamide
[0929] Pyridine (0.5 ml) and a methylene chloride (0.5 ml) solution
containing 6-ethyl-3-pyridinesulfonyl chloride (30 ml) were added
to 3-amino-8-bromoquinoline (18 mg, Production Example 5b) at
0.degree. C. After stirring at room temperature for 30 minutes,
water was added thereto and the mixture was extracted with ethyl
acetate. The extract was purified by preparative TLC (hexane-ethyl
acetate=1:1), to give the title compound (20 mg).
[0930] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.25(3H, t, J=7.5
Hz), 2.70 (2H, q, J=7.50 Hz), 7.34-7.98(5H, m), 8.19(1H, d, J=3.3
Hz),8.54 (1H, s), 8.83(1H, d, J=3.3 Hz).
SYNTHETIC EXAMPLE 20b
[0931] 4-Chloro-N-(5-chloroquinoline-2-yl)-benzenesulfonamide
[0932] Pyridine (1 ml) and 4-chlorobenzenesulfonyl chloride (255
mg) were added to 2-amino-5-chloroquinoline (119mg, Production
Example 2b) at room temperature, followed by stirring at room
temperature for 3 days. Then, water was added thereto, followed by
extracting with ethyl acetate. The ethyl acetate layer was dried
over sodium sulfate and concentrated. Then, the resulting solid was
washed with methanol, to give the title compound (20 mg).
[0933] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 6.96(1H, d, J=9.7
Hz), 7.34(1H, d, J=8.4 Hz), 7.42-7.48(3H, m), 7.54(1H, t, J=8.4
Hz),7.94(2H, d, J=6.3 Hz), 8.29(1H, d, J=9.7 Hz).
SYNTHETIC EXAMPLE 21b
[0934] N-(8-Chloroquinoline-3-yl)
-6-ethyl-3-pyridinesulfonamide
[0935] The title compound was obtained from
3-amino-8-chloroquinoline (Production Example 9b) and
6-ethyl-3-pyridinesulfonyl chloride in the same manner as in
Synthetic Example 1b.
[0936] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.28(3H, t, J=8.3
Hz), 2.86 (2H, q, J=8.3 Hz), 7.24(1H, d, J=8.0 Hz), 7.49(1H, t,
J=8.0 Hz) 7.73 (1H, d, J=8.0 Hz ), 7.78(1H, d, J=8.0 Hz), 7.95(1H,
dd, J=8.0 Hz, 2.1 Hz), 8.18 (1H, d, J=2.5 Hz), 8.67(1H, d, J=2.5
Hz), 8.93 (1H, d, J=2.1 Hz).
SYNTHETIC EXAMPLE 22b
[0937] N-(5-Chloroquinoline-2-yl)-6-ethyl-3-pyridinesulfonamide
[0938] The title compound was obtained from
2-amino-5-chloroquinoline (Production Example 2b) and
6-ethyl-3-pyridinesulfonyl chloride in the same manner as in
Synthetic Example 1b.
[0939] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.32(3H, t, J=8.3
Hz), 2.89(2H, q, J=8.3 Hz), 6.97(1H, d, J=9.4 Hz), 7.29(1H, d,
J=8.0 Hz), 7.35(1H, d, J=8.0 Hz), 7.44(1H, d, J=8.0 Hz), 7.56(1H,
t, J=8.0 Hz), 8.18(1H, dd, J=8.0 Hz, 2.6Hz), 8.30(1H, d, J=9.4 Hz),
9.10(1H, d, J=2.6 Hz).
SYNTHETIC EXAMPLE 23b
[0940] N-(8-Chloroquinoline-3-yl)-benzenesulfonamide
[0941] The title compound was obtained from
3-amino-8-chloroquinoline (Production Example 9b) and
benzenesulfonyl chloride in the same manner as in Synthetic Example
1b.
[0942] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.30-7.48(6H, m),
7.84(2H, d, J=7.4 Hz), 8.11(1H, d, J=3.1 Hz), 8.66(1H, d, J=3.1
Hz).
SYNTHETIC EXAMPLE 24b
[0943] 4-Cyano-N-(5-chloroquinoline-2-yl) -benzenesulfonamide
[0944] The title compound was obtained from
3-amino-8-bromoquinoline (Production Example 2b) and
4-cyanobenzenesulfonyl chloride in the same manner as in Synthetic
Example 1b.
[0945] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 6.96(1H, d, J=9.5
Hz), 7.35(1H, d, J=8.7 Hz), 7.45(1H, d, J=8.7 Hz), 7.57(1H, tJ=8.7
Hz), 7.78(2H, d, J=8.9 Hz), 8.10(2H, d, J=8.9 Hz ), 8.33(1H, d,
J=9.5 Hz).
SYNTHETIC EXAMPLE 25b
[0946] N-(5-Chloroquinoline-2-yl) -4-methylbenzenesulfonamide
[0947] The title compound was obtained from
2-amino-5-chloroquinoline (Production Example 2b) and
4-toluenesulfonyl chloride in the same manner as in Synthetic
Example 1b.
[0948] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 2.41(3H, s), 6.98(1H,
d, J=9.3 Hz), 7.28(2H, d, J=8.2 Hz), 7.35(1H, d, J=7.9 Hz),
7.41(1H, d, J=7.9 Hz), 7.53(1H, t, J=7.9 Hz), 7.88(2H, d, J=8.2
Hz), 8.26(1H, d, J=9.3 Hz).
SYNTHETIC EXAMPLE 26b
[0949] N-(5-Chloroquinoline-2-yl)-4-sulfamoylbenzenesulfonamide
[0950] The title compound was obtained from
2-amino-5-chloroquinoline (Production Example 2b) and
4-sulfamoylbenzenesulfonyl chloride in the same manner as in
Synthetic Example 1b.
[0951] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 7.42-7.49 (3H, m,),
7.58(1H, t, J=8.0 Hz), 8.00-8.12(4H, m,) 8.39(1H, d, J=9.3 Hz).
SYNTHETIC EXAMPLE 27b
[0952]
N-(5-Bromoquinoline-2-yl)-4-(N-ethylsulfamoyl)benzenesulfonamide
[0953] The title compound was obtained from
2-amino-5-chloroquinoline (Production Example 2b) and
4-(N-ethylsulfamoyl)benzenesulfonyl chloride in the same manner as
in Synthetic Example 1b.
[0954] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.14(3H, t, J=7.5
Hz), 3.01-3.09(2H, m), 7.08(1H, d, J=9.5 Hz), 7.42(1H, dd, J=7.6
Hz, 1.3 Hz), 7.49(1H, t, J=7.6 Hz), 7.65(1H, dd, J=7.6 Hz,1.3Hz ),
7.96(2H, d, J=8.7 Hz), 8.10(2H, d, J=8.7 Hz), 8.31(1H, d, J=9.5
Hz).
SYNTHETIC EXAMPLE 28b
[0955] 3-Cyano-N-(8-chloroquinoline-3-yl)benzenesulfonamide
[0956] The title compound was obtained from
3-amino-8-chloroquinoline (Production Example 9b) and
3-cyanobenzenesulfonyl chloride in the same manner as in Synthetic
Example 1b.
[0957] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 7.52(1H, t, J=7.9
Hz), 7.59 (1H, t, J=7.9 Hz), 7.72-7.86(3H, m), 8.00(1H, d, J=7.9
Hz), 8.13(1H, d, J=3.2 Hz), 8.16(1H, s), 8.64(1H, d, J=3.2 Hz).
SYNTHETIC EXAMPLE 29b
[0958] N-(8-Chloroquinoline-3-yl)-3-methylbenzenesulfonamide
[0959] The title compound was obtained from
3-amino-8-chloroquinoline (Production Example 9b) and
3-toluenesulfonyl chloride in the same manner as in Synthetic
Example 1b.
[0960] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 2.35(3H, s),
7.16-7.79 (7H, m), 8.09(1H, d, J=2.7 Hz), 8.65(1H, d, J=2.7
Hz).
SYNTHETIC EXAMPLE 30b
[0961] N-(8-Chloroquinoline-3-yl)-3-sulfamoylbenzenesulfonamide
[0962] The title compound was obtained from
3-amino-8-chloroquinoline (Production Example 9b) and
3-sulfamoylbenzenesulfonyl chloride in the same manner as in
Synthetic Example 1b.
[0963] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 7.46(1H, t, J=7.6
Hz), 7.53(1H, t, J=7.6 Hz), 7.58-7.78(2H, m), 8.00(1H, d, J=7.6
Hz), 8.04(1H, d, J=7.6 Hz), 8.14(1H, d, J=2.8 Hz), 8.47(1H, s),
8.59(1H, d, J=2.8 Hz).
SYNTHETIC EXAMPLE 31b
[0964] N-(8-Methylquinoline-3-yl)-3-pyridinesulfonamide
[0965] 562 mg of white crystals were obtained using 1.02 g (5.2
mmol, Production Example 16b) of 7-amino-2-chloro-4-methylquinoline
and 0.9 g (5.2 mmol) of 3-pyridinesulfonyl chloride in the same
manner as in Synthetic Example 1b. Methanol (4 ml), tetrahydrofuran
(4 ml) and 10% palladium carbon (5 mg) were added to 102 mg (0.29
mmol) of the white crystals, followed by stirring for 6 hours in a
hydrogen atmosphere. The reaction solution was filtered through
Celite, and then evaporated. The residue was washed with ethyl
acetate, to give 65 mg of the title compound.
[0966] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.82(3H, s),
7.64-7.66(2H, m), 7.73(1H, d, J=5.2 Hz), 8.03(1H, s), 8.30-8.35(2H,
m), 8.82(1H, dd, J=1.2, 4.8 Hz), 9.00(1H, d, J=5.2 Hz), 9.11(1H, d,
J=2.0 Hz).
SYNTHETIC EXAMPLE 32b
[0967] N-(8-Methylquinoline-3-yl)-4-cyanobenzenesulfonamide
[0968] 358 mg of white crystals were obtained using 305 mg (1.58
mmol, Production Example 16b) of 7-amino-2-chloro-4-methylquinoline
and 0.48 g (2.4 mmol) of 4-cyanobenzenesulfonyl chloride in the
same manner as in Synthetic Example 1b. Acetic acid (6 ml), water
(2 ml) and zinc (122 mg) were added to 140 mg (0.38 mmol) of the
white crystals, followed by stirring at 60.degree. C. for 15
minutes. After the reaction solution was filtered through Celite,
an aqueous saturated sodium bicarbonate solution was added,
followed by extracting with ethyl acetate. The organic layer was
washed with brine, dried over magnesium sulfate and concentrated.
Then, the residue was purified by silica gel chromatography, to
give 82 mg of the title compound.
[0969] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.60(3H, s),
7.26(1H, dd, J=1.2, 4.4 Hz), 7.41(1H, dd, J=2.4, 8.8 Hz), 7.64(1H,
d, J=2.4 Hz), 7.97-8.06(1H, m), 7.98(2H, d, J=8.4 Hz), 8.04(2H, d,
J=8.4 Hz), 8.66(1H, d, J=4.4 Hz), 11.06(1H, s).
SYNTHETIC EXAMPLE 33b
[0970] N-(6-Chloro-8-cyanoquinoline-3-yl)
-3-pyridinesulfonamide
[0971] 764 mg of white crystals were obtained using 3.0 mg (13
mmol, Production Example 13b) of
ethyl-7-amino-2-chloroquinoline-4-carboxylate and 2.3 g (13 mmol)
of 3-pyridinesulfonyl chloride in the same manner as in Synthetic
Example 1b. An aqueous 1 N sodium hydroxide solution (0.5 ml) was
added to an ethanol solution (6 ml) of 108 mg (0.28 mmol) of the
white crystals, followed by stirring overnight. An aqueous 1 N
hydrochloric acid solution was added to the reaction solution,
followed by extracting with ethyl acetate twice. The organic layer
was washed with brine, dried over magnesium sulfate and
concentrated, to give the residue. Under ice-cooling, oxalyl
chloride (0.04 ml) and one droplet of dimethylformamide were added
to a tetrahydrofuran solution (10 ml) containing the residue,
followed by stirring at room temperature for 30 minutes. After 30
minutes, an aqueous saturated ammonium solution (5 ml) was added
thereto, followed by stirring for further 10 minutes. Brine was
added to the reaction solution, followed by extracting with ethyl
acetate. The organic layer was dried over magnesium sulfate and
concentrated, to give the residue. Under ice-cooling, pyridine
(0.06 ml) and trifluoroacetic acid anhydride (0.05 ml) were added
to a tetrahydrofuran solution (6 ml) containing the residue,
followed by stirring at room temperature for 30 minutes. Brine was
added to the reaction solution, followed by extracting with ethyl
acetate. The organic layer was dried over magnesium sulfate and
concentrated. The residue was purified by silica gel
chromatography, to give 37 mg of the title compound.
[0972] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.62-7.66(1H, m),
7.68-7.72(2H, m), 8.08(1H, d, J=8.8 Hz), 8.23(1H, s), 8.26-8.29(1H,
m), 8.81(1H, dd, J=1.6, 4.8 Hz), 9.04(1H, d, J=2.4 Hz).
SYNTHETIC EXAMPLE 34b
[0973] N-(8-Chloroquinoline-3-yl)-4-cyanobenzenesulfonamide
[0974] 58 mg of the title compound was obtained using 38 mg (0.21
mmol) of 3-amino-8-chloroquinoline (0.21 mmol, Production Example
9b) and 43 mg (0.21 mmol) of 4-cyanobenzenesulfonyl chloride in the
same manner as in Synthetic Example 1b.
[0975] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.55(1H, t, J=7.6
Hz), 7.84(1H, d, J=7.6 Hz), 7.95(1H, t, J=7.6 Hz), 7.99(2H, d,
J=8.8 Hz), 8.04(2H, d, J=8.8 Hz), 8.09(1H, d, J=2.8 Hz), 8.73(1H,
d, J=2.8 Hz), 11.39(1H, s).
SYNTHETIC EXAMPLE 35b
[0976]
N-(8-Chloroquinoline-3-yl)-4-(N-ethylsulfamoyl)benzenesulfonamide
[0977] 36 mg of the title compound was obtained using 36 mg (0.19
mmol, Production Example 9b) of 3-amino-8-chloroquinoline and 52 mg
(0.19 mmol) of 4-(N-ethylsulfamoyl)benzenesulfonyl chloride in the
same manner as in Synthetic Example 1b.
[0978] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 0.84(3H, t, J=7.2
Hz), 2.78-2.71(2H, m), 7.54 (1H, t, J=7.6 Hz), 7.77 (1H, t, J=6.0
Hz), 7.83 (1H, t, J=7.6 Hz), 7.92-7.95(1H, m), 7.93(2H, d, J=8.8
Hz), 8.03(2H, d, J=8.8 Hz), 8.07(1H, d, J=2.4 Hz), 8.73(1H, d,
J=2.4 Hz), 11.20(1H, s).
SYNTHETIC EXAMPLE 36b
[0979] N-(8-Chloroquinoline-3-yl)-3-pyridinesulfonamide
[0980] 29 mg of the title compound was obtained using 33 mg (0.19
mmol, Production Example 9b) of 3-amino-8-chloroquinoline and 33 mg
(0.19 mmol) of 3-pyridinesulfonyl chloride in the same manner as in
Synthetic Example 1b.
[0981] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.54(1H, t, J=7.6
Hz), 7.60(1H, dd, J=4.8, 7.6 Hz), 7.81(1H, d, J=7.6 Hz), 7.94(1H,
d, J=7.6 Hz), 8.09(1H, d, J=2.8 Hz), 8.19-8.26(1H, m), 8.72(1H, d,
J=2.8 Hz), 8.77(1H, d, J=1,6,4,8 Hz), 9.00(1H, d, J=2.8 Hz),
11.46(1H, s).
SYNTHETIC EXAMPLE 37b
[0982]
N-(8-Chloroquinoline-3-yl)-5-ethylsulfamoyl-2-pyridinesulfonamide
[0983] 10 mg of the title compound was obtained using 30 mg (0.17
mmol, Production Example 9b) of 3-amino-8-chloroquinoline and 95 mg
(0.34 mmol) of 5-ethylsulfamoyl-2-chlorosulfonylpyridine in the
same manner as in Synthetic Example 1b.
[0984] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 0.88(3H, t, J=7.6
Hz), 2.79-2.86(2H, m), 7.55(1H, t, J=7.6 Hz), 7.85(1H, t, J=7.6
Hz), 7.94(1H, d, J=7.6 Hz), 8.00(1H, t, J=6.4 Hz), 8.16(1H, d,
J=2.8Hz), 8.27(1H, d, J=8.0 Hz), 8.41(1H, d, J=2.4, 8.0 Hz),
8.84(1H, d, J=2.8 Hz), 9.04(1H, d, J=2.4 Hz), 11.47(1H, s).
SYNTHETIC EXAMPLE 38b
[0985]
N-(8-Trifluoromethylquinoline-3-yl)-4-cyanobenzenesulfonamide
[0986] 59 mg of the title compound was obtained using 35 mg (0.17
mmol, Production Example 10b) of 3-amino-8-trifluoromethylquinoline
and 37 mg (0.18 mmol) of 4-cyanobenzenesulfonyl chloride in the
same manner as in Synthetic Example 1b. p0
.sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.71(1H, t, J=7.6 Hz),
8.03-8.09(5H, m), 8.19(1H, d, J=2.4 Hz), 8.30(1H, d, J=7.6 Hz),
8.78(1H, d, J=2.4 Hz), 11.72(1H, s).
[0987] SYNTHETIC EXAMPLE 39b
[0988]
N-(8-Trifluoromethylquinoline-3-yl)-4-(N-ethylsulfamoyl)benzenesulf-
onamide
[0989] 60 mg of the title compound was obtained using 35 mg (0.17
mmol, Production Example 10b) of 3-amino-8-trifluoromethylquinoline
and 56 mg (0.20 mmol) of 4-(N-ethylsulfamoyl)benzenesulfonyl
chloride in the same manner as in Synthetic Example 1b.
[0990] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 0.83(3H, t, J=7.2
Hz), 2.71-2.78(2H, m), 7.69(1H, t, J=8.0 Hz), 7.76(1H, t, J=5.6
Hz), 7.93(1H, d, J=8.8 Hz), 8.04-8.07(3H, m), 8.13(1H, d, J=2.8
Hz), 8.25(1H, d, J=8.0 Hz), 8.75(1H, d, J=2.8 Hz), 11.28(1H,
s).
SYNTHETIC EXAMPLE 40b
[0991]
N-(8-Trifluoromethylquinoline-3-yl)-3-pyridinesulfonamide
[0992] 71 mg of the title compound was obtained using 45 mg (0.21
mmol, Production Example 10b) of 3-amino-8-trifluoromethylquinoline
and 45 mg (0.25 mmol) of 3-pyridinesulfonyl chloride in the same
manner as in Synthetic Example 1b.
[0993] .sup.1H-NMR (DMSO-d.sub.6) .delta. (ppm): 7.59-7.63 (1H, m),
7.70 (1H, t, J=7.6 Hz), 8.06(1H, d, J=7.6 Hz), 8.20(1H, d, J=2.8
Hz), 8.23-8.24(1H, m), 8.30(1H, d, J=7.6 Hz), 8.76(1H, d, J=2.8
Hz), 8.79(1H, dd, J=1.6, 4.8 Hz), 9.03(1H, d, J=2.0 Hz), 11.64(1H,
s).
SYNTHETIC EXAMPLE 41b
[0994]
N-(8-Chloroquinoline-3-yl)-1,2,3,4-tetrahydro-6-naphthalenesulfonam-
ide
[0995] 46 mg of the title compound was obtained using 33 mg (0.19
mmol, Production Example 9b) of 3-amino-8-chloroquinoline and 73 mg
(0.22 mmol) of 6-chlorosulfonyl-1,2,3,4-tetrahydronaphthalene in
the same manner as in Synthetic Example 1b.
[0996] .sup.1H-NMR(DMSO-d.sub.6) 6 (ppm): 1.68(4H, br), 2.71(4H,
br), 7.20(1H, t, J=8.4 Hz), 7.52(1H, t, J=7.6 Hz), 7.53(1H, dd,
J=2.0, 8.4 Hz), 7.58(1H, d, J=2.0 Hz), 7.80(1H, d, J=7.6 Hz), 7.93
(1H, d, J=7.6 Hz), 8.06(1H, d, J=2.4 Hz), 8.73(1H, d, J=2.4 Hz),
10.94(1H, s).
SYNTHETIC EXAMPLE 42b
[0997]
N-(8-Chloroquinoline-3-yl)-2,3-dihydro-5-benzofuransulfonamide
[0998] 57 mg of the title compound was obtained using 30 mg (0.17
mmol, Production Example 9b) of 3-amino-8-chloroquinoline and 44 mg
(0.20 mmol) of 5-chlorosulfonyl-2,3-dihydrobenzofuran in the same
manner as in Synthetic Example 1b.
[0999] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.19(2H, t, J=8.8
Hz), 4.58(2H, t, J=8.8 Hz), 6.86(1H, d, J=8.8 Hz), 7.23(1H, t,
J=7.6 Hz), 7.62(1H, dd, J=1.6, 8.8 Hz), 7.72(1H, d, J=1.6 Hz),
7.80(1H, d, J=7.6 Hz), 7.92(1H, d, J=7.6 Hz), 8.03(1H, d, J=2.4
Hz), 8.73(1H, d, J=2.4 Hz), 10.85(1H, s).
SYNTHETIC EXAMPLE 43b
[1000]
N-(8-Chloro-4-vinylquinoline-3-yl)-4-cyanobenzenesulfonamide
[1001] 15 mg of the title compound was obtained using 30 mg (0.15
mmol, Production Example 12b) of 3-amino-4-vinyl-8-chloroquinoline
and36mg (0.18mmol) of 4-cyanobenzenesulfonyl chloride in the same
manner as in Synthetic Example 1b.
[1002] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 5.29(1H, d, J=17.6
Hz), 5.59(1H, d, J=11.6 Hz), 6.75(1H, dd, J=11.6, 17.6 Hz),
7.59(1H, t, J=8.0 Hz), 7.80(2H, dd, J=8.8 Hz), 7.96(1H, d, J=8.0
Hz), 8.00-8.04(3H, m), 8.74(1H, s), 10.58(1H, s).
SYNTHETIC EXAMPLE 44b
[1003]
N-(8-Trifluoromethylquinoline-3-yl)-5-(N-acethylindoline)sulfonamid-
e
[1004] 186 mg of the title compound was obtained using 109 mg (0.51
mmol, Production Example 10b) of 3-amino-8-trifluoromethylquinoline
and 200 mg (0.77 mmol) of 5-chlorosulfonyl-N-acethylindoline in the
same manner as in Synthetic Example 1b.
[1005] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.13(3H, s),
3.14(2H, t, J=8.0 Hz), 4.09(2H, t, J=8.8 Hz), 7.67(1H, t, J=8.4
Hz), 7.69-7.73(2H, m), 8.01(1H, d, J=7.2 Hz), 8.07-8.09(2H, m),
8.24(1H, d, J=8.4 Hz), 8.73(1H, d, J=2.8 Hz), 10.98(1H, s).
SYNTHETIC EXAMPLE 45b
[1006]
N-(8-Bromoquinoline-3-yl)-2-methylthio-5-pyridinesulfonamide
[1007] 197 mg (0.556 mmol) of white crystals were obtained using
100 mg (0.56 mmol, Production Example 5b) of
3-amino-8-bromoquinoline and 142 mg (0.67 mmol) of
2-chloro-5-pyridinesulfonyl chloride in the same manner as in
Synthetic Example 1b. Dimethylformamide (1 ml), pyridine (1 ml) and
111 mg (1.6 mmol) of sodium thiomethoxide were added to 60 mg (0.17
mmol) of the crystals, followed by stirring at room temperature for
3 hours. Brine was added to the reaction solution, followed by
extracting with ethyl acetate. The organic layer was dried over
magnesium sulfate and concentrated, to give the residue. The
residue was purified by silica gel chromatography, to give 62 mg of
the title compound.
[1008] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.33(3H, s),
7.47(1H, d, J=8.8 Hz), 7.55(1H, t, J=8.0 Hz), 7.84(1H, d, J=6.8
Hz), 7.97(1H, d, J=8.8 Hz), 7.98(1H, d, J=8.8 Hz), 8.13(1H, d,
J=2.0 Hz), 8.74(1H, d, J=2.4 Hz), 8.82(1H, d, J=2.0 Hz), 11.16(1H,
s).
SYNTHETIC EXAMPLE 46b
[1009]
N-(8-Bromoquinoline-3-yl)-4-(2-methylsulfonylethyl)benzenesulfonami-
de
[1010] 55 mg of the title compound was obtained using 30 mg (0.13
mmol, Production Example 5b) of 3-amino-8-bromoquinoline and 57 mg
(0.20 mmol) of 4-(2-methylsulfonylethyl)benzenesulfonyl chloride in
the same manner as in Synthetic Example 1b.
[1011] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.92(3H, s),
3.00-3.05(2H, m), 3.37-3.44(2H, m), 7.46(1H, t, J=7.6 Hz), 7.48(2H,
d, J=8.0 Hz), 7.80(2H, d, J=8.0 Hz), 7.96(1H, d, J=77.6Hz),
7.99(1H, d, J=7.6 Hz), 8.04(1H, d, J=2.4 Hz), 8.71(1H, d, J=2.4
Hz), 11.02(1H, s)
SYNTHETIC EXAMPLE 47b
[1012]
N-(8-Bromoquinoline-3-yl)-4-oxa-7-benzothiochromansulfonamide
[1013] 99 mg of the title compound was obtained using 51 mg (0.23
mmol, Production Example 5b) of 3-amino-8-bromoquinoline and 86 mg
(0.34 mmol) of 7-chlorosulfonyl-4-oxa-benzothiochroman in the same
manner as in Synthetic Example 1b.
[1014] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.18(2H, t, J=8.4
Hz), 4.39(2H, t, J=8.4 Hz), 6.92 (1H, d, J=8.8 Hz), 7.42 (1H, dd,
J=2.4, 8.8 Hz), 7.46(1H, t, J=7.6 Hz), 7.59(1H, d, J=2.4 Hz),
7.99(1H, d, J=7.6 Hz), 8.02(1H, d, J=7.6 Hz), 8.05(1H, br),
8.71(1H, d, J=2.4 Hz), 10.92(1H, s).
SYNTHETIC EXAMPLE 48b
[1015]
N-(8-Bromoquinoline-3-yl)-4-(2-acetamidoethyl)benzenesulfonamide
[1016] 56 mg of the title compound was obtained using 30 mg (0.13
mmol, Production Example 5b) of 3-amino-8-bromoquinoline and 201 mg
(0.77 mmol) of N-(4-chlorosulfonylphenethylethyl)acetamide in the
same manner as in Synthetic Example 1b.
[1017] 1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.71(2H, t, J=7.2 Hz),
3.25-3.20(2H, m), 7.37(2H, d, J=8.4 Hz), 7.46(1H, t, J=8.0 Hz),
7.78(2H, d, J=8.4 Hz), 7.86(1H, br), 7.97(1H, d, J=8.0 Hz),
8.00(1H, d, J=8.0 Hz), 8.04(1H, d, J=2.8 Hz), 8.72(1H, d, J=2.8
Hz), l0.99(1H, s).
SYNTHETIC EXAMPLE 49b
[1018]
N-(8-Bromoquinoline-3-yl)-1,2,3,4-tetrahydro-N-acetyl-7-isoquinolin-
esulfonamide
[1019] 180 mg of white crystals were obtained using 145 mg (0.65
mmol, Production Example 5b) of 3-amino-8-bromoquinoline and 277 mg
(0.85 mmol) of 1,2,3,4-tetrahydro-2-(trifluoroacetyl)
isoquinoline-7-sulfonyl chloride in the same manner as in Synthetic
Example 1b. Ethanol (20 ml) and an aqueous 1 N sodium hydroxide
solution (0.5 ml) were added to the crystals, followed by stirring
at room temperature for 30 minutes. An aqueous 1 N hydrochloric
acid solution (0.4 ml) was added to the reaction solution, followed
by extracting with ethyl acetate. The organic layer was washed with
brine, dried over magnesium sulfate and concentrated, to give the
residue. Pyridine (0.5 ml) and acetic acid anhydride (0.014 ml)
were added to the residue, followed by stirring at room temperature
for one hour. Brine was added thereto, followed by extracting with
ethyl acetate. The organic layer was dried over magnesium sulfate
and concentrated. Then, the residue was purified by silica gel
chromatography, to give 113 mg of the title compound.
[1020] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.19-1.28(2H, m),
2.05(3H, s), 2.97(1H, t, J=6.4 Hz), 3.03(1H, t, J=6.4 Hz), 3.75(1H,
t, J=6.4 Hz), 4.73(1H, s), 7.37(1H, t, J=8.8 Hz), 7.53-7.58(1H, m),
7.75-7.87(2H, m), 7.91(1H, d, J=8.0 Hz), 8.19-8.27(2H, m),
8.76-8.78(1H, m).
SYNTHETIC EXAMPLE 50b
[1021]
N-(8-Bromoquinoline-3-yl)-1,1-dioxido-6-benzothiochromansulfonamide
[1022] White crystals were obtained using 71 mg (0.32 mmol,
Production Example 5b) of 3-amino-8-bromoquinoline and 119 mg (0.48
mmol) of 6-chlorosulfonylbenzothiochroman. Under ice-cooling,
chloroform (10 ml) and methachloroperbenzoic acid (145 mg) were
added to the crystals under ice-cooling, followed by stirring at
room temperature for one hour. An aqueous saturated sodium
thiosulfate solution was added thereto, followed by extracting with
ethyl acetate. The organic layer was washed with brine and dried
over magnesium sulfate. After concentrating, the residue was
purified by silica gel chromatography, to give 113 mg of the title
compound.
[1023] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.26-2.29(2H, m),
3.05(2H, t, J=6.0 Hz), 3.53-3.56(2H, m), 7.48(1H, t, J=7.6 Hz),
7.86-7.90(2H, m), 7.96-8.04(3H, m), 8.10(1H, d, J=2.4 Hz), 8.75(1H,
d, J=2.4 Hz), 11.24(1H, s).
SYNTHETIC EXAMPLE 51b
[1024]
N-(8-Bromoquinoline-3-yl)-4-(3-methylsulfonylpropyl)benzenesulfonam-
ide
[1025] 62 mg of the title compound was obtained using 33 mg (0.14
mmol, Production Example 5b) of 3-amino-8-bromoquinoline and 66mg
(0.22mmol) of4-(3-methylsulfonylpropyl)benzenesulfonyl chloride in
the same manner as in Synthetic Example 1b.
[1026] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.90-1.98(2H, m),
2.72(2H, t, J=8.0 Hz), 2.93(3H, s), 3.06(2H, t, J=8.0 Hz), 7.42(2H,
d, J=8.0 Hz), 7.46(1H, d, J=7.6 Hz), 7.97(2H, d, J=7.6 Hz),
8.00(1H, d, J=7.6 Hz), 8.05(1H, d, J=2.4 Hz), 8.72(1H, d, J=2.4
Hz), 11.01(1H, s).
SYNTHETIC EXAMPLE 52b
[1027] N-(8-Bromoquinoline-3-yl)-4-fluorobenzenesulfonamide
[1028] 50 mg of the title compound was obtained using 33 mg (0.14
mmol, Production Example 5b) of 3-amino-8-bromoquinoline and 39 mg
(0.20 mmol) of 4-fluorobenzenesulfonyl chloride in the same manner
as in Synthetic Example 1b.
[1029] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.40(1H, t, J=8.8
Hz), 7.47(1H, t, J=7.66 Hz), 7.89-7.93(2H, m), 9.78(1H, dd, J=0.9,
7.6 Hz), 8.01(1H, dd, J=0.9, 7.6 Hz), 8.06(1H, d, J=2.4 Hz),
8.71(1H, d, J=2.4 Hz), 11.06(1H, s).
SYNTHETIC EXAMPLE 53b
[1030]
N-(8-Bromoquinoline-3-yl)-4-methoxy-2-pyridazinesulfonamide
[1031] Under ice-cooling, chlorine gas was brown into a
concentrated hydrochloric acid solution (8 ml) containing 0.86 g
(3.7 mmol, Production Example 14b) of
2-benzylthio-5-methoxypyridazine for one hour, followed by
stirring. Then, ice-water was added to the reaction solution,
followed by extracting with ethyl acetate. The organic layer was
successively washed with water and brine, dried over magnesium
sulfate and concentrated, to give 700 mg (2.1 mmol) of the residue.
93 mg of the title compound was obtained using 180 mg (0.54 mmol)
of the residue and 60 mg (0.27 mmol, Production Example 5b) of
3-amino-8-bromoquinoline in the same manner as in Synthetic Example
1b.
[1032] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 4.07(3H, s),
7.44(1H, d, J=9.2 Hz), 7.47(1H, t, J=7.6 Hz), 7.96(1H, t, J=7.6
Hz), 8.02(1H, t, J=7.66 Hz), 8.13(1H, d, J=2.4 Hz), 8.17(11H, d,
J=9.2 Hz), 8.82(1H, d, J=2.4 Hz), 11.54(1H, s).
SYNTHETIC EXAMPLE 54b
[1033] N-(8-Bromoquinoline-3-yl)-benzenesulfonamide
[1034] 49 mg of the title compound was obtained using 30 mg (0.13
mmol, Production Example 5b) of 3-amino-8-bromoquinoline and 35 mg
(0.20 mmol) of benzenesulfonyl chloride in the same manner as in
Synthetic Example 1b.
[1035] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.45(1H, d, J=7.6
Hz), 7.53-7.63(3H, m), 7.84-7.86(2H, m), 7.96(1H, dd, J=1.2, 7.6
Hz), 7.99(1H, dd, J=1.2, 7.6 Hz), 8.04(1H, d, J=2.8 Hz), 8.71(1H,
d, J=2.8 Hz), 11.02(1H, s).
SYNTHETIC EXAMPLE 55b
[1036]
N-(8-Bromoquinoline-3-yl)-4-carboxyamido-2-pyridinesulfonamide
[1037] Chlorine gas was brown into a concentrated hydrochloric acid
solution (16 ml) containing 1.1 g (4.3 mmol, Production Example
15b) of 2-benzylthio-4-carboxyamidopyridine for one hour under
ice-cooling, followed by stirring. Then, the reaction solution was
added to ice-water, followed by extracting with ethyl acetate. The
organic layer was successively washed with water and brine, dried
over magnesium sulfate and concentrated.
[1038] 37 mg of the title compound was obtained using 140 mg (0.40
mmol) of the residue and 45 mg (0.20 mmol) of
3-amino-8-bromoquinoline in the same manner as in Synthetic Example
1b.
[1039] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.46(1H, d, J=8.0
Hz), 7.94-7.96(2H, m), 8.00-8.02(2H, m), 8.12(1H, d, J=2.4 Hz),
8.44(1H, br), 8.49(1H, br), 8.83-8.85(2H, m), 11.35(1H, s)
SYNTHETIC EXAMPLE 56b
[1040] N-(8-Bromoquinoline-3-yl)-3-methoxybenzenesulfonamide
[1041] 70 mg of the title compound was obtained using 40 mg (0.18
mmol, Production Example 5b) of 3-amino-8-bromoquinoline and 56 mg
(0.27 mmol) of 3-methoxybenzenesulfonyl chloride in the same manner
as in Synthetic Example 1b.
[1042] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.76(3H, s),
7.17(1H, dd, J=2.8, 8.0 Hz), 7.34-7.40(2H, m), 7.45(1H, t, J=7.6
Hz), 7.46(1H, t, J=7.6 Hz), 7.99(2H, t, J=7.6 Hz), 8.07(1H, d,
J=2.4 Hz), 8.72(2H, m), 11.35(1H, d, J=2.4 Hz)
SYNTHETIC EXAMPLE 57b
[1043] N-(8-Bromoquinoline-3-yl)-3-hydroxybenzenesulfonamide
[1044] 73 mg of the title compound was obtained using 45 mg (0.20
mmol, Production Example 5b) of 3-amino-8-bromoquinoline and 117 mg
(0.61 mmol) of 3-hydroxybenzenesulfonyl chloride in the same manner
as in Synthetic Example 1b.
[1045] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.97(1H, d, J=8.0
Hz), 7.18(1H, br), 7.25(1H, d, J=8.0 Hz), 7.34 (1H, t, J=8.0 Hz),
7.47(1H, t, J=8.0 Hz), 7.97(1H, d, J=8.0 Hz), 8.01(1H, d, J=8.0
Hz), 8.04(1H, d, J=2.4 Hz), 8.73(1H, d, J=2.4 Hz), 10.15(1H, s),
10.96(1H, s).
SYNTHETIC EXAMPLE 58b
[1046] N-(4-Bromoquinoline-7-yl)-4-chlorobenzenesulfonamide
[1047] 20 mg (0.09 mmol, Production Example 20b) of
7-amino-4-bromoisoquinoline was dissolved in 1.5 ml of pyridine, to
which was then added 23 mg of 4-chlorobenzenesulfonyl chloride,
followed by stirring at room temperature overnight. Water was added
to the reaction solution, and the mixture was extracted with ethyl
acetate. The extract was dried over magnesium sulfate and
concentrated. Then, the resulting residue was purified by silica
gel thin layer chromatography, to give 13 mg of the title
compound.
[1048] Melting point: gradually decomposed from 229.degree. C.
[1049] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.59-7.61 (2H, m),
7.66 (1H, dd, J=2 Hz, 9.2 Hz), 7.82-7.84 (3H, m), 7.99 (1H, d,
J=9.2 Hz), 8.60 (1H, s).
SYNTHETIC EXAMPLE 59b
[1050]
N-(4-Bromoisoquinoline-7-yl)-6-chloro-3-pyridinesulfonamide
[1051] The title compound was obtained using 7-amino-4-isoquinoline
(Production Example 20b) and 6-chloro-3-pyridinesulfonyl chloride
in the same manner as in Synthetic Example 57b.
[1052] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.66(1H, dd, J=2.4
Hz, 9.2Hz), 7.70(1H, d, J=8.4 Hz), 7.89(1H, d, J=2.4 Hz), 8.02(1H,
d, J=9.2 Hz), 8.20(1H, dd, J=2.4 Hz, 8.4 Hz), 8.64(1H, s), 8.84(1H,
d, J=2.4 Hz), 9.26(1H, s).
SYNTHETIC EXAMPLE 60b
[1053] 2-(4-Chlorobenzenesulfonylamino)-1,6-naphthyridine
[1054] 2-Amino-1,6-naphthyridine (200 mg, Production Example 25b)
was dissolved in dichloromethane (6.0 ml), to which were then added
triethylamine (0.20 ml) and 4-chlorobenzenesulfonyl chloride (0.31
g), followed by stirring at 40.degree. C. for 1.5 hours. An aqueous
saturated sodium bicarbonate was added thereto, followed by
extracting with ethyl acetate. The extract was washed with brine
and dried over anhydrous magnesium sulfate. The solvent was
evaporated and the residue was purified by silica gel column, to
give the title compound (84 mg, 21.44%) as pale yellow
crystals.
[1055] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 7.10 (1H, d, J=9.2
Hz), 7.37 (1H, d, J=5.4 Hz), 7.46 (2H, d, J=8.8 Hz), 7.93 (2H, d,
J=8.8 Hz), 8.94 (1H, d, J=9.2 Hz), 8.66 (1H, d, J=5.4 Hz), 8.92
(1H, brs).
SYNTHETIC EXAMPLE 61b
[1056] 1-Chloro-6-(4-cyanobenzenesulfonylamino)isoquinoline
[1057] The title compound was obtained using
6-amino-1-chloro-isoquinoline (Production Example 23b) and
4-cyanobenzenesulfonyl chloride in the same method as in Synthetic
Example 1b.
[1058] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.52(1H, dd, J=2.0,
8.8 Hz), 7.68(1H, d, J=2.0 Hz), 7.79(1H, d, J=5.6 Hz), 8.03(4H, m),
8.18(1H, d, J=5.6 Hz), 8.21(1H, d, J=8.8 Hz), 11.36(1H, s).
SYNTHETIC EXAMPLE 62b
[1059] 1-Chloro-6-(4-chlorobenzenesulfonylamino)isoquinoline
[1060] The title compound was obtained using
6-amino-1-chloro-isoquinoline (Production Example 23b) and
4-chlorobenzenesulfonyl chloride in the same method as in Synthetic
Example 1b.
[1061] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 7.33(1H, brs),
7.39(1H, dd, J=2.0, 8.8 Hz), 7.44(2H, d, J=8.8 Hz), 7.50(1H, d,
J=5.6 Hz), 7.58(1H, d, J=2.0 Hz), 7.81 (2H, d, J=8.8 Hz), 8.24 (1H,
d, J=5.6 Hz), 8.25 (1H, d, J=8.8 Hz).
[1062] FAB-MS: 353.
SYNTHETIC EXAMPLE 63b
[1063]
1-Chloro-6-(4-pyrrolidine-1-ylsulfonyl)benzenesulfonylamino)isoquin-
oline
[1064] The target compound was obtained using
6-amino-1-chloro-isoquinolin- e (Production Example 23b) and
4-(pyrrolidine-1-ylsulfonyl)benzenesulfonyl chloride in the same
method as in Synthetic Example 1b.
[1065] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 1.71(4H, m), 3.20(4H,
t, J=7.0 Hz), 7.46(1H, d, J=5.4 Hz), 7.49(1H, dd, J=2.0, 9.2 Hz),
7.61(1H, d, J=2.0 Hz), 7.87 (2H, d, J=8.8 Hz), 8.02 (2H, d, J=8.8
Hz), 8.19 (1H, d, J=9.2 Hz), 8.20(1H, d, J=5.4 Hz), 9.72(1H,
s).
SYNTHETIC EXAMPLE 64b
[1066]
1-Chloro-6-(4-(N-ethylsulfamoyl)benzenesulfonylamino)isoquinoline
[1067] The title compound was obtained using
6-amino-1-chloro-isoquinoline (Production Example 23b) and
4-(N-ethylsulfamoyl)benzenesulfonyl chloride in the same method as
in Synthetic Example 1b.
[1068] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 0.81 (3H, t, J=7.2
Hz), 2.73 (2H, m), 7.53 (1H, d, J=9.2 Hz), 7.67 (1H, s), 7.75 (1H,
d, J=6.0 Hz), 7.78 (1H, d, J=6.0 Hz), 7.92 (2H, d, J=8.0 Hz).
SYNTHETIC EXAMPLE 65b
[1069] 1-Methoxy-6-(pyridine-3-ylsulfonylamino)isoquinoline
[1070] The title compound was obtained using
6-amino-1-methoxyisoquinoline (Production Example 43b) and
3-pyridinesulfonyl chloride in the same method as in Synthetic
Example 1b.
[1071] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 4.09 (3H, s), 7.09
(1H, d, J=6.0 Hz), 7.25 (1H, dd, J=2.0, 8.8 Hz), 7.37 (1H, d,
J=8.0, 8.8 Hz), 7.48 (1H, d, J=2.0 Hz), 7.96 (1H, d, J=6.0 Hz),
8.07 (1H, ddd, J=1.6, 2.0, 8.0 Hz), 8.14 (1H, d, J=8.8 Hz), 8.74
(1H, dd, J=1.6, 8.8 Hz), 9.08 (1H, d, J=2.0 Hz).
[1072] ESI-MS: 316.0.
SYNTHETIC EXAMPLE 66b
[1073] 6-(4-Cyanobenzenesulfonylamino)-1-methoxyisoquinoline
[1074] The title compound was obtained using
6-amino-1-methoxyisoquinoline (Production Example 43b) and
4-cyanobenzenesulfonyl chloride in the same method as in Synthetic
Example 1b.
[1075] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.97(3H, s),
7.25(1H, d, J=5.6 Hz), 7.32(1H, d, J=8.8 Hz), 7.51(1H, s), 7.90(1H,
d, J=5.6 Hz), 7.97(2H, d, J=7.6 Hz), 8.01(2H, d, J=7.6 Hz),
8.03(1H, d, J=8.8 Hz).
SYNTHETIC EXAMPLE 67b
[1076] 6-(4-Carbamoylbenzenesulfonylamino)-1-methoxyquinoline
[1077] The title compound was obtained using
6-(4-cyanobenzenesulfonylamin- o)-1-methoxyisoquinoline (Production
Example 65b) according to the method described in Synthesis, 949
(1989).
[1078] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.96 (3H, s), 7.24
(1H, d, J=6.4 Hz), 7.33 (1H, d, J=9.2 Hz), 7.51 (1H, s), 7.55 (1H,
brs), 7.88 (1H, d, J=6.4 Hz), 7.89 (2H, d, J=8.0 Hz), 7.93 (2H, d,
J=8.0 Hz), 8.01 (1H, d, J=9.2 Hz), 8.06 (1H, brs), 10.95 (1H,
s).
[1079] FAB-MS: 358.
SYNTHETIC EXAMPLE 68b
[1080]
6-(4-(N-Ethylsulfamoyl)benzenesulfonylamino)-1-methoxyisoquinoline
[1081] The title compound was obtained using
6-amino-1-methoxyisoquinoline (Production Example 43b) and
4-(N-ethylsulfamoyl)benzenesulfonyl chloride in the same method as
in Synthetic Example 1b.
[1082] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 0.81(3H, t, J=6.8
Hz), 2.71(2H, m), 3.96(3H, s), 7.23(1H, d, J=6.4 Hz), 7.32(1H, d,
J=8.8 Hz), 7.48(1H, s), 7.73(1H, brs), 7.89(2H, d, J=8.0 Hz),
7.90(1H, d, J=6.4 Hz), 8.01(3H, m), 11.03(1H, brs).
[1083] ESI MS: 422.0.
SYNTHETIC EXAMPLE 69b
[1084]
6-(2-Aminopyridine-5-ylsulfonylamino)-1-methoxyisoquinoline
[1085] The title compound was obtained using
6-amino-1-methoxyisoquinoline (Production Example 43b) and
6-amino-3-pyridinesulfonyl chloride in the same method as in
Synthetic Example 1b.
[1086] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.96(3H, s),
6.39(1H, d, J=8.8 Hz), 6.89(2H, s), 7.25(1H, d, J=4.2 Hz), 7.32(1H,
d, J=9.2 Hz), 7.47(1H, s), 7.64(1H, d, J=9.2 Hz), 7.89(1H, d, J=4.2
Hz), 8.01(1H, d, J=8.8 Hz), 8.31(1H, s), 10.95(1H, s).
[1087] ESI MS: 331.0.
SYNTHETIC EXAMPLE 70b
[1088] 1-Methoxy-6-(4-methylbenzenesulfonylamino)isoquinoline
[1089] The title compound was obtained using
6-amino-1-methoxyisoquinoline (Production Example 43b) and
4-toluenesulfonyl chloride in the same method as in Synthetic
Example 1b.
[1090] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.28 (3H, s), 3.96
(3H, s), 7.22 (1H, d, J=6.0 Hz), 7.32 (3H, m), 7.48 (1H, s), 7.71
(2H, d, J=8.4 Hz), 7.88 (1H, d, J=6.0 Hz), 8.00 (1H, d, J=9.2 Hz),
10.79 (1H, s).
[1091] ESI MS: 329.0.
SYNTHETIC EXAMPLE 71b
[1092]
6-(4-Acetylaminobenzenesulfonylamino)-1-methoxyisoquinoline
[1093] The title compound was obtained using
6-amino-1-methoxyisoquinoline (Production Example 43b) and
4-acetamidobenzenesulfonyl chloride in the same method as in
Synthetic Example 1b. .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm):
2.01(3H, s), 3.96(3H, s), 7.23(1H, d, J=6.0 Hz), 7.32(1H, d, J=9.2
Hz), 7.47(1H, s), 7.67(2H, d, J=8.8 Hz), 7.76 (2H, d, J=8.8 Hz).
7.88 (1H, d, J=6.0 Hz), 8.00 (1H, d, J=9.2 Hz), 10.26 (1H, s),
10.75 (1H, s).
[1094] ESI MS: 372.1.
SYNTHETIC EXAMPLE 72b
[1095]
6-(4-Methanesulfonylaminobenzenesulfonylamino)-1-methoxyisoquinolin-
e
[1096] The compound synthesized using 6-amino-1-methoxyisoquinoline
(Production Example 43b) and 4-nitrobenzenesulfonyl chloride in the
same manner as in Synthetic Example 1b was processed in the same
manner as in Production Example 170b, to reduce the nitro group
thereof. The resulting compound was dissolved in pyridine and
methanesulfonyl chloride was added thereto under ice-cooling,
followed by stirring for 4 hours as it was. Brine was added
thereto, followed by extracting with ethyl acetate. The extract was
washed with brine and dried over anhydrous magnesium sulfate. After
evaporating the solvent, the residue was purified by silica gel
column and the resulting crystals were recrystallized from ethanol,
to give the title compound.
[1097] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.06 (3H, s), 3.97
(3H, s), 7.24 (3H, m), 7.33 (1H, d, J=9.0 Hz), 7.49 (1H, s), 7.79
(2H, d, J=8.8 Hz), 7.89 (1H, d, J=6.0 Hz), 8.01 (1H, d, J=9.0 Hz),
10.39 (1H, s), 10.80 (1H, s).
[1098] ESI MS: 372.1.
SYNTHETIC EXAMPLE 73b
[1099]
6-(2-Chloropyridine-5-ylsulfonylamino)-1-methoxyisoquinoline
[1100] The title compound was obtained using
6-amino-1-methoxyisoquinoline (Production Example 43b) and
6-chloro-3-pyridinesulfonyl chloride in the same method as in
Synthetic Example 1b.
[1101] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.31 (3H, s), 3.99
(3H, s), 7.30 (1H, d, J=6.0 Hz), 7.34 (1H, d, J=8.8 Hz), 7.56 (1H,
s), 7.71 (1H, d, J=8.8 Hz), 7.92 (1H, d, J=6.0 Hz), 8.06 (1H, d,
J=8.8 Hz), 8.19 (1H, d, J=8.8 Hz), 11.13 (1H, s).
[1102] ESI MS: 350.1. SYNTHETIC EXAMPLE 74b
[1103] 1-Methoxy-6-(3-methylbenzenesulfonylamino)isoquinoline
[1104] The title compound was obtained using
6-amino-1-methoxyisoquinoline (Production Example 43b) and
3-toluenesulfonyl chloride in the same method as in Synthetic
Example 1b.
[1105] .sup.1H-NMR(DMSO-d6) .delta. (ppm): 2.31(3H, s), 3.96(3H,
s), 7.22(1H, d, J=6.0 Hz), 7.32(1H, dd, J=2.0, 8.8 Hz), 7.39 (2H,
m), 7.47(1H, d, J=2.0 Hz), 7.62(1H, m), 7.67 (1H, s), 7.87 (1H, d,
J=6.0 Hz), 8.00 (1H, d, J=8.8 Hz), 10.84 (1H, s).
SYNTHETIC EXAMPLE 75b
[1106] 6-Benzylsulfonylamino-1-methoxyisoquinoline
[1107] The title compound was obtained using
6-amino-1-methoxyisoquinoline (Production Example 43b) and
benzylsulfonyl chloride in the same method as in Synthetic Example
1b.
[1108] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 4.13 (3H, s), 4.42
(2H, s), 6.69 (1H, brs), 7.13 (2H, m), 7.22 (2H, m), 7.30-7.37 (3H,
m), 7.50 (1H, d, J=2.4 Hz), 7.99 (1H, d, J=6.0 Hz), 8.20 (1H, d,
J=8.8 Hz).
SYNTHETIC EXAMPLE 76b
[1109] 6-(3-Cyanobenzenesulfonylamino)-1-methoxyisoquinoline
[1110] The title compound was obtained using
6-amino-1-methoxyisoquinoline (Production Example 43b) and
3-cyanobenzenesulfonyl chloride in the same method as in Synthetic
Example 1b.
[1111] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 3.98(3H, s),
7.28(1H, d, J=6.0 Hz), 7.34(1H, dd, J=2.0, 8.8 Hz), 7.53(1H, d,
J=2.0 Hz), 7.75(1H, dd, J=8.0, 8.0 Hz), 7.91 (1H, d, J=6.0 Hz),
8.04 (1H, d, J=8.8 Hz), 8.09 (2H, m), 9.29 (1H, m), 11.05(1H,
s).
SYNTHETIC EXAMPLE 77b
[1112]
1-Methoxy-6-(4-thiazole-2-ylbenzenesulfonylamino)isoquinoline
[1113] The compound (40 mg) obtained using
6-amino-1-methoxyisoquinoline (Production Example 43b) and
4-iodobenzenesulfonyl chloride in the same method as in Synthetic
Example 1b, 2-tri-n-butylstannylthiazole (136 mg) and
tetrakis(triphenylphosphine)palladium (0) (11 mg) were heated under
reflux for one hour in toluene in a nitrogen atmosphere. After
evaporating the solvent, the residue was purified by silica gel
column. The resulting crystals were recrystallized from methanol,
to give the title compound (20 mg).
[1114] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 4.08 (3H, s), 6.94
(1H, brs), 7.09 (1H, d, J=6.0 Hz), 7.23 (1H, dd, J=2.0, 8.8 Hz),
7.41 (1H, d, J=3.6 Hz), 7.45 (1H, d, J=2.0 Hz), 7.89 (2H, d, J=8.4
Hz), 7.90 (1H, d, J=8.6 Hz), 7.95 (1H, d, J=6.0 Hz), 7.82 (2H, d,
J=8.4 Hz), 8.13 (1H, d, J=8.8 Hz).
SYNTHETIC EXAMPLE 78b
[1115] 6-(4-Chlorobenzenesulfonylamino)-1-methoxyisoquinoline
[1116] The title compound was obtained using
6-amino-1-methoxyisoquinoline (Production Example 43b) and
4-chlorobenzenesulfonyl chloride in the same method as in Synthetic
Example 1b.
[1117] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 4.00 (3H, s), 7.27
(1H, d, J=5.6 Hz), 7.45 (1H, dd, J=2.0, 8.8 Hz), 7.53 (1H, d, J=2.0
Hz), 7.63 (2H, d, J=8.8 Hz), 7.85 (1H, d, J=8.8 Hz), 7.92 (1H, d,
J=5.6 Hz), 8.06, (1H, J=8.8 Hz), 10.97 (1H, s).
SYNTHETIC EXAMPLE 79b
[1118] 6-(4-Chlorobenzenesulfonylamino)-1-methylisoquinoline
[1119] The title compound was obtained using
6-amino-1-methylisoquinoline (Production Example 33b) and
4-chlorobenzenesulfonyl chloride in the same method as in Synthetic
Example 1b.
[1120] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.76 (3H, s), 7.56
(1H, d, J=6.0 Hz), 7.52 (2H, m), 7.60 (2H, d, J=8.8 Hz), 7.82 (2H,
d, J=8.8 Hz), 8.08 (1H, d, J=9.2 Hz), 8.20 (1H, d, J=6.0 Hz).
[1121] ESI-MS: 333.0.
SYNTHETIC EXAMPLE 80b
[1122] 6-(4-Chlorobenzenesulfonylamino)-1-ethylisoquinoline
[1123] The title compound was obtained using
6-amino-1-ethylisoquinoline (Production Example 48b) and
4-chlorobenzenesulfonyl chloride in the same manner as in Synthetic
Example 1b.
[1124] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.39 (3H, t, J=7.6
Hz), 3.25 (2H, q, J=7.6 Hz), 7.35 (1H, dd, J=2.4, 9.2 Hz), 7.38
(1H, d, J=5.6 Hz), 7.41 (2H, d, J=8.8 Hz), 7.53 (1H, d, J=2.4 Hz),
7.81 (2H, d, J=8.8 Hz), 8.05 (1H, d, J=9.2 Hz), 8.37 (1H, d, J=5.6
Hz).
[1125] ESI-MS: 347.0.
SYNTHETIC EXAMPLE 81b
[1126] 6-(4-Chlorobenzenesulfonylamino)-4-ethylisoquinoline
[1127] The title compound was obtained using
6-amino-4-ethylisoquinoline (Production Example 66b) and
4-chlorobenzenesulfonyl chloride in the same method as in Synthetic
Example 1b.
[1128] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.18 (3H, t, J=7.2
Hz), 2.85 (2H, q, J=7.2 Hz), 7.38 (1H, d, J=8.8 Hz), 7.60 (1H, s),
7.62 (2H, d, J=8.0 Hz), 7.82 (2H, d, J=8.0 Hz), 8.00 (1H, d, J=8.8
Hz), 8.26 (1H, s), 8.99 (1H, s).
SYNTHETIC EXAMPLE 82b
[1129] 6-(4-Chlorobenzenesulfonylamino)-4-methylisoquinoline
[1130] The title compound was obtained using
6-amino-4-methylisoquinoline (Production Example 58b) and
4-chlorobenzenesulfonyl chloride in the same method as in Synthetic
Example 1b.
[1131] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.43 (3H, s), 7.41
(1H, d, J=8.8 Hz), 7.56 (1H, s), 7.62 (2H, d, J=8.8 Hz), 7.85 (2H,
d, J=8.8 Hz), 7.99 (1H, d, J=8.8 Hz), 8.26 (1H, 8), 8.98 (1H, s),
11.09 (1H, brs).
SYNTHETIC EXAMPLE 83b
[1132] 6-(4-Chlorobenzenesulfonylamino)-3-methylisoquinoline
[1133] The title compound was obtained using
6-amino-3-methylisoquinolinne (Production Example 76b) and
4-chlorobenzenesulfonyl chloride in the same method as in Synthetic
Example 1b.
[1134] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.53 (3H, s), 7.30
(1H, d, J=8.8 Hz), 7.45 (1H, s), 7.50 (1H, s), 7.62 (2H, d, J=8.4
Hz), 7.84 (2H, d, J=8.4 Hz), 7.93 (1H, d, J=8.8 Hz), 9.03 (1H,
s).
SYNTHETIC EXAMPLE 84b
[1135] 6-(4-Chlorobenzenesulfonylamino)-1-cyanoisoquinoline
[1136] The compound obtained using 6-aminoisoquinoline (0.5 g,
Synthesis, 733 (1975)) and 4-chlorobenzenesulfonyl chloride (0.88
g) in the same method as in Synthetic Example 1b was dissolved in
chloroform (150 ml). Under ice-cooling, m-chloroperbenzoic acid
(0.9 g) was added theterto, followed by stirring at room
temperature overnight. The solvent was evaporated, and the
resulting crystals were washed with diethyl ether, collected by
filtration and dried, to give 6-(4-chlorobenzenesulfonylamin-
o)isoquinoline-N-oxide (1.072 g). In acetonitrile (1.5 ml) was
dissolved 50 mg in the amount of the product, to which were then
added trimethyl cyanide (0.08 ml) and triethylamine (0.04 ml),
followed by heating under reflux for 3.5 hours. After evaporating
the solvent, the residue was purified by silica gel column, to give
the title compound (23 mg, 64%) as yellow crystals.
[1137] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.66 (2H, d, J=8.8
Hz), 7.67 (1H, dd, J=2.0, 9.2 Hz), 7.80 (1H, d, J=2.0 Hz), 7.93
(2H, d, J=8.8 Hz), 8.17 (1H, d, J=9.2 Hz), 8.18 (1H, d, J=5.6 Hz),
8.59 (1H, d, J=5.6 Hz).
[1138] ESI-MS: 344.1
SYNTHETIC EXAMPLE 85b
[1139] 1-Carbamoyl-6-(4-chlorobenzenesulfonylamino)isoquinoline
[1140] Crystals obtained from
6-(4-chlorobenzenesulfonylamino)-1-cyanoisoq- uinoline (30 mg,
Synthetic Example 83b) according to the method described in
Synthesis, 949 (1989) were washed with diethyl ether, to give the
title compound (26 mg, 82%) as colorless crystals.
[1141] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 6.25(1H, brs),
7.35(2H, d, J=8.8 Hz), 7.43(1H, dd, J=2.0, 9.2 Hz), 7.62(1H, d,
J=2.0 Hz), 7.66(1H, d, J=6.8 Hz), 7.81 (2H, d, J=8.8 Hz), 8.04 (1H,
brs), 8.37 (1H, brs), 9.32(1H, d, J=9.2 Hz), 9.76(1H, brs).
SYNTHETIC EXAMPLE 86b
[1142]
6-(4-Chlorobenzenesulfonylamino)-1-methylaminoisoquinoline
[1143] 1-Chloro-6-(4-chlorobenzenesulfonylamino)isoquinoline (50
mg, Synthetic Example 61b) and a 40% methylamine methanol solution
(5.0 ml) were heated at 130.degree. C. in a sealed tube for 18
hours. After cooling as it was, an aqueous saturated sodium
bicarbonate was added thereto, and the mixture was extracted with
ethyl acetate. The extract was washed with brine and dried over
anhydrous magnesium sulfate. After evaporating the solvent, the
residue was purified by silica gel column, to give the title
compound (28 mg, 52%) as a pale yellow solid.
[1144] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 3.14 (3H, s), 5.22
(1H, brs), 6.89 (1H, d, J=6.0 Hz), 7.19 (1H, dd, J=2.4 Hz, 9.2 Hz),
7.31 (1H, d, J=2.4 Hz), 7.40 (2H, d, J=8.8 Hz), 7.64 (1H, d, J=9.2
Hz), 7.73 (2H, d, J=8.8 Hz), 7.98 (1H, d, J=6.0 Hz).
SYNTHETIC EXAMPLE 87b
[1145] 1-Amino-6-(4-chlorobenzenesulfonylamino)isoquinoline
[1146] Crystals obtained using
6-(4-chlorobenzenesulfonylamino)isoquinolin- e-N-oxide
(intermediate in Synthetic Example 83b, 50 mg) according to the
method described in J. Medicine 84,35 (1964) were washed with
diethyl ether and dried, to give the title compound (2 mg) as pale
brownish crystals.
[1147] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 7.76 (1H, d, J=6.0
Hz), 6.93 (2H, brs), 7.15 (1H, dd, J=2.0, 8.8 Hz), 7.27 (1H, d,
J=2.0 Hz), 7.59 (2H, d, J=8.8 Hz), 7.63 (1H, d, J=6.0 Hz), 7.80
(2H, d, J=8.8 Hz), 9.05 (1H, d, J=6.0 Hz).
[1148] ESI-MS: 334.1.
SYNTHETIC EXAMPLE 88b
[1149]
6-(4-Chlorobenzenesulfonylamino)-1-dimethylaminisoquinoline
[1150] 1-Chloro-6-(4-chlorobenzenesulfonylamino)isoquinoline
(Synthetic Example 61b, 60 mg) was dissolved in dimethyl sulfoxide
(1 ml), to which was then added a 50% dimethylamine methanol
solution (0.04 ml), followed by heating under stirring at
80.degree. C. for 10 hours. After cooling as it was, water was
added thereto, followed by extracting with ethyl acetate. The
extract was washed with brine and dried over anhydrous magnesium
sulfate. After evaporating the solvent, the residue was purified by
preparative TLC and solidified using isopropyl ether, to give the
title compound (17 mg).
[1151] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 2.96 (6H, s), 7.12
(1H, d, J=6.0 Hz), 7.27 (1H, dd, J=2,0, 9.2 Hz), 7.45 (1H, d, J=2.0
Hz), 7.64 (2H, d, J=8.8 Hz), 7.85 (2H, d, J=8.8 Hz), 7.93 (1H, d,
J=6.0 Hz), 8.01 (1H, d, J=9.2 Hz), 10.91 (1H, brs).
SYNTHETIC EXAMPLE 89b
[1152] 6-(4-Chlorobenzenesulfonylamino)-1-hydroxyisoquinoline
[1153] 6-(4-Chlorobenzenesulfonylamino)isoquinoline-N-oxide
(intermediate in Synthetic Example 83b, 50 mg) was dissolved in
acetic acid anhydride (0.75 ml), followed by heating under stirring
at 80.degree. C. for 16 hours. Then, the mixture was refluxed under
heating for 2 hours. After cooling as it was, an aqueous saturated
sodium bicarbonate was added thereto, followed by extracting with
ethyl acetate. The extract was washed with brine and dried over
anhydrous magnesium sulfate. After evaporating the solvent, the
residue was dissolved in ethanol (2.0 ml) and water (0.5 ml),
followed by heating under reflux for 0.5 hours. After evaporating
the solvent, the residue was purified by silica gel column, to give
the title compound (20 mg) as a pale red solid.
[1154] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 6.58 (1H, d, J=7.2
Hz), 7.22 (1H, d, J=7.2 Hz), 7.31 (1H, dd, J=2.0, 8.4 Hz), 7.54
(1H, d, J=2.0 Hz), 7.56 (2H, d, J=8.8 Hz), 8.01 (2H, d, J=8.8 Hz),
8.53 (1H, d, J=8.4 Hz), 10.36 (1H, brs).
[1155] ESI-MS: 335.1.
SYNTHETIC EXAMPLE 90b
[1156] 6-(4-Chlorobenzenesulfonylamino)-1-ethoxyisoquinoline
[1157] 1-Chloro-6-(4-chlorobenzenesulfonylamino)isoquinoline
(Synthetic Example 61b, 57 mg) was dissolved in dimethyl sulfoxide
(1 ml). Ethanol (0.1 ml) and 60% sodium hydride (14 mg) were added
thereto, followed by heating under stirring at 80.degree. C. for 9
hours. After cooling as it was, water was added thereto, followed
by extracting with ethyl acetate. The extract was washed with brine
and dried over anhydrous magnesium sulfate. After evaporating the
solvent, the residue was purified by preparative TLC and solidified
using isopropyl ether, to give the title compound (21 mg).
[1158] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 1.38 (3H, t, J=7.2
Hz), 4.46 (2H, q, J=7.2 Hz), 7.24 (1H, d, J=6.0 Hz), 7.35 (1H, dd,
J=2.0, 9.2 Hz), 7.50 (1H, d, J=2.0 Hz), 7.63 (2H, d, J=8.8 Hz),
7.90 (1H, d, J=6.0 Hz), 8.04 (1H, d, J=9.2 Hz), 10.94 (1H,
brs).
SYNTHETIC EXAMPLE 91b
[1159] N-(5-Vinylquinoline-2-yl)-3-pyridinesulfonamide
[1160] A solution containing 2-amino-5-bromoquinoline (510 mg,
Production Example 1b), vinyltributyltin (0.94 ml), toluene (4 ml),
tetrakistriphenylphosphinepalladium (0 valence) (20 mg) and
2,6-ditertiarybutyl/p-cresol (about 0.1 mg) was stirred at
120.degree. C. for 4 hours. After the reaction mixture was returned
to room temperature, water was added thereto, followed by
extracting with ethyl acetate. The ethyl acetate layer was dried
over sodium sulfate and concentrated. Then, the resulting solid was
washed with hexane, to give 282 mg of a solid including a vinyl
material. The solid was dissolved in 2 ml of pyridine and 412 mg of
3-pyridinesulfonyl chloride was added thereto, followed by stirring
at room temperature overnight. Water was added thereto, followed by
extracting with ethyl acetate. The ethyl acetate layer was dried
over sodium sulfate and concentrated. Then, the resulting solid was
washed with methanol, to give the title compound (235 mg).
[1161] .sup.1H-NMR(CDCl.sub.3) .delta. (ppm): 5.59(1H, dd, J=10.8
Hz, 1.5 Hz), 5.82(1H, dd, J=16.9 Hz, 1.5 Hz), 6.95(1H, d, J=10.3
Hz),7.20(1H, dd, J=10.8 Hz,16.9 Hz), 7.36(1H, d, J=8.5 Hz ),
7.43(1H, m), 7.50(1H, d, J=8.5 Hz ), 7.62(1H, t, J=8.5 Hz ),
8.24(1H, d, J=10.3 Hz ), 8.29(1H, m), 8.74(1H, m), 9.22(1H, m).
SYNTHETIC EXAMPLE 92b
[1162]
N-(4-Trifluoromethylcumarin-7-yl)-4-chlorobenzenesulfonamide
[1163] 203 mg (0.96 mmol) of 4-chlorobenzenesulfonyl chloride was
added to a pyridine solution (3 ml) containing 200 mg (0.87 mmol)
of 7-amino-4-trifluoromethylcumarin and 1 mg of
4-dimethylaminopyridine, followed by stirring at 70.degree. C. for
50 minutes. An aqueous 2 N hydrochloric acid was added thereto,
followed by extracting with ethyl acetate. The organic layer was
washed with water and brine, dried over magnesium sulfate and
evaporated. The resulting residue was crystallized from ethyl
acetate-diisopropyl ether, to give 253 mg of the title compound as
a pale yellow solid.
[1164] .sup.1H-NMR(DMSO-d.sub.6) .delta. (ppm): 6.87(1H, s),
7.12(1H, d, J=2.4 Hz), 7.17(1H, dd, J=2.6, 8.4 Hz), 7.60(1H, d,
J=8.4 Hz), 7.67(2H, d, J=6.8 Hz), 7.87(2H, d, J=6.8 Hz), 11.29(1H,
s).
* * * * *